A study of the impact of substituting Warfarin with Direct Oral Anticoagulants (DOAC), in Atrial Fibrillation (AF) patients over 65 years old: The Patients’ and Clinicians’ Perspectives. by Richards, P. & Richards, P.
WestminsterResearch
http://www.westminster.ac.uk/westminsterresearch
A study of the impact of substituting Warfarin with Direct Oral 
Anticoagulants (DOAC), in Atrial Fibrillation (AF) patients over 65 
years old: The Patients’ and Clinicians’ Perspectives.
Richards, P.
This is an electronic version of a PhD thesis awarded by the University of Westminster. 
© Mrs Patricia Richards, 2020.
The WestminsterResearch online digital archive at the University of Westminster aims to 
make the research output of the University available to a wider audience. Copyright and 
Moral Rights remain with the authors and/or copyright owners.
   
1  
Student ID: W10503030 v8 – 05/08/2020 
  
A study of the impact of 
substituting Warfarin with Direct  
Oral Anticoagulants (DOAC), in  
Atrial  
Fibrillation (AF) patients over 65 
years old: The Patients’ and 
Clinicians’ Perspectives.  
  







A thesis submitted in partial fulfilment of the requirements of the University of  
Westminster for the Professional Doctorate Award in Health & Social Science  
   
2  
Student ID: W10503030 v8 – 05/08/2020 
Abstract  
The need for this research was identified during the researcher’s daily practice in 
her Haematology clinic in London. The clinic specialises in anticoagulated patients, 
particularly those with the condition of Atrial Fibrillation. The researcher noted that 
while extensive research had been undertaken into the medical issues associated 
with the established oral anticoagulant Warfarin, the newer medication referred to 
as Direct Oral Anticoagulants (DOACs) was less broadly studied. Importantly, little 
was known about how patients coped on a daily basis with this new treatment. 
Furthermore, the practical and social impact of a switch from Warfarin to a DOAC 
for clinical reasons had rarely been studied from the patient’s perspective.  
An inductive, mixed-method research study was set up comprising two 
questionnaires and individual interviews. A sample of 56 patients, aged 65ys and 
over, grouped by age and sex, were selected from the clinic. The first questionnaire 
was a Perceived Stress Scale (PSS), which explored the participants’ levels of 
stress at three time points: the switch over, then at 30 and 90 days. Concurrently a 
Medical Outcome Study (SF-36), a health survey was administered. Twenty of 
these patients were also interviewed by the researcher on two occasions, at the 
switch over then at 90 days. Thematic analysis was undertaken on the transcripts 
to identify themes across the patients’ responses. 
The findings showed that the switch to a DOAC had a positive impact on most of 
the respondents. They felt liberated from several of the constraints of taking 
Warfarin, for example, of not needing regular clinical monitoring so being able to 
travel further and more often, and eating a wider, healthier diet. The patients also 
reported feeling less stressed in general at the 30 day point, this was sustained over 
the remainder of the study period. There were some small differences between the 
ages, the older patients reported fewer benefits from the switch, although remaining 
positive about the experience. No significant difference was noted between the 
sexes. Patients highlighted the importance of personal resilience throughout, but 
that good GP support was also crucial in their continued wellbeing.  
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Definitions  
Anticoagulant – A drug or medicine that has the ability to help stop the blood from 
clotting (blood thinner).  
Atrial fibrillation – An abnormal heart rhythm which presents as irregular and rapid 
heartbeats.  
Bias – A prejudice shown from one person or group against another, especially in 
a way which may be considered unfair. In the context of this study, bias may be the 
author’s own perspective that may be inadvertently introduced in the type of 
questions being asked, or the interpretation of answers given.  
Bioavailability – The degree and rate at which an administered drug is absorbed 
by the body's circulatory system, the systemic circulation. Bioavailability is an 
essential measurement tool since it determines the correct dosage of drugs which 
are not administered via injections such e.g. oral therapy drugs such as Warfarin 
and direct oral anticoagulants.  
Bridging – Therapy using short-acting anticoagulants such as Heparin or Low 
Molecular Weight Heparin (LMWH) for a period of time for patients whose Warfarin 
therapy is out of its prescribed therapeutic range and must be interrupted e.g. during 
surgery.  
CHADS2 score – Is a score acronym for Congestive heart failure, Hypertension,  
Age (≥ 65 = 1 point, ≥ 75 = 2 points), Diabetes, and Stroke/TIA (2 points). Patients 
with high CHADS2 scores (>2) are at significant risk for stroke.  
CHA₂DS₂-VASc Score – This is an updated version (calculation) of the  
CHADS2 score. It is a score acronym for Congestive heart failure, Hypertension,  
Age (≥ 65 = 1 point, ≥ 75 = 2 points), Diabetes, and Stroke/TIA (2 points). VASc 
stands for Vascular disease (peripheral arterial disease, previous MI, aortic 
atheroma) and Sex category. The female gender is also included in this scoring 
system.  
Coagulation Pathway – The process by which blood changes from a liquid to a gel 
(clot), happens via several mechanisms or pathways.  
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Concomitant – Describes when several relevant factors exist concurrently e.g. 
taking multiple medications or having multiple medical conditions at the same time.  
Direct oral anticoagulants – Anticoagulant medications which acts by directly 
targeting specific parts of the coagulation pathway.  
Dyspepsia – Also known as indigestion, and the discomfort or pain felt in the upper 
abdomen.  
European Society for Cardiology (ESC) – The (ESC) is an independent, non-
profit organisation which aims to reduce the burden of cardiovascular disease by 
organising cardiac related discussion and generating medical guidelines on the 
treatment and prevention of heart diseases.  
Heart rate – Also known as the pulse, which is the number of times a person’s heart 
beats per minute. Normal heart rate varies from person to person, but a normal 
range for adults is 60 to 100 beats per minute.  
Heparin – A fast acting anticoagulant (blood thinner) that prevents the formation of 
blood clots. Heparin is given to the patient as an injection and is therefore usually 
given in a hospital setting (e.g. during surgery).  
International Sensitivity Index (ISI) – An internationally standardized number that 
is calculated and assigned to each batch of Warfarin testing reagent which is made 
from tissue factor.  
International Normalised Ratio – INR –, The unit of measure for patients who are 
on Warfarin and is calculated using the ISI. For normal patients who are not on 
anticoagulation, the INR is usually 1.0 regardless of the ISI or the particular 
performing laboratory. Patients who are on anticoagulant therapy, the expected 
therapeutic INR range is between 2.0 to 3.0.  
Intracranial haemorrhages (ICH) – A type of bleeding that occurs inside the skull 
(cranium). Bleeding around or within the brain itself is known as a cerebral 
haemorrhage (or intracerebral haemorrhage).  
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Metabolism – The process in which food is processed by the body and converted 
to energy. It is also the process used to describe the conversion of medicinal drugs 
into substances which can be more easily removed from the body.  
Pharmacokinetics – The process by which the body processes the passage or 
movement of drugs through the body, including the time course of its absorption, 
bioavailability, distribution, metabolism, and excretion.  
Pharmacology – The branch of biology concerned with the study of drug or 
medication action, where a drug can be broadly defined as any man-made, natural, 
or endogenous (from within the body) molecule which exerts a biochemical or 
physiological effect on the cell, tissue, organ, or organism.  
Prothrombin – A clotting factor or protein which is integral to the clotting of blood.  
Prothrombin time (PT) – A blood test that measures the time it takes for the liquid 
portion (plasma) of your blood to clot, the ISI calculation is then applied to covert to 
the INR which is a unit of measure of patients on Warfarin.  
Rhythm control – Patients with Atrial Fibrillation require medical interventions to 
help return the heart to a normal rate. Rhythm control medications is one method 
of treatment to restore a normal heart rate and in order to reduce the risk of a stroke.  
Stroke – A serious life-threatening medical condition that happens when the blood 
supply to part of the brain is cut off.  
Vitamin K – A group of fat-soluble vitamins that, among other properties, plays a 
key role in the clotting of blood and so prevents excessive bleeding. The body needs 
vitamin K to produce prothrombin, a protein and clotting factor that is important in 
blood clotting and bone metabolism.  
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1.0 Background   
This chapter provides an introduction to the topic of Atrial Fibrillation (AF) in UK 
patients over 65 years, the current treatments for AF, and recent changes in 
treatment. Finally, it outlines the structure of the thesis. The researcher first became 
interested in knowing more about AF patients’ broader perceptions of their 
treatment when at the Haematology clinic in west London where she was working. 
While extensive clinical research had been undertaken into the medical issues 
associated with these patients’ treatments, little was known about their responses 
to the condition or treatment provided. Anecdotal evidence indicated that, while 
patients varied in their response to their long-term condition, some patterns 
emerged relating to individual coping styles with medication management and also 
with the personal and social impact of living with long term anti-coagulant 
medication. The researcher was not alone in her curiosity. The doctor, nurses, and 
pharmacists in the team were also keen to better understand their patients’ 
perspectives of the treatment they were delivering, and whether their service could 
be improved. Given the lack of research in this area, it was clear to the researcher 
that a study was required which involved the patients directly so that their story 
could be heard.  The researcher was working face to face with patients in clinic so 
would have no difficulty identifying and accessing a sample of participants.  She did 
not have a research role at the hospital, therefore, in order to provide a sound 
academic basis for the study she applied for the University of Westminster’s 
Professional Doctorate programme.  
 
Since the government’s call for more public and personal involvement (PPI) in all 
aspects of health care in the early 2000s, much work has been done to include 
patients in decision making. However, this has generally taken the form of patients 
joining committees for local health care planning and becoming lay members on 
hospital boards where: ‘they can do little to challenge the prevailing clinical culture 
that affects the everyday experience of patients’ (Binstock et al., 2011). Binstock 
goes on to say: ‘People can contribute to their own health by, among other things, 
contributing to the understanding of coping with the effects of chronic illness and 
managing care’. Richards et al., (2015) also highlighted this problem, pointing to the 
rising number of people living with long term conditions of multimorbidity and frailty, 
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requiring services to be radically redesigned. Any revised service, they claim, must 
be: ‘based on a better understanding of what people need from health and social 
service’ (Wittenberg et al., 2019).   
 
 
1.1 The Situation in the UK.  
People in the UK are living longer. In 2010 there were 10 million people over the 
age of 65 years, with that number expected to rise to 19 million by 2050 (Davis et 
al., 2012). The growing number of patients using the NHS anti-coagulant services 
is having a huge impact on hospitals and General Practitioner (GP) surgeries, with 
state benefits and NHS treatments combined accounting for almost 50% of the total 
government expenditure in 2009/10 (Cracknell, 2010). Approximately 1.6% of the 
population suffers from Atrial Fibrillation (AF) (Scowcroft and Cowie, 2014). AF has 
an estimated prevalence in the United Kingdom of 15% of all patients over 75ys and 
is the most preventable cause of stroke. AF is the most common reason for taking 
Warfarin an anti-coagulant which was approved for use in 1954 (Pink et al., 2011). 
It is estimated that in the first year of a stroke, the cost of an AF patient to the NHS 
is £11,900 (Bauer, 2013; Folkerts et al., 2019). 
Atrial Fibrillation requires lifelong treatment with oral anticoagulation therapy with 
many patients requiring surgical intervention for heart rate or rhythm control: 
pacemakers or mechanical heart valves, (OAT) (Worrall et al., 2018). Managing a 
patient on OAT is often multi-faceted as other medical conditions, such as diabetes 
mellitus, heart failure and hypertension are commonly present (Dagan et al., 2018, 
p1534). Concomitant drugs, age, mental capacity, diet and lifestyle also need to be 
taken into consideration (Patel et al., 2019, p912). Ongoing support, education and 
monitoring of OAT is usually conducted in a clinic setting, with the involvement of 
medical professionals such as anticoagulation nurses, doctors and medical 
scientists.  
Usually when a patient is first prescribed Warfarin, a baseline measurement of the 
patient’s Prothrombin Time (PT) and Internationalized Normalized Ratio (INR) is 
taken. The induction dose of 10mg daily for the first 2 days is then administered with 
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regular monitoring of the patient’s Prothrombin Time (PT) and Internationalized 
Normalized Ratio (INR) conducted.  
Primarily, these clinics focus on educating the patient in identifying and monitoring 
indicators of their disease. They provide information on how food, especially those 
rich in vitamin K such as green leafy vegetables, drugs (both prescribed and 
recreational) and lifestyle choices, such as excessive alcohol consumption, can 
affect Warfarin’s very narrow therapeutic and prophylactic range (Kayyali et al., 
2019, p425).  Also, of major concern to clinicians is non-compliance which may 
increase or decrease the patient’s INR. Very poorly managed INR patients may be 
seen as often as weekly in a hospital out-patient clinic setting. An effective clinic for 
testing the patient’s INR usually requires laboratory staff, coagulation testing 
equipment with reagents and a specialist nurse. A specialist medical professional 
such as a consultant must also be on hand to make dosage amendments, to order 
further testing, reversal of Warfarin, or in some cases make hospital admissions.   
Figures released by the Department of Health in 2013 revealed that poor 
management of anticoagulation in AF patients has resulted in 7,000 preventable 
strokes and the preventable loss of 2,100 lives each year in England alone 
(Constitution, 2013). Therefore, finding an alternative to Warfarin which is easier to 
manage was deemed a priority. This was achieved in 2010 when three novel 
anticoagulants where approved for use. These anticoagulants are referred to 
collectively as Direct Oral Anticoagulants (DOACs) previously called Novel Oral 
Anticoagulants (NOACs)  (Connolly and Spyropoulos, 2013). 
 
1.2 Oral Alternatives to Warfarin    
There are now 4 main Warfarin substitutes (DOACs) available on the market 
(Apixaban, Dabigatran, Endoxaban and Rivaroxaban). DOACs have a short half-
life, a rapid onset of 2.5 to 4 hours (as opposed to Warfarin which requires 4 to 7 
days for an optimal effect), have minimal drug and food interactions, and do not 
require bridging. Bridging is the use of short-term, interim anticoagulants such as 
heparin when an oral anticoagulant has to be stopped, for example in pre-surgical 
procedures. Bridging is commonly used as a Warfarin replacement during medical 
and surgical procedures, as even temporarily stopping Warfarin may result in the 
formation of blood clots which can lead to strokes. Dabigatran and other DOACs 
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have a predictable anti-coagulant effect and are pharmacokinetically stable, in 
contrast to Warfarin (Baglin et al., 2006; Chen et al., 2019).  
 
1.3 The Structure of this Thesis  
This study sought to ascertain the quality of life changes in patients with AF and 
over 65 years of age who had been asked to switch from Warfarin to DOACs. It 
comprises eight chapters including this introductory chapter.  
Chapter 2 focuses on the current scientific research and highlights issues relating 
to Warfarin, direct oral anticoagulants and the rationale and decision making 
pathway for choosing one method of anticoagulant over the other. It also looks 
briefly at the role of patient responsibility and treatment.  
Chapter 3 discusses the qualitative research approach employed, the sample size 
its composition and the data collection methods used. It justifies the data analysis 
methods and explains how the data was collected. Also explained are the scale 
instruments used to determine the patients’ current health and perceived stress self-
assessment.  
Chapter 4 sets out the information governance and ethical approval process 
undertaken in order to fulfil the permissions and indemnity insurance requirements 
at the University of Westminster as well as the site of study – St Mary’s Hospital, 
Paddington. Also included are the legal requirements for the storage and 
transportation of patient information.  
Chapter 5 – Findings One – reports the qualitative findings of the first interviews 
with twenty patients at the time of the switch from Warfarin to a new anticoagulant. 
It explores their perceptions of their own health and stress levels before they 
switched, and their understanding of the need to change medication. Several 
themes emerged from the data that informed the subsequent data analysis.  
Chapter 6 – Findings Two – reports on the material which emerged from the second 
interview with the same patients undertaken at 90 days after the switch of their 
medication regime. The original themes are elaborated on and findings clarified. 
The findings from the staff interviews are also described here.  
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Chapter 7 – Findings Three – reports on the findings emerging for the scale data 
administered to 56 patients at three points: at the time of the switch-over, and then 
at 30 and at 90 days afterwards. These findings support the themes emerging from 
the interviews.  
Chapter 8 is the discussion and conclusions chapter which concludes the thesis 
with a summary of the findings as well as recommendation for the improvement of 
services for the elderly population. This includes, but is not limited to, patients who 
have Atrial Fibrillation.  
Chapter 9 offers a self-reflection of the author’s journey through this professional 
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2.0 Literature Review Introduction   
During the 1920’s, farmers in the town of Wisconsin noticed that local cows were 
sometimes bleeding to death, often due to minor or unexplained injuries. An 
investigation followed, and it was determined that the haemorrhaging was caused 
by the cows eating mouldy sweet clover plants (Attaya et al., 2012). Later in 1948, 
scientists showed that the haemorrhagic property of the plant was coumarin. This 
compound was then extracted, synthesised, and sold as rodenticide until 1954, 
when it was marketed for human use as the oral anticoagulant Warfarin 
(Pirmohamed, 2006). Warfarin quickly become the most commonly used oral 
anticoagulant and stroke prevention medication in the world (Scully, 2002). Warfarin 
remained the primary prescribed stroke prophylaxis for 56 years until 2010 when 
the first safe comparable alternative was found (Davis et al., 2012).  
  
2.1 Atrial Fibrillation     
The heart is made up of four chambers, two on each side of the heart (Figure 2.1 
below). The two chambers on top are referred to as the atria (singular atrium), and 
the chambers below are referred to as ventricles (Steffel et al., 2018). Separating 
the left side and the right side of the heart is a thick wall of muscle referred to as a 
septum. The muscular walls of the atria relax to allow blood into the heart, then 
contract tightly to pump blood into the ventricles and from there out of the heart and 
around the body (Forslund et al., 2018). 
    
Figure 2.1    
Diagram of the heart  
(Hohnloser, et al., 2000)    
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The contracting of the ventricles allows for the relaxing of the atria, which then fill 
again with blood (Baglin et al., 2006). This pattern, referred to as the sinus rhythm 
or the heart rate, is repeated approximately 60 to 100 beats per minute when a 
normal, healthy person is at rest. The direction of the flow of blood is controlled by 
heart valves (mitral, tricuspid, aortic, and pulmonary). These valves open and close 
quickly to stop the blood from flowing backwards (Mitchell et al., 2019, p6-7).  
Atrial Fibrillation (AF) in which the heart beats can be as much as can be as much 
as 200 to 600 beats per minute, is a very common heart condition which occurs 
when the natural pacemaker of the heart is interrupted by abnormal electrical 
impulses in the atria, see Figure 2.2 and 2.3 below.  
     
Figure 2.2 
Atrial Fibrillation (Connolly et al., 2009) 
  
  
Figure 2.3  
Atrial Fibrillation (Connolly et al., 2009) 
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AF symptoms are usually headaches, dizziness, tiredness, and shortness of breath. 
Some patients may be unaware of these symptoms which can last a few seconds 
or a few minutes (Fuster et al., 2006). The abnormal, irregular, and rapid heart 
rhythm often leads to the formation of blood clots inside the chambers of the heart, 
which is the leading cause of a stroke (see Figure 2.4). Untreated AF can lead to 
stasis of the blood (pooling) and clot formations in the heart, as blood is not 
completely pumped out of the heart chambers. If the resulting clot breaks away and 
travels to the blood vessels supplying the brain then there is a reduction in oxygen 
and nutrient supply which can lead to an ischemic stroke (Pirmohamed, 2006).  
    
Figure 2.4 
Image of the route of a stroke   
(Healthjade.com, 2017) 
 
Almost two-thirds of all stroke survivors have a life-changing disability because of 
their stroke. In Atrial Fibrillation patients, 20% are fatal and 60% are disabling. The 
social care costs and NHS costs associated with stroke treatment are approximately 
£1.7 billion. Therefore, investing in stoke prevention measures is important not just 
for reducing the number of stroke patients, but also the cost to the NHS (Camm et 
al., 2012). Stroke is the fourth single leading cause of death in the UK (See Figure 
2 below). The incidence of strokes in black people is double that in non-blacks 
(Mabley et al., 2019). Stroke is also the leading cause of disability in the UK (Ware, 
2004). 
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The initial treatment for AF is focused on controlling the rate of the fibrillation. This 
is usually achieved with heart rate control medicines, such as Diltiazem (Cardizem) 
which is a calcium channel blocker, Metoprolol (Lopressor) which is a beta blocker, 
or Digoxin (Lanoxin). The second line of AF treatment is focused on prescribing 
lifelong anticoagulation (blood thinners) to prevent the formation of clots, and 
therefore minimise the patient’s risk of suffering a stroke. The risk of stroke in AF 
patients is age dependent with the risk increasing with age (Lip and Halperin, 2010). 
Common causes of AF are excessive alcohol consumption, hypertension, physical 
inactivity, diabetes, smoking, thyrotoxicosis (over-active thyroid) and heart valve 
disease. (Connolly et al., 2009). 
Warfarin has been the prescription of choice for stroke prevention since 1954, 
despite all its known drug and food interactions, and has been proven to reduce the 
risk of stroke by 65% (Baglin et al., 2006; Shamloo et al., 2019). A survey carried 
out in 2014 showed that there were 1.2 million people in the UK on Warfarin, 
resulting in 17 million out-patient appointments per year for Warfarin levels (INR) 
monitoring (Wenger, 2002; Patel et al., 2019). Warfarin monitoring is essential to 
ensure patient compliance in taking the medication. In the event of a major bleed 
there are effective, proven drugs for the reversal of Warfarin.  
Negative characteristics of Warfarin include:    
• High maintenance  
• Affected by foods rich in vitamin K  
• A very narrow therapeutic index  
• Many drug interactions   
• A slow/delayed pharmacodynamic onset  
 
There is published evidence that describes the association between known 
modifiable risk factors, underlying conditions, and the development and progression 
of AF (Cutler et al., 2014) see Figure 2.5 below. Early management of underlying 
conditions to improve AF outcomes may provide perspective on the implementation 
of tailored AF management in daily clinical practice, as all these underlying issues 
as well as comorbidities have an impact on the patient’s perception of their well-
being.  
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Figure 2.5  
Risk Factors and underlying Comorbidities of Atrial Fibrillation  
(Shamloo, et al., 2018)  
  
Taking Warfarin has a significant impact on an individual’s life as it requires complex 
organisation, which has both drawbacks and benefits, (Clemens et al., 2013). For 
example, the required regular monitoring may have an impact on planned activities 
such as holidays that last more than 3 or 4 days. The social impact of clinic 
attendance for the over 65s may also be significant as they often have transport 
arranged by the hospital for the day and may need to arrange other non-Warfarin 
related hospital appointments for the same day. On the positive side, the visit to the 
clinic has social benefits, often resulting in long conversations with other patients or 
with the health professional conducting the blood test (Camm et al., 2012).  
2.2 Recent Publications   
When this study began six years ago there were few publications examining the 
patient’s perspective of life on Warfarin or the new anticoagulants. However, more 
recently, a few papers have appeared in the medical press. None, however, 
interviewed their respondents over time or enquired into daily life on their 
medication. Attaya et al., (2012)  surveyed patients 18 years and over about their 
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willingness to switch from Warfarin to other anticoagulants. The research method 
was a ‘one off’ self-completion questionnaire with no face to face patient contact. 
Elewa et al., (2014) looked at patient satisfaction on Warfarin and Dabigatran using 
a short questionnaire administered in outpatients. No interviews were undertaken.  
Pink et al., (2009) argued that the Quality of Life of AF patients is significantly lower 
than the general population or those with other types of coronary diseases. A review 
of Quality of Life studies conducted with elderly patients with AF in 2008 confirmed 
that there was a ‘poorer Quality of Life among patients with AF compared to age 
matched population’ (Lane and Lip, 2009, p243). Just over 26% of patients older than 
65 may forget to take Warfarin, or accidentally take the dosage twice (Wang et al., 
2014). This finding is also reflected in a patient compliance study carried out by 
Kumar et al., (2014), which showed that there are several socio-economic factors 
which influence compliance for taking long term medicines such as Warfarin. Such 
factors include diet, exercise, and alcohol consumption, as well as a network of 
support from friends and family.  
Several other randomised control studies have explored Quality of Life (QoL) in AF 
patients, and appear to support the claim that the QoL of AF patients is significantly 
lower than that of the general population or of those with other types of coronary 
diseases. These surveys are as follows:    
• The Atrial Fibrillation Follow-up Investigation of Rhythm Management 
(AFFIRM) study (Jenkins et al., 2005);    
• Results from the Rate Control Versus Electrical Cardioversion (RACE) study 
(Hagens et al., 2004);     
• Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial 
(Hohnloser et al., 2000);    
• The Strategies of Treatment of Atrial Fibrillation (STAF) study (Carlsson et al., 
2003);     
• How to Treat Chronic Atrial Fibrillation (HOT-CAFÉ) (Opolski et al., 2004). 
However, these studies compare cardiac rhythm control methods, such as cardiac 
ablation (inserting a catheter into the heart to destroy small areas which may be 
causing the disruptive signals), cardioversion (using electrical shocks similar to a 
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defibrillator to re-introduce a synchronized heart rhythm) or rate control medicines 
such as Digoxin or Dronedarone (Camm et al., 2012). The long-term impact of the 
Quality of Life of patients who switch from Warfarin to DOAC has not been studied, 
most studies exploring short-term perceptions. A study conducted in Chicago by 
Attaya et al., (2010) attempted to examine patients’ attitudes towards the new 
DOAC in a survey entitled SWITCH. 180 patients were invited to take part in the 
patient survey; uptake was 86% with 155 patients participating. Of these 56% 
declined the use of the DOAC’s due to various reasons including lack of information, 
as well as a lack of monitoring and effective reversal mechanism (Rottenstreich et 
al., 2018). The patient survey also revealed that women were less likely to use the 
DOACs than men, but that the elderly patients (over 70 years old) were more likely 
to use the DOAC as a long term oral anticoagulant. Garcia et al., (2009) reported 
that the risk of haemorrhages and stoke in AF patients was greatly reduced when 
Warfarin was substituted for the DOAC. The creatinine clearance (CrCl) rate for the 
DOAC patients showed dramatic improvements as well, for example in the 
RECORD study the CrCl increased from 30 to 49ml/min clearance. This is 
significant as these DOACs rely on good renal functionality for effectiveness and 
excretion.  
Since 2014, a series of patient-reported health survey studies have been 
conducted, involving AF patients who had switched from Warfarin to a direct oral 
anticoagulant (DOAC), each looking at a different perspective. One such study 
looked at the convenience of taking DOACs by asking a series of patient 
satisfaction questions via a survey (Choi et al., 2014). Several papers looked at 
the patience perception of adherence and how this impacts on their willingness to 
switch given a choice (Di Minno et al., 2014; Pandya and Bajorek, 2017; Auyeung 
et al., 2016). Other papers looked at the cost to the NHS including the Folkerts 
study, which used a Markov model to examine the impact of healthcare costs 
(Briere et al., 2019). A Canadian study conducted by Gomes et al., (2012) 
concluded that for Warfarin patients 66 years or older the rate of bleeding over a 
13-year period was 3.8% per person per year. The study also showed that there 
was 1% rate of bleeding with Warfarin patients in the first 30 days of the Warfarin 
treatment. The study also found that 20% of all Warfarin patients who were 
admitted for a bleed died in hospital or very shortly after leaving hospital (Gomes 
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et al., 2013). Usually in elective surgical procedures, patients on Warfarin are 
advised to stop taking the prescribed dose at least 3 days before the surgery. In 
an emergency surgical situation, or in cases of Warfarin overdose, the bleeding 
related effects of Warfarin can be reversed with the administration of Prothrombin 
Complex Concentrate (PCC) in the first instance, Fresh Frozen Plasma (FFP) as 
a second option, and thirdly intravenous Vitamin K (Baglin et al., 2012; Keeling et 
al., 2011; Millar and Laffan, 2017).  
This recent interest in the patient’s perspective of their treatment is to be welcomed 
and demonstrates that their views are increasingly valued and seen as contributing 
to the general knowledge base around this subject (Elewa et al., 2014). The current 
study would still appear to be unique in that it alone has combined qualitative 
(interviews) and quantitative (questionnaire / scales) data in its design. In addition, 
the patients were met at three points in time and focused on non-clinical factors.   
 
2.3 Cost of Atrial Fibrillation to the NHS    
For some time, Aspirin has been used as an alternative antiplatelet for patients with 
an adverse reaction to Warfarin, who cannot take Warfarin, or who have poor 
compliance with Warfarin (Sconce et al., 2005). In 2011 the British Society for 
Haematology (BSH) released guidelines which recommended stopping the routine 
use of aspirin as an anticoagulant for patients with atrial fibrillation (Bauer, 2011). 
Subsequently, a study into the cost of switching was commissioned (Cowie, 2014). 
The clinical experts involved in the study considered not only the stroke prevention 
rates as a result of switching, but also considered other factors such as the on-going 
difficulties some patients experience with adherence to the Warfarin dosage regime, 
especially as the dosage for some patients who do not cope well on Warfarin may 
require monitoring and dosage adjustments (NICE, 2012).   In June 2014, The 
National Institute for health and Clinical Excellence (NICE) looked at the costing per 
year implications of patients in the United Kingdom who were on Warfarin and those 
who switched from Warfarin to DOACs. The estimated cost per patient for one year 
for a patient on Warfarin at the time was £283. This includes the cost of monitoring 
the patient (See table 2.1 & 2.2 below). It is estimated that 2.5% of people will 
continue to take aspirin against the BSH’s recommendations.  
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Treatment  Percentage 
of population  
Number of 
people (000s)  
Warfarin  34.32%  305  
Aspirin  22.49%  200  
Dabigatran etexilate  4.73%  42  
Rivaroxiban  4.73%  42  
Apixaban  4.73%  42  
No treatment  28.99%  258  
Table 2.1  




Treatment  Annual Cost of Treatment (£) 
Warfarin (including monitoring)  283  
Aspirin  32  
Dabigatran etexilate  802  
Rivaroxiban  767  
Apixaban  802  
Table 2.2  
Annual cost of treatments for Atrial Fibrillation 
http://www.preventaf-strokecrisis.org/report/chapter4  
 
The increase in drug cost resulting from switching from Warfarin to DOACs is 
significant, especially when taking into consideration the size of the population 
involved. It is estimated by the panel of experts involved in the study on the cost 
implications of switching, that the change in anticoagulation treatment would result in 
a major bleed in 3 out of 100,000 people (Till and Cowie, 2014). This would result in 
an increased cost of £4,000 per 100,000 people to the NHS (Department of Health, 
2013). The daily cost of Dabigatran, Apixaban and Rivaroxaban in the community is 
approximately £2.60 and in hospital £1.60. The daily cost of Warfarin (drugs + 
monitoring and dosing etc) is between £0.67 - £0.83 (Shah and Gage, 2011; 
Healthjade.com, 2017). It is also estimated that the cost of the newer drugs to the 
NHS will increase as more people are being offered them. However, the cost of the 
giving the newer anticoagulants may be offset by the reduction in cost due to fewer 
atrial fibrillation patients experiencing a stroke or AF-related hospital visit 
(Scowcroft and Cowie, 2014). In addition, savings will be gained from the reduced 
   
32  
Student ID: W10503030 v8 – 05/08/2020 
anticoagulation clinic service, which would not be needed for DOAC patients. As a 
result the resources, financial and otherwise, that would have been spent on 
Warfarin, atrial fibrillation and the stroke related events (including secondary care 
providers and community nursing for these patients) can be reallocated to other 
areas of priory medical services such as cancer (Camm et al., 2012).   According 
to the West Hampshire Clinical Commissioning Group, in January 2017 there were 
106,000 patients in the West Hampshire area over 65 and 16,000 over 85. Of these 
it was estimated that 2,000 patients had undiagnosed AF, 12,000 had diagnosed 
AF and 10,500 patients with AF had a high risk of a stroke. Surprisingly 3,700 
patients in this area were on no form of anticoagulation.  
 
2.4 Pivotal Papers – Anticoagulation Policy Determinants    
There are two key papers that directly influence this study as they were the principal 
safety and efficacy studies conducted comparing Warfarin with DOACs. The results 
of these two studies formed the basis of the decision from the National Institute for 
Health and Clinical Excellence (NICE) to introduce a new Warfarin alternative to the 
National Health Service for the treatment of AF patients. The first paper was on the 
RE-LY randomized control trial which compared Warfarin with Dabigatran in 18,113 
patients with AF, using the two recommended doses of Dabigatran 110mg or 150mg 
twice daily (Connolly et al., 2009). The study found that Dabigatran performed as 
well as Warfarin at 110mg with a lower haemorrhagic rate of 2.71% for Dabigatran 
and 3.36% for Warfarin (Ganetsky et al., 2011). Conversely the 150mg dose of 
Dabigatran had a lower rate of stroke and embolus formation compared with 
Warfarin patients, but a similar rate of haemorrhage. The higher dose of Dabigatran 
was also linked to a series of intracranial haemorrhages (ICH). There is still limited 
information available relating to these bleeding events. 57% of the patients on 
Dabigatran continued with the Direct Oral medication after the bleeding event 
(Connolly et al., 2009) 
The second paper was the ROCKET-AF study (Executive Steering Committee 
2010), which looked at treatment of Non-Valvular Atrial Fibrillation. It involved 
14,264 patients with non-valvular AF and compared Warfarin to Rivaroxaban. This 
was conducted using the two doses of 20mg daily and 15mg daily Executive 
Steering Committee 2010. The ROCKET study determined that in patients with AF, 
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Rivaroxaban was noninferior to Warfarin (i.e. performs as well as Warfarin) for 
stroke and embolism prevention. The study also showed no significant between 
group differences in the risk of major bleeding. The findings from the ROCKET study 
was later substantiated in 2014, by two research cardiologist looking at stroke 
identification and prevention in the International journal of cardiology (Scowcroft and 
Cowie, 2014). At about the same time, Camm et al., (2011) on behalf of the 
European Society for Cardiology (ESC) wrote guidelines on the safe use, dosage, 
long term management and contraindications for the use of DOACs. These 
guidelines brought together coagulation specialist representatives from eight 
European countries to decide how and when the new DOACs should be used, and 
in what circumstances Warfarin patients can be switched safely to DOACs. They 
also suggested a follow-up 90 days post DOAC substitution and suggested that this 
follow-up be performed by a clinician or medical professional in a locally arranged 
agreement.  
As these DOACs currently have no routine mode of monitoring, testing or reversal, 
each NHS and primary care trust must use local arrangements to decide on the 
implementation of their own local anticoagulation arrangements according to the 
guidelines and their resources. The most practical and cost-effective solutions were 
considered. This resulted in a scoring system known as the CHA2DS2-VASc score 
(congestive heart failure, hypertension, age which has 3 age ranges (<65, 65-74 
and ≥75), diabetes mellitus, stroke vascular disease history and sex (Ruff, 2011). 
This will be discussed in more detail later. Heidbuchel et al., (2013) wrote a practical 
guide on behalf of the European Heart Rhythm Association (EHRA). A key 
suggestion from their work was the use of a patient card (see Figures 2.6a&b. 
below), to record the scheduled and unscheduled visits of the health professional 
or clinician to the patient during a follow-up. This card would then be used as clinical 
notes in the event of an adverse event such as a bleed or emergency surgical 
intervention to calculate information such as dosage, the most recent time the 
tablets were taken, etc., in order to assert the half-life and therefore the likelihood 
of a major bleed.  
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   Figure 2.6a (front)  
Atrial Fibrillation Oral Anticoagulation Card (Camm, et al., 2011)  
  
 
Figure 2.6b (back)  
Atrial Fibrillation Oral Anticoagulation Card (Camm, et al., 2011)  
  
On a similar theme, a three month survey entitled Study of Warfarin Patients 
Investigating Attitudes Toward Therapy Change (SWITCH Survey) was conducted 
in Chicago (Attaya et al., 2012). It examined the attitudes of life-long Warfarin 
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patients towards the new DOACs, to assess whether patients would be interested 
in switching from Warfarin to the new drugs. One hundred and eighty patients were 
offered a place on their patient survey; the uptake was 86%, with 155 patients 
participating. Of these, 56% declined the use of the DOAC’s for various reasons, 
including lack of information and cost, as well as monitoring and the absence of an 
effective reversal agent. The survey also revealed that women were less likely to 
use the DOACs than men, and that patients over 70 years old were more likely to 
use the DOAC as a long term oral anticoagulant (Attaya, et al., 2012). Patients on 
life-long Warfarin have commonly cited the negative social impacts on their Quality 
of Life. These include the regular need for clinic trips for blood testing, dietary and 
alcohol restrictions, increased stress, and anxiety from the increased risk of 
Warfarin-associated bleeds and drug interactions with concomitant drugs (Lip and 
Halperin, 2010). Their study, although valuable, showed that there are gaps in the 
literature regarding the impact of the medical, social, and personal implications to 
the QoL of patients who switch. The social and personal implications of any 
treatment are important (Frendl and Ware Jr, 2014), but are virtually unexplored for 
the over 65s. Research has already demonstrated the vital role of patient 
information provision to compliance and other areas of treatment, as well as in 
treatment outcomes (McNaughton and Shucksmith, 2015; Horne et al., 2005; 
Horne, Robert and Weinman, 1999).  
One such example is an article from the Journal of Public Health in which the paper 
determined that ‘sustained compliance was due, in part, to a number of individuals 
being afforded the opportunity to reconFigure their medications’ and ‘indicates that 
patients experiencing side effects…. are more likely to remain adherent if GPs are 
willing to listen to their concerns and review medication’ (McNaughton and 
Shucksmith, 2015, p124). Therefore, the more that is known about the challenges 
of switching treatment for the over 65s, the better able healthcare providers and 
clinicians will be to help patients achieve effective treatment. In addition, it is known 
that the written information (supplied by the pharmaceutical company) given to the 
patient may vary in amount and quality. Patients often enquire about information 
regarding their personal medical situation (Bauer, 2011), therefore, it is important to 
investigate the patient’s perception of the information source or information given to 
them as well as any other factors that might raise. Garcia et al., (2009) looked at 
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bleeding outcomes and reported that the risk of haemorrhages and stoke in atrial 
fibrillation patients was greatly reduced when Warfarin was substituted for the 
DOAC. He also looked at co-morbidities such as renal function and noted that the 
creatinine clearance (CrCl) rate for the DOAC patients showed dramatic 
improvements as well. For example, in the RECORD study the CrCl increased from 
30 to 49ml/min clearance. This is significant, as these DOACs rely on the renal 
functionality for effectiveness and excretion.  
The existing literature explores the many complexities and challenges faced by the 
elderly on lifelong medications such as Warfarin. These include concomitant 
therapies, clinic visits for monitoring and adjustments of the medication, and 
logistical challenges such as transportation of the patient to and from hospital. The 
literature, however, does not explore the patients’ perceptions of being on Warfarin 
or of switching from Warfarin to the Direct Oral Anticoagulants (DOACs).  
2.5 Direct Oral Anticoagulant Patient’s Review.    
The assessment criterion when selecting patients for initiating or substituting 
prescription medication involves the balancing of risk versus benefit (Connolly and 
Spyropoulos, 2013). Currently there are no routine monitoring tests for DOACs, and 
routine coagulation parameters such as the prothrombin time (PT) which is used to 
measure Warfarin, thrombin time (TT), and activated partial thrombin time (APTT), 
have limited diagnostic value in measure the DOACs (Connolly and Spyropoulos, 
2013; Ganetsky et al., 2011). There are also variations in sensitivities of different 
laboratory reagents to the DOACs (Ganetsky et al., 2011). At the start of this study, 
there were also no key policies governing testing, reversal, monitoring, or reference 
ranges of DOACs (Baglin et al., 2006). A select number of specialised laboratories 
now offer testing of DOACs (Patel et al., 2019), but testing is still not universally or 
routinely offered. Baglin et al., (2012) suggested that the use of a reference range 
should consider the dose-dependent reactions of DOAC to laboratory routine clotting 
tests. The absence of a test or reference range can complicate medical decisions for 
patients, especially pre-operatively for DOAC patients or in emergency situations, 
such as in the event of a major bleed (Martin and Moll, 2016).  
There is a concern within the scientific community with the lack of data which 
addresses what happens with non-compliance. As with Warfarin, sometimes 
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patients for a variety of reasons, such as simply forgetting or feeling unwell, do not 
take their medication. Having conducted a database search on the safety and 
efficacy of DOAC administration at extremes of patient body weight, no such 
literature could be found. There are, however, several articles which address the 
cost to the National Health Service as well as the implications of renal impairment 
(Baglin et al., 2012). 
According to a review on the DOACs by Connelly et al., (2013), the predictability of 
the new drugs’ pharmacokinetics as well as their rapid onset makes the DOACs 
very appealing to both patients and clinicians. As stated above, the unpredictability 
of Warfarin as well as the variability of the doses and the many interactions with 
food, alcohol and other medications has been a considerable problem for patients 
and clinicians over the years (Lip and Halperin, 2010). 
The variation in modes of action for each of these new drugs is the main focus of a 
paper by Schulman et al., (2011). Potentially it will become very expensive if 
hospitals stock all three new agents as well as the currently used anti-coagulation 
agents such as Fondaparinux, Enoxaparin and the various forms of Heparin (as low 
molecular weight heparin, LMWH, and unfractionated heparin, UFH) which all have 
different modes of actions (Mani, 2014). Warfarin stops the formation of clots by 
interfering with a set of vitamin K dependent blood clotting factors in the body. 
However, the new DOACs work by targeting and blocking a single coagulation 
factor within the coagulation pathway. For example, Apixaban, Rivaroxaban 
(Xarelto®) and Edoxaban all work on activated Factor 10 (FXa) to prevent 
coagulation from progressing past this point in the pathway (cascade), as shown in 
Figure 2.7 below. 
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Figure 2.7  
Mode of action of Anticoagulation Drugs  
(Asselin, 2003)     
 
There are still no approved reversal agents for use in the UK, nor is there a 
requirement for regular medication compliance checking in the form of finger 
pricking or attending clinics. However, the assessment of renal function must be 
regularly checked as the mode of elimination from the body is the kidney. The age, 
sex, weight, other medical conditions of the patient such as diabetes and other 
medications that the patient is on, should also be considered. 
The principle benefits of DOACs are: 
• They are not impacted by dietary vitamin K.  
• They have more consistent pharmacokinetics.  
• There are fewer drug interactions.  
• There is a relatively quick onset of action; and    
• They do not require Heparin administration at the start (bridging).  
DOACs are pharmacokinetically stable and have a short half-life, which is the time 
taken to lose half its effective biological and pharmacological concentration in the 
blood plasma, and this negates the need for routine monitoring (Bauer, 2013). They 
also have a rapid onset of two and a half to four hours as opposed to Warfarin which 
requires four to seven days for optimal effect. This means that DOACs work faster 
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at thinning the blood and leave the blood faster, some within a few hours. Warfarin 
on the other hand, could take at least two to three days to leave the circulation. As 
DOACs leave the circulation so quickly, it is therefore imperative that the patient 
adheres to their daily dose of DOAC. Not taking the daily dose of DOAC may result 
in the patient being prothrombotic, forming clots and thereby increasing the risk of 
a stroke (Mesko, 2014). A full comparison list of Warfarin and DOACs is listed in 
Appendix 12.  
There are several factors which determine whether a patient can take DOACs. 
These include the health condition of the patient, such as atrial fibrillation (but only 
in the absence of heart valve disease), or deep vein thrombosis (DVT) or pulmonary 
embolisms (PE). The ability for the kidney to metabolise and process these 
medications is also considered, and generally would not be offered to patients who 
have poor renal function. If the kidneys are unable to clear these DOACs from the 
bloodstream, they build up in the blood and lead to an increased risk of bleeding. In 
these situations, Warfarin may be a better alternative to DOAC, since Warfarin does 
not require the use of the kidney for metabolism, using the liver instead. Patients on 
DOACs do not require regular prothrombin time and INR monitoring, but will require 
regular monitoring of their kidney function (Pink et al., 2011). The kidneys are 
required for the elimination and excretion of DOACs, therefore periodic assessment 
of the kidney’s ability to function is carried out in the lab. The metric is usually the 
measurement of the rate at which creatine is cleared by the kidneys. This creatinine 
clearance (CrCl) should be >30ml/min. A CrCl of 30-50 ml/min requires close 
monitoring of the patient and the dose of DOACs should be adjusted or halted 
depending on the result of the CrCl. 
 
2.5.1 Dabigatran (Pradaxa®)    
Dabigatran is a direct inhibitor of thrombin (the final intermediate of coagulation), 
has a rapid onset, a predictable anti-coagulant effect and very few drug interactions, 
with the main exception of p-glycoprotein inducers such as Rifampicin which 
reduces the efficacy of Dabigatran through p-glycoprotein induction (Camm et al., 
2012; Folkerts et al., 2019). Dabigatran capsules are made from tartaric acid which 
induces an acidic environment aiding in the rapid intestinal tract absorption of the 
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drug. This often results in the most common side effect of Dabigatran which is 
dyspepsia (Heidbuchel et al., 2013). These capsules are sensitive to moisture and 
therefore need to be kept in their original blister pack and should not be decanted 
into another container such as a Dosette box (shown in Figure 2.8 below). Dosette 
boxes are usually used by older patients to help keep track of multiple daily 
medications.  
 
    
Figure 2.8  
Dosette boxes (Amazon.co.uk, 
2018)  
  
Dabigatran is prescribed as either a 100mg or 150mg dose. The larger dose has 
been shown to cause more GI bleeds than Warfarin as previously mentioned in the 
RELY study. The 110mg dose has been shown to be non-inferior to Warfarin but 
causes fewer intracranial haemorrhages (ICH) (Eikelboom et al., 2011).  
2.5.2 Rivaroxaban (Xarelto®)    
Rivaroxaban has 3 doses: 10mg, 15mg and 20mg and is taken once daily, advisably 
at the same time each day, and is typically the 20mg dose taken with the evening 
meal. Patients wishing to switch or who have been cleared to switch to Rivaroxaban 
must discontinue Warfarin and their prothrombin time and INR monitored. The 
patient may only switch to Rivaroxaban once the INR falls below 3. Other 
anticoagulants such as heparin (often given peri-operatively or post operatively), 
must be discontinued before the commencement of Rivaroxaban. To date there are 
no clinical trial data available for switching from Rivaroxaban to Warfarin. For 
patients who need to be switched from Rivaroxaban to Warfarin, one approach is 
to stop the Rivaroxaban, then give the first dose of Warfarin at the time that the next 
dose that the next dose of Rivaroxaban would have been given, along with a 
parenteral anticoagulant such as heparin or a heparinoid. There are very few 
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interactions with other medications. However, patients who are prescribed 
concomitant drugs which also influence coagulation, such as aspirin and antiplatelet 
medications (e.g. clopidogrel), must be closely monitored.  
There is documented evidence that compared with Warfarin there may be an 
increased incidence of bleeding in patients taking Rivaroxaban. Below are some 
possible side effects of Rivaroxaban:     
• bloody, black, or tarry stools (an indicator of an overdose)   
• pink, or brown urine (an indicator of an overdose)    
• coughing up or vomiting blood or material that looks like coffee grounds (an 
indicator of an overdose)    
• frequent nosebleeds  
• bleeding from the gums  
• heavy menstrual bleeding    
• weakness      
• tiredness    
• headache    
• dizziness or fainting   
• blurred vision  
• pain in arm or leg    
• rash    
• itching    
• difficulty breathing or swallowing   
• hives    
• pain or swelling at wound sites    
    
2.5.3 Apixaban (Eliquis®),  
This medication needs to be taken twice daily. Apixaban has a short duration of 
action. Therefore, if a dose is missed, the patient is at an increased risk of 
thrombosis (clot formations) and stroke. Inversely, for patients who accidentally take 
more than the required dose, they are at an increased risk of bleeding. There is no 
specific reversal or antidote for Apixaban. It is not uncommon for patients on 
Apixaban to experience joint pain, headaches, and bleeds. Since Apixaban is a new 
medication, interactions with the patient’s other medications, as well as side effects 
are being still being discovered as new studies are conducted (Mabley et al., 2019). 
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2.5.4 Edoxaban (Savaysa ®)    
Edoxaban works directly on Factor Xa inhibitors and prevents the triggering of the 
normal clot formations portion (thrombin) of the coagulation pathway. Thrombin is 
the protein portion of the blood needed for the formation of clots and does so by 
trapping platelets and red cells in a mesh, which is referred to as a thrombus (clot). 
By blocking the thrombin formation, this enables the blood to remain fluid and 
Edoxaban is therefore referred to as an oral blood thinner. This drug has a black 
box warning from the Food and Drug Administration (FDA). A black box warning is 
the most serious warning that can be issued by the FDA about a product. This alerts 
clinicians and patients to the side effects of a medicine that can be very dangerous. 
These effects include increased risk of a potentially fatal bleed, increased incidents 
of unexpected bleeding, poor efficacy in AF patients who have good kidney function, 
and an increased risk of stroke or thrombosis if a dose is missed or if the drug is 
stopped. There is no specific reversal for Edoxaban, and there are several non-
steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen, and 
diclofenac, which interact with Edoxaban to increase the risk of bleeding.  
2.6 Review of Aanticoagulation Guidelines  
A systematic review of 36 published consensus guidelines, original and review 
journal articles was sourced from the online databases: PubMed, Cochrane Library, 
SCIENCE DIRECT, MEDLINE, and GOOGLE SCHOLAR. The search was limited 
to the English language and to publications between 2008 and 2017. The online 
critical appraisal skills programme (CASP), was then used to determine the 
usefulness and validity of the papers (Appendix 17). Based on the CASP criteria 31 
articles were included. Five papers were excluded for the following reasons: they 
were not related to the area of atrial fibrillation or did not directly address the 
questions related to the topic of interest. Eight key papers were then selected from 
the 31 for detailed critical appraisal and data analysis. In addition to published 
articles, pharmaceutical package inserts and patient information leaflets were 
reviewed to evaluate information available to the patients about their medications.  
Key search phrases used for the searches were as follows:  
1. Direct Oral anti-coagulants + patient survey    
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2. New oral anti-coagulants + patient survey    
3. Direct Oral anticoagulants guidelines    
4. Apixaban + Rivaroxiban + Dabigatran clinical trials    
5. Quality of life of oral anti-coagulated patients.  
6. Apixaban + Rivaroxiban + Dabigatran laboratory testing    
The same search string was used across each database, initially resulting in 
thousands of searches relating to oral anti-coagulation in post hip replacement 
surgery and hip-revision, pre-dental extraction or background information related to 
Warfarin. Once the filter of ‘atrial fibrillation’ was added then this dramatically cut 
the search outputs to just a few hundred. After this the various databases were 
compared and any duplication of publications was omitted, resulting in 42 papers.  
Five of these papers were reviewed which overlapped in the references cited and 
were omitted. Of the remaining 36 papers (selected based on reading the abstract 
only) five were excluded as they did not meet the CASP criteria. As well as the 
CASP criteria. An example of the CASP criteria can be seen in Appendix 17.    
 
2.7 Review of Quality of life in AF patients    
‘The quality of life is determined by its activities’. - Aristotle  
The well-being of patients over 65 is recognized by the World Health Organization 
as determinant to overall health and Quality of Life (Peterson et al., 2006). The 
WHO defined health as ‘a state of complete physical, mental, and social well-being 
and not merely the absence of disease or infirmity’ (Lip and Halperin, 2010, p127). 
The Quality of Life of the AF patient is therefore impacted by the increased risk of 
stroke and morbidity by these conditions as well as the constant need for 
physiological assessment (Pink et al., 2011; Pirmohamed, 2006; Rottenstreich et 
al., 2018). Hughes et al., (2009) argued that the quality of life of AF patients is 
significantly less than the general population or those with other types of coronary 
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diseases. Several other randomised control studies have been conducted on the 
quality of life (QoL) with AF patients, and appear to support this claim.  
A search of EMBASE, Cochrane Library, SCIENCE DIRECT, MEDLINE, CINAHL, 
and GOOGLE SCHOLAR revealed that there are currently no studies or patient 
surveys undertaken to assess the QoL of AF patients currently receiving DOACs 
apart from the SWITCH survey by Attaya et al., (2010) as outlined above. The 
patient survey also revealed that women were less likely to use the DOACs than 
men, and that the elderly patients (over 70 years old) were more likely to use the 
DOAC as a long-term oral anticoagulant.  
  
2.8 Safety and Efficacy of DOAC    
As with most medicines, there is patient exclusion for the DOACs based primarily 
on their mode of removal, which is via renal excretion (Bauer, 2011). Therefore, 
patients who currently have poor renal function are not allowed to switch from 
Warfarin by the clinical team.  
While no papers relating to allergies and DOACs have been found, there are 
however several sources of information highlighting Dyspepsia (indigestion) as a 
major side effect. These sources include Garcia et al., (2013); Camm et al., (2010) 
and Connelly (2009), as well as the Dabigatran (Pradaxa©) and Rivaroxaban 
patient information leaflet and medication insert. Camm et al., (2009) also 
highlighted other issues surrounding laboratory monitoring such as detecting DOAC 
levels in a suspected overdose, as the current coagulation panel of tests is 
insensitive to the DOACs. The concern is that by the time the level is detected the 
patient may be several times over the therapeutic dose and at risk of a major bleed 
or intracranial haemorrhage.  
 
2.9 Pharmacology of DOACS  
According to a review on the DOACs by Connelly et al., (2013), the predictability of 
the new drugs’ pharmacokinetics as well as their rapid onset, makes the DOACs very 
appealing to both patients and clinicians. Unpredictability of Warfarin as well as the 
variability of the doses and the many interactions with food, alcohol and other 
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medications has been a considerable problem for patients and clinicians over the 
years. Direct Oral anticoagulants for stroke prevention in non-valvular AF has been 
greeted with excitement by the scientific and medical community. They offer several 
benefits such as the rapid onset of action, broad therapeutic window, renal excretion, 
fixed dose administration, minimal monitoring (generally 2 follow ups), before a life-
long prescription is issued to the patient. The ease of use by the patient, and the 
stability of the drugs pharmacokinetics are all also significant bonuses. DOACs also 
have a short half-life and have minimal known interactions with food and concomitant 
medications as does its predecessor Warfarin. However, there is limited knowledge 
of long term use of these drugs due to their novelty, and several issues exist 
regarding a lack of effective antidote, as well as a routine diagnostic test to be used 
in the case of a bleeding event or unplanned surgical intervention. My thesis will 
attempt to address some of these issues as well to gain a unique patient perspective 
on the medium-term use of these drugs.  
 
2.10 Literature Review of Stroke     
A stroke is a serious life-threatening condition and occurs due to the disruption of 
the blood supply to the brain. The blood supply the brain provides oxygen and 
nutrients to the brain as well as removing the waste materials produced by the 
brain’s activity. A reduction of blood or disruption to the supply of blood to the brain 
therefore leads to loss of brain cells and tissues which relies on the blood supply. 
There are two types of strokes, ischemic and haemorrhagic (Figure 2.9). Ischaemic 
stokes occurs when the blood vessels are blocked. This blockage may result from 
the narrowing of blood vessels caused by: (a) increased plaque formation from 
cholesterol (lipids) or calcium or nicotine in the blood vessels, a condition known as 
atherosclerosis; (b) clots (thrombus) in the blood vessel, a condition known as 
thrombosis; or (c) narrowed blood vessels due to disease.    
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Figure 2.9  
Types of strokes  
(Lip & Halperin, 2010)  
  
  
There are two types of Haemorrhagic stroke: intracerebral and subarachnoid. 
Intracerebral haemorrhages occur when there is leakage of blood from the 
circulatory system into the brain. This leakage usually results from ruptured blood 
vessels, or a brain aneurysm burst. This collection of blood around the brain results 
in swelling and increased pressure, which damages the cells and tissues of the 
brain. Subarachnoid haemorrhagic stroke is the term used to describe when the 
bleed occurs between the brain and the tissue covering the brain, known as the 
subarachnoid space. Haemorrhagic stroke is less common than ischaemic strokes 
as only 15% of all strokes are haemorrhagic. However, 40% of all stroke deaths are 
related to haemorrhagic strokes.  
Risk factors which increase the likelihood of a stroke occurring include diet (high 
cholesterol and fat), obesity, illnesses, drug use (nicotine and cocaine) and some 
birth control medication. The risk of a stroke increases 5- to 7-fold following AF 
(Ganetsky et al., 2011), and this risk is further increased by compounding factors 
which are scored and used as a predicative index of stroke - the CHA2DS2-VASc 
score as mentioned above (based on congestive heart failure, three age ranges, 
sex and co-morbidities (Ruff, 2011), see Figure 2.10.        
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Figure 2.10  
Stroke Risk Factors – CHA2DS2-VASc Score  
(Pisters, et al., 2010)  
  
The CHA2DS2-VASc score is used in conjunction with the HAS-BLED score  
(hypertension, abnormal renal and liver function, stroke, bleeding history, labile INR 
(the measurement unit of Warfarin), elderly >65, and drugs and alcohol 
concomitantly (see Appendix 10). The HAS-BLED score is essentially an estimate 
of the risk of a major bleeding occurrence in patients who have AF. This is done by 
assigning a score to each risk factor, then adding them together to get a predictive 
risk value. The higher the value, the higher the risk of a stroke event. See Figure 
2.11.  
    
Figure 2.11  
Bleeding Risk Factors -HASBLED Score  
(Pisters, et al., 2010)  
  
2.11 Ischaemic Stroke and morbidity    
In 2013 Public Health England determined that ischaemic stroke is the third largest 
cause of mortality in the country (National Audit Office, 2013). Results from a meta-
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analysis of 33 studies showed that Warfarin-related complications are the third most 
common cause of all hospital admissions in the UK (Pink et al., 2011; Pirmohamed, 
2006; Mitchell et al., 2019). This is partially due to its narrow therapeutic window 
and multiple interactions with concomitant drugs and food, as well as its well 
documented side effects. The study, which analysed 6554 patients, also discovered 
that AF patients’ INR was outside their target range for almost 50% of the time. 
Being above the INR range results in a threefold increased risk of a haemorrhage 
and being below the INR range results in an increased risk of clot formation 
(thrombotic event) (Pirmohamed, 2006 and Mabley et al., 2019). 
 
2.12 Warfarin    
Clotting or blood thickening is a particularly complex process that involves many 
proteins or substances called clotting factors. These clotting factors are primarily 
produced by the liver. When a cut or bleeding occurs, clotting factors are activated 
by platelets. A domino effect of these clotting factor proteins is then initiated which 
results in the formation of a stable clot, therefore stopping the bleed. The liver needs 
a healthy supply of vitamin K rich foods to produce these clotting factors.  
Warfarin works by inhibiting vitamin K dependent coagulation factors (F) such as 
FII, FVII, FIX & FX. Warfarin also inhibits two co-factor anticoagulant proteins known 
as Protein C and Protein S. See Figure 2.7. As mentioned above, in the normal 
clotting process vitamin K in its reduced form is required for clotting; Warfarin 
prevents vitamin K from being reduced therefore preventing the clotting process. 
Warfarin does not, however, reverse the effects of already synthesized and 
circulating clotting factors.  
As Warfarin also reduces the activity of the anticoagulant proteins C and S, the 
patient may become hypercoagulable and prone to the formation of clots shortly 
after the initiation of Warfarin. Therefore, in some situations, such as following an 
emergency surgical intervention, the initiation of Warfarin should be given with 
heparin (Baglin et al., 2012). This is known as ‘bridging’. As concomitant heparin 
can affect the laboratory tests for Warfarin, the use of heparin is usually discontinued 
at least six hours before monitoring of Warfarin is conducted.  
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Vitamin K rich foods tend to be green fruits and vegetables such as those shown in 
Figure 2.12. Patients who are prescribed Warfarin are advised to monitor their 
intake of these sources of vitamin K as they interact with Warfarin to produce an 




Figure 2.12  
Vitamin K rich foods 
(Healthjade.com, 2017)   
Most often Warfarin is prescribed as prophylaxis for the primary prevention of stroke 
or following a stroke as secondary prevention. It is also prescribed following surgical 
intervention to prevent the formation of clots, to correct cardiac arrhythmias or 
irregular heart rhythms such as atrial fibrillation (Davis et al., 2012). Warfarin is also 
used to prevent the formation of clots in patients who have had a heart attack, deep 
vein thrombosis (DVT) or pulmonary embolism (PE). Warfarin can also be used to 
help treat a group of congenital or acquired blood clotting disorders known as 
thrombophilia.  
Warfarin oral tablets (Figure 2.13) are available in a range of dosages and are colour 
coded to assist the patients in taking the correct dose. This is particularly useful for 
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the elderly who often have several other medications to take or may require 
Warfarin dosage adjustments.  
   
Figure 2.13  
Warfarin tablet doses (CanadianPharmacy.com,2018)  
  
Usually when a patient is first prescribed Warfarin, a baseline measurement of the 
patient’s Prothrombin Time (PT) and Internationalized Normalized Ratio (INR) is 
taken. The induction dose of 10mg daily for the first 2 days is then administered, 
with regular monitoring of the patient’s PT and INR conducted.  
The patient’s Warfarin dose therapeutic range (INR range), is determined by 
whether the drug being given as a preventative measure (prophylaxis), which is 2.0-
3.0 or therapeutically 2.5-3.5. It is also influenced by the recommended dose for 
each patient’s medical condition, the prothrombin time and their INR. Some patients 
may require other coagulation tests to be done. The daily maintenance dose for 
Warfarin patients is usually 3 to 9mg, and it is recommended that that this dose is 
taken at the same time every day (Baglin et al., 2012). This dose may be changed 
or stopped if the prothrombin time and INR are excessively prolonged. Once the 
maintenance dose is stabilised within the required therapeutic range, then there is 
no need to make dosage adjustments. Patients not optimally coagulated with 
Warfarin for reasons such as concomitant drugs interactions, bleeding risk, lifestyle 
issues, poor compliance, allergy (or other reactions to Warfarin e.g. alopecia), or if 
the time within their therapeutic INR range (TTR) on Warfarin falls below ≥65%, are 
considered suitable for scoring for DOACs (Clemens et al., 2013).     
Warfarinised patients are offered regular blood tests on a finger prick or venous 
sample to calculate the time it takes for the blood to clot, and the subsequent 
Warfarin maintenance dose is further adjusted according to these results (as in 
Figure 2.14). The effect after a single dose of Warfarin can last for as long as 5-7 
days (Keeling et al., 2011). Lack of familiarity with the interactions between Warfarin 
   
51  
Student ID: W10503030 v8 – 05/08/2020 
and other drugs may lead to clinically relevant and avoidable increases or 
decreases in prothrombin time (PT).  
    
Figure 2.14  
Warfarin Clinic-Monitoring Machines  
(http://www.elitmedical.com/images/technoclone/thrombotrack_duo.jpg, n.d.)  
 
The following circumstances have an exaggerative effect on Warfarin and may 
indicate the requirement of a reduction of Warfarin dosage:    
• Loss of weight    
• Acute illness    
• Cessation of smoking    
• Excessive alcohol consumption    
The following circumstances have a reducing effect on Warfarin and may indicate 
the requirement of an increase of Warfarin dosage:    
• Weight gain    
• Diarrhoea    
• Vomiting    
• Antibiotics    
 
2.13 Contraindications for Warfarin    
According to Connelly et al., (2013) Warfarin is haemo-dynamically unstable and 
has a wide spectrum of interactivity with foods, alcohol, nutrients, other drugs (e.g. 
antibiotics) and herbs. Warfarin is also affected by the following:     
• Alteration of intestinal flora (increased INR)    
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• Fever (increased INR)    
• Hepatic failure (increased INR)    
• Thyroid function (hypo decrease INR, hyper increase INR)    
• Stress (increase INR)    
• Smoking (decrease INR)    
• Non-compliance (may increase or decrease INR)    
Therefore, Warfarin must be constantly monitored closely and tested routinely.  
Additionally, Warfarin is contraindicated in the following situations and should not be 
administered:     
• Allergy or hypersensitivity to any of the active ingredients in Warfarin.  
• Following or during and haemorrhagic stroke episode.  
• Following or during any significant bleeding episodes.  
• Within 72 hours of any major surgery which carries the risk of severe bleeding.  
• Within 72 hours post-partum.  
• During pregnancy, especially the first and third trimesters); and during labour. 
• With concomitant drugs which are known to be increase the risk of bleeding, 
e.g. anti-platelet medication and aspirin etc. See list below in Figure 2.15.  
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Figure 2.15  
Drugs that interact with Warfarin 
Patel, 1999 & Scowcroft & Cowie 2014     
 
It is widely accepted and published that Warfarin is a particularly effective drug for 
oral anticoagulation. However, due to its narrow therapeutic range, the margin 
between Warfarin efficiency and Warfarin toxicity is also very narrow. Added to this 
is the fact that the patient’s response to Warfarin varies widely between patients. 
This means that there is no ‘one size fits all’ or fixed dose for all patients. The 
measurement of Warfarin (the INR) is used to maintain the haemostatic balance 
between risk of thrombosis, stroke, or venous thrombosis (thrombophilia) and the 
risk of bleeding (haemophilia).  
Other common food and drugs that interact with Warfarin are shown below in Figure 
2.16. 
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Figure 2.16 
Warfarin Food and Drug Interactions (Gogna & Arun,2005)     
 
The benefits of Warfarin can be summeries as:    
• Is extensively studied   
• Clearance is not affected by renal function    
• Inexpensive    
• Poor adherence is rectifiable.  
• Can be used for many indications  
• Antidote available for effect reversal    
• There is much clinical experience    
• Efficacy is well established  
 
Warfarin is also not without adverse effects. These can include:    
• Nausea and vomiting    
• Haemorrhage    
• Alopecia    
• Rash    
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• Diarrhoea  
• Skin and soft tissue necrosis  
• Priapism    
• Hypersensitivity/Allergy  
 
2.14 Cytochrome P450 CYP2C9    
Cytochrome P450 is a group of more than 50 enzymes which are responsible for 
the metabolism of many medications including Warfarin. It is also essential in 
assisting the liver to detoxify. Some genetic variations of the cytochrome P450 
genes can result in a varied metabolic response of the patient to medications such 
a Warfarin. Commonly Warfarin patients who have cytochrome P450 variants may 
have responses to Warfarin which vary from reduced activity in metabolising the 
drug to complete inhibition of Warfarin. This may lead to increased toxicity in the 
liver and peripheral circulation, haemorrhages, or death. Fifty-five percent of 
Warfarin patients who have poor control of the drug have been found to have a 
genetic polymorphism of their CYP2C9 gene, which is responsible for the 
metabolism of Warfarin (Sconce et al., 2005). Therefore, the AF patient’s benefit-
risk ratio for DOAC and Warfarin is paramount in determining the clinician’s decision 
to switch (Camm et al., 2010).  
 
2.15 Warfarin Self-Testing    
NICE in 2012 ran a small pilot study in which Warfarin patients self-monitored at 
home and digitally transmitted the results back their GP or local anti-coagulation 
centre. The trial had some successes in the younger age groups (under 50 years), 
who were on Warfarin and only a marginal uptake in the older population of Warfarin 
patients (NICE, 2014a). Self-monitoring of OATs involves the use of a small hand-
held device. See Figure 2.17. The patient pricks their finger to acquire a single drop 
of blood, which is then dropped onto the machine to measure Warfarin level and 
generate an INR result. The patient can then seek Warfarin dosage adjustment 
advice from a medical professional if the INR is outside of their own reference range. 
Often patients may adjust their own Warfarin dose based on their own experience 
of taking Warfarin long-term.  
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Figure 2.17 
Warfarin Self-Monitoring Device 
https://heartveinvascular.com/heart/advanced-lipid-and-inr-monitoring/ 
 
Self-monitoring encourages self-care and can promote a positive approach to 
managing long-term condition and is a key NHS initiative. Self–monitoring is a 
convenient way to check INR at any time and avoids the need for Warfarin patients 
to attend clinics and the waiting time for their results. 
 
2.16 The Patient Experience.  
Much has been written in the last ten years about the value of engaging patients in 
their own treatment. This arose from a recognition of the absence of the patient’s 
voice in previous decades. Coulter (2011, p3) quotes the Secretary of State for 
Health 2010:8.  
‘The NHS scores relatively poorly on being responsive to the patients it serves. It 
lacks a genuinely patient-centred approach in which services are designed around 
individual needs’.   
(Richards et al., 2015) concur with this statement, reporting that patients should be 
led away from dependency on professionals to be confident self-managers, 
particularly the frail with long-term, multiple conditions. Coulter lists four areas that 
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particularly lend themselves to improvement with more patient input: patient’s 
knowledge; patient’s experiences; services utilization; and health behaviour status. 
Each relates to the study presented in this thesis in varying degrees. In the first area 
of focus the patients experience, (knowledge of condition and long-term 
complications, self-care knowledge, comprehension of information, and recall of 
information) are pertinent here. In the second area, the patient’s experience (doctor-
patient communication, confidence to manage health problems; self-care activities) 
is also key. Coulter’s third area, service provision (quality of life, psychological well-
being, treatment adherence, system control and functional ability) is, in varying 
degrees, at the core of this study’s aim and objectives. Finally, Coulter’s discussion 
on the education of healthcare professionals is also regarded as key to improved 
patient care; just knowing what patients want and need is not enough, staff education 
must follow newly found knowledge about patient’s needs. This study aims to 
contribute to staff education.  
 
2.17 Study Background and Originality   
Research into the long-term use of Direct Oral Anticoagulants (DOACs) is still 
relatively limited, as the first was only introduced in the United Kingdom in 2010 and 
validated for use in 2012 (Patel et al., 2019). As such, there are no key policies 
regarding their long-term use or associated quality of life changes in patients over 
65. In fact, each NHS trust or primary care facility uses their own local set of 
guidelines on the use of these new drugs and has their own set of rules that govern 
how and when patients currently on Warfarin are switched to the new drugs. Whilst 
the pharmacokinetics of these drugs may be well researched, the speed with which 
these medicines and technologies are being introduced has meant that little is 
known about the long-term effects of these drugs, particularly in the over 65s.  
Testing Warfarin in an anti-coagulation clinic for over 8 years has resulted in the 
author having a clear understanding of some of the challenges faced by the Warfarin 
patients, who often have other commitments such as jobs, children, grandchildren, 
partners, the care of elderly relatives and social activities to attend. From brief 
conversations with patients in the clinic, it was noted that having to attend the clinic 
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once or twice a week for monitoring also had an impact on planned activities which 
may last more than 3 or 4 days, such a holiday. The social impact of clinic 
attendance for the over 65s can therefore be complex. They often have 
transportation arranged by the hospital, and so try to arrange other non-Warfarin 
related hospital appointments for the same day. The visit to the clinic may also give 
opportunities for long conversations with other patients or the scientist conducting 
the blood test, as frequently these elderly patients are housebound, widowed or may 
be lonely. Often their Warfarin may be poorly controlled due to a variety of reasons 
such as alcohol consumption, interaction with concomitant drugs, or food 
interactions particularly with foods rich in vitamin K. Also, the over 65s may forget 
to take Warfarin, or accidentally take the dosage twice. Over-Warfarinisation has an 
increased risk of an intracranial haemorrhage, and therefore requires immediate 
quantitation in the laboratory and reversal. Patients may also require hospitalisation 
and monitoring during the reversal process.  
The number of patients living past 65 is increasing, and the number of patients living 
with AF is expected to double by the year 2040 (Ganetsky et al., 2011). 
Anticoagulation clinics are already struggling to meet the increasing demands of 
testing oral anticoagulated patients. Patients may not therefore receive the best 
quality of service due to recent national cuts in NHS finances, with consequent time 
constraints and staffing shortages. However, the success of using these Direct Oral 
anticoagulants may result in a standardised level of care as well as an improvement 
to the services currently offered to patients on long term anticoagulant therapy. 
Nevertheless, the social impact on the removal of these clinics for the over 65s 
needs to be explored. The financial implications of the implementation of these 
Direct Oral drugs are also discussed though are not the focus of this study.  
From a laboratory perspective, there is no linear value associated with the DOACs, 
coagulation assays values and drug dosage. The international normalised ratio 
(INR) currently used for testing Warfarin is not sensitive enough for DOACs. With 
so little in-depth knowledge known about the Direct Oral drugs and with such limited 
resources in the NHS, particularly in small district general hospitals, there is a need 
to examine whether these new drugs will provide a better quality of life for patients. 
What impact will the lack of testing or monitoring have on patients’ health and social 
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well-being? Would the investment made in introducing costly Direct Oral drugs be 
better spent improving clinic services? It is therefore the author’s intention to 
ascertain whether this key change in the way oral anti-coagulants are monitored 
has significant impact on the quality of life of patients who are over 65 years.  
There is undoubtedly a cost/quality of life equation to be addressed. Somerset NHS 
trust estimates that Dabigatran will cost £9.5 million per year as opposed to the 
current cost of £1 million for Warfarin patients - including prescription and clinic 
services (NOAC innovation in anticoagulation report. 2014). So, it is important that 
we know more about the positive impact on the new medications and identify what 
are the main concerns of the patients and clinicians regarding these Direct Oral 
drugs. For example, should there be a rapid laboratory diagnostic test available as 
standard procedure for emergency situations? Would this reduce anxiety or save 
lives? There is no published research worldwide which looks at the long term quality 
of life of patients receiving anticoagulation drugs who have switched from Warfarin 
to the new DOACs. This gap in the literature demonstrates the originality of this 
paper. The quality of life as well as social and personal implications of any treatment 
are important, as research outlined above has already demonstrated the vital role 
of compliance and patient information provision in other areas of treatment as well 
as in treatment outcomes. One such example is an article from the Journal of Public 
Health in which the authors determined that ‘sustained compliance was due, in part, 
to a number of individuals being afforded the opportunity to reconFigure their 
medications’ and ‘indicates that patients experiencing side effects…. are more likely 
to remain adherent if GPs are willing to listen to their concerns and review 
medication’ (McNaughton and Shucksmith, 2015). 
 
The exploration of the patient’s experience with regards to compliance and long 
term use of this treatment in patients over 65 is explored here for the first time. By 
‘experience’ it is meant the patient’s sense of life quality issues such as well-being, 
side effects of the medication, and the challenges they face with self-monitoring and 
compliance. This research provides information for clinicians responsible for the 
management of the oral anticoagulation service at the London NHS Trust where the 
study was conducted, and elsewhere with the aim of improving the patient 




Student ID: W10503030 v5 20.07.2020 
experience of this demanding medication regime. The research has explored, from 
both the patients’ and clinicians’ perspective, the patients’ quality of life after 
switching to DOACs with respect to the clinical, personal, and social issues that may 
arise. It has also looked at the impact on the patient’s overall perception of their 
health and wellbeing, and the issues which relate to taking a lifelong medication 
such as Warfarin or DOAC, as well as the impact of the switch-over on their 
compliance with treatment. 
 
2.18 Research Aim and Objectives  
The principal aim of the study was to explore the patient’s perspective of switching 
from a life-long medication on Warfarin to one of three Direct Oral Anticoagulants 
(Apixaban, Rivaroxiban or Dabigatran), none of which required monitoring and have 
fewer side effects than Warfarin as well as fewer drug and food interactions. Of 
primary focus was the impact from the patients’ perspective of the substitution on 
the daily life. Additionally, the clinicians’ knowledge of the impact of the switch on 
their patients’ lives was also explored with the aim of developing a more patient 
focused anticoagulant service.  
Objectives: 
1. To describe a sample of 20 patients’ perceptions and understanding of their 
treatment using individual interviews at the time of the switch and at 90 days 
afterwards. 
2. To explore the Consultant’s, nurses’ and pharmacists’ level of knowledge  
      relating to issues faced by the patients with regards to safety and   
     compliance, as well as their awareness of the social implications of  
      switching to DOACs through the use of interviews.  
3. To ascertain the impact of switching on a sample of 50 patients by assessing 
their perceived quality of life and stress levels at three points: at the switch, 
then at 30 and 90 days into the new treatment regime, through the use of 
standardised questionnaires.  
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4. To explore the effects sex and age may have on the participants’ quality of life 
and perceived stress level.  
5. To produce recommendations to provide a more effective and personalised 
patient-involved treatment programme for older AF patients.  
The following chapter sets out how the research was achieved: the research approach, 
















Chapter 3 - Research Approach 
and Methods    
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3.0 Introduction – the research approach and methods 
When this research was in the design stage a purely qualitative study was the 
approach decided upon.  This was because the author had noted that nearly all the 
literature on this subject was clinical or quantitative in nature and there had been few 
opportunities for the patient’s voice to be heard in its natural form. This study would, 
therefore, adopt an ‘inductive’ reasoning approach - drawing meaning from specific 
observations (the interviews) as opposed to ‘deductive’ reasoning - testing an 
established theory, Robson (2011). This study attempts to fill the gap in the literature 
discussed in chapter two. Green and Thorogood (2005) call this the ‘deficit model’ and 
state that ‘the value of qualitative methods to public health lies in their ability to answer 
important questions that cannot be answered from a quantitative perspective’ (p22). 
The ‘usefulness of this approach is to sensitize professionals to the patient’s point of 
view’ (p23). 
However, this position changed as a result of discussions with Dr Abdul Shlebak, the 
haemostasis and thrombosis consultant in charge of the clinic at St Mary’s where the 
patients were located. His concern was that a purely qualitative study would not gather 
all the potential data from the patients and that it would be seen, in the medical world 
at least, as less valuable research than a study which included some quantitative data 
and statistical analysis as evidence of change.  This view is in line with commentators’ 
observations that research in healthcare has been traditionally quantitative or 
‘positive’ in nature with a bias towards measurable data (Doyle et al., 2009).  Given 
that the author of the current study hoped to influence practice in the clinical field of 
haematology, producing results that were considered to be ‘credible’ in that field was 
important. On reflection, the author and supervision team agreed that that producing 
a standardised, quantifiable data set would indeed support the primary method of 
individual interviews.  It would also allow the sample size to be larger for part of the 
study: 50+ patients not 20 which was the interview sample size.   A mixed-method 
study was, therefore, undertaken.  
Pragmatism is the paradigm underpinning this research. Robson (2011) cites 
Onwuegbuzie and Leech (2005) who hold that ‘pragmatic researchers’ are simply 
those who learn to utilize and to appreciate both quantitative and qualitative research’ 
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p171.  Doyle et al., (2016) support this view arguing that it ‘offers health researchers 
the freedom to choose the best methods to answer the research question to hand 
(Bishop, 2015a), advocating for a balance between subjectivity and objectivity 
throughout the research’ p625. But Robson (2011) cautions researchers employing 
mixed-methods not to be encouraged down the ‘anything goes’ route that he fears 
pragmatism may seem to allow’ (p29). ‘There is a danger of being open to the criticism 
of carrying out incoherent projects lacking a rationale and of dubious validity’ (p171). 
The research reported here although mixed-method is a relatively small study using 
only two methods both of which address the same issues but from a different 
perspective. 
Doyle et al., (2016) offers a clear definition of mixed-methods research given by 
Creswell (2015). ‘An approach in which the researcher collects, analyses and 
interprets both quantitative and qualitative data, integrates the two approaches in 
various ways and frames the study within a specific design’ p624. The secondary 
method used in this study were two health-based questionnaires: The Perceived 
Stress Scale (PSS) and the Short Form 36 Health Survey, (SF36) which are discussed 
in full below.  The interviews were semi-structured and would generate qualitative 
material on the general experiences of the respondent’s life on anticoagulants. The 
questionnaires, on the other hand, allowed for the collection and measurement of 
group and subgroup data focused on the patient’s feelings about their health in 
general and, more specifically, their stress levels at three time points during and after 
the switch of medication.  Any change in perception over the three-month research 
period would be captured.  
Mixed-method research is now common in healthcare, but this was not always the 
case.  Doyle et al., (2009) outline the struggle mixed-methods research has had to 
find acceptance. The days of a strict demarcation between the traditional positive 
(quantitative data) paradigm and the emerging naturalistic (qualitative material) 
approach softened during the 1980s and mixed-methods were increasingly found to 
be useful in a wide range of social science settings.  Its popularity grew, in part, due 
to the encouragement of interdisciplinary research. Doyle et al., (2016) offer a list of 
rationales for a mixed-method approach. To summarise:  
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Triangulation: different methods may be mutually corroborated. (Convergence)  
Expansion: a qualitative method may offer an explanation of the quantitative data. 
Exploration: an initial qualitative phase is required to develop secondary quantitative 
tools. 
Completeness: it provides a more detailed and comprehensive picture of the 
phenomena under study.  
Offsetting weaknesses: the limitations of each method can, to some extent, be 
neutralised by the strengths of the other.  
Different research questions can be asked:  both quantitative and qualitative 
questions can be asked. 
Illustration of findings: using a qualitative approach to illustrate quantitative findings 
(p624). 
Several of these factors can be applied to this study. A more complete picture of the 
patient’s perspective was sought than could be produced with interviews alone. The 
questionnaires would offset the limitations of the individual interview method by 
providing a group analysis of standardised data to support the personal stories.  The 
questionnaires would also answer different research questions, one focused on the 
participant’s self-reported general health and the second had a particular focus on 
stress.  To complete the picture, the qualitative data would, it was hoped, both explain 
and illustrate the quantitative findings.  
Creswell (2015) offers three mixed-method designs: convergent, explanatory 
sequential and exploratory sequential (Doyle et al., 2016, p625).   The mixed-method 
design used here is a convergent design (concurrent). ‘It is used to address one 
overarching research question but employs more than one method when looking for 
convergence affording a more complete understanding of the phenomena’ (Doyle et 
al., 2016, p626). Findings from the qualitative data (interviews) and quantitative data 
(questionnaires/scales) were compared and contrasted during the interpretive stage 
of this design.  
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3.1 Mixed-method health related studies are now numerous and reach across the 
whole field of healthcare, being particularly popular when exploring patient’s 
perceptions of their quality of life. They are now also increasingly used within the field 
of anticoagulant research.  For example, Barns et al., (2017) employed semi-
structured interviews and a survey to study the personal barriers to integrating direct 
oral anticoagulants into outpatient clinic care.  Bhat et al., (2019) used retrospective 
and prospective medical records, and a prospective patient survey, to evaluate the 
real-world use of anticoagulants with ischaemic stroke patients. A study that also 
included clinic staff was undertaken by Barns et al., (2019). They used patient 
interviews and staff computer assisted surveys to explore the potential of reducing 
the frequency of INR test clinic visits among patients who were stable on Warfarin.  A 
study which is close in focus to the study reported here is by Bajorek et al., (2018).  
Their aim was to explore and compare the level of patient satisfaction with Warfarin 
and the new anticoagulants; a vignette-based questionnaire and patient interviews 
were used.   
Despite its popularity, mixed-method research is not without its problems. Bressan et 
al., (2017) provides a critical review of mixed-methods research in nursing. They 
found it to be increasingly popular but that, at times, training in mixed-methods was 
limited and inconsistent and that methods may be applied in a less than rigorous way.  
Concerns were also expressed about a novice researcher’s potentially poor choice of 
tool and weak administration of the chosen instruments. To ensure the correct choice 
of quantitative data collection instrument here expert help was sought from Dr Trudy 
Edginton (Westminster University) for the selection of the health questionnaires. She 
also provided training in their administration and data analysis Therefore, in the 
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3.2 Research Methodology  
The outline of the data gathering process is shown in Figure 3.1. 
  
Figure 3.1 
Research Process outline     
The population from which the sample was drawn are the current AF patients within 
the Imperial Hospital Trust. The AF population accounts for approximately 85% of 
the total 1394 orally anti-coagulated patients (St Charles site 262, St Mary’s site 
820, Queens Park site 112 and Hammersmith site 200). Of these more than 70% 
are over the age of 65 (829 patients). The numbers are approximate, as patient 
numbers change due to being discharged from the anti-coagulation monitoring 
centres for reasons such as clinical requirement for the patients to be switched to 
DOACs or else moved to other forms of anti-coagulation. 
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The target group is therefore, the over 65s attending the clinic and the range of 
problems that they can encounter related to their treatment. The inclusion criteria 
were 1) being on Warfarin for more than 6 months (established long term use) and 
2) needing to switch from Warfarin to any of the 3 DOACs: Dabigatran, Apixaban or 
Rivaroxaban for clinical resaons. The exclusion criteria were patients who were not 
switching medication, those under 65ys and those covered by the Mental Capacity 
Act. As this last group of patients are generally treated at home, they are unlikely to 
appear in clinic. In addition, patients who speak English as a second language and 
require an interpreter were excluded. Although a relative or carer could assist with 
this task eliminating bias can be an issue. Within the current funding constraints, it 
was not possible to translate the questionnaire and supporting material into other 
languages. After this research is completed, there may well be a case for further 
research focused on these excluded groups of patients.  
3.3 Recruitment and the sample frame     
Imperial Trust anti-coagulated patients on Warfarin attend a designated outpatient 
centre at Queens Park Health Centre (QPCH), Hammersmith Hospital (HH), St 
Mary’s Hospital (SMH) or St Charles Health Centre (SCHC). This is weekly, 
biweekly, or monthly, depending on the stability of their results as well as changes 
to their medical condition or concomitant medical regimen (e.g. taking antibiotics 
which interfere with Warfarin). The patients are then subjected to a finger prick 
blood test to monitor Warfarin levels, which are then recorded into the electronic 
database DAWN® or INRstar®. This session is where the researcher recruited the 
research sample. The database not only records the patient’s results, but trends 
changes in these results and calculates the next Warfarin dose adjustment for the 
patient. This is plotted on a graph and helps determine the time in therapeutic 
range (TTR). Patients outside the TTR for ≥65% over the last 12 months are 
referred to the clinician for a switch by the anti-coagulation nurse, who can then 
inform the researcher of patients who have been invited to attend for switching 
from Warfarin to DOACS. Surprisingly, there is no national database of patients 
who have been switched from Warfarin to DOACs; this may because DOACs do 
not require regular monitoring and testing.  
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It is difficult to establish a precise projection of how many patients would be 
switching to DOACs, as patients are switched when they are not coping on Warfarin. 
Switching is not uncommon, but is also not easy to predict. Difficulties arising with 
Warfarin control are usually due to changes in patient’s health circumstances which 
can cause interference with the Warfarin from concomitant medications or from the 
physiological condition itself.  
According to the chief coagulation scientist in the Imperial Trust, since December 
2012 there have been 148 recorded requests for DOAC testing by clinicians within 
the laboratory for reasons such as DOAC associated bleeding events, or that the 
DOAC plasma level is required for unrelated surgical interventions, representing 
almost 18% (17.85%) of the total imperial DOAC patients. Patients who are deemed 
to be too frequently outside their therapeutic range for Warfarin, and therefore 
suitable for switching, are assessed over a period of 6 months and are therefore 
commonly known to the anti-coagulation team. I looked at the number of patients in 
the trust who had been switched over the past 4 years and estimated that 50 could 
be recruited within 12 months or sooner.  
 
Table 3.1  
CHADS2 /CHA2DS2-VASc Score Chart Lip 
et al 2010 page 41  
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3.4  Interviewing older people    
Research shows that interviewing older people presents several challenges for all 
concerned. These include physiological changes such as memory loss, 
deteriorating health, loss of vision, and hearing impairment The interviewer(s) need 
to prepare for these, allowing plenty of time for interview, and ensuring written 
material is clear with large print when necessary (Connolly and Spyropoulos, 2013; 
Lane and Lip, 2009; Davis et al., 2012).  In this study the interviews were conducted 
over a relatively short period of time, so memory loss, deterioration of hearing, sight 
or medical condition were not an issue. Each patient was assessed by their medical 
consultant who deemed them fit for interview. The researcher was aware of the 
possibility of tiredness and checked from time to time with the patient that they were 
happy to continue.  
The patients were approached by the researcher or named clinic nurse as they 
arrived for their regular appointment until a sample of 50 was achieved. Only one 
person declined to participate. Indeed, six additional patients volunteered to 
participate and were interviewed bringing the total up to 56. They were recruited 
according to the convenience method of arriving the quotas required (Neuman and 
Robson, 2012; McNaughton and Shucksmith, 2015). This included choosing the 
nearest and most convenient persons to act as respondents (Neuman and Robson, 
2012). The research aims and the terms of their involvement were explained to 
them, and they were interviewed after their next appointment or as soon afterwards 
as possible depending on the researcher’s availability.  
The patients attending this clinic do so by appointment made by the anti-coagulation 
team to monitor their Warfarin, therefore assistance in identifying potential patients 
was required from a member of the anticoagulation team. The patient was given 
time to consider and was approached again at the next appointment for a decision. 
If, however, they responded positively right away, a time was made for the interview 
there and then. They were assured that participation was voluntary and that there 
would be no difference to their treatment if they participated or not, and that they 
could withdraw from the study as any point if they wished. Permission was asked to 
maintain further contact for later interviews. The approach was made easier by the 
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familiarity of the team nurse and researcher with the patient; however, the 
questionnaires and interviews were conducted only by the researcher. The consent 
form would be signed at the start of the interview.  
The second interview, 90 days after the switch, reflected and built on the information 
gathered at interview one in the light of new experiences, and recorded any changes 
to the patient’s wellbeing after switching medication. It should be noted that these 
interviewees had also completed the scales at the 30-day point. Only two of the 
patient interviews were completed by telephone, the rest  were face-to-face. 
Respondents were given the opportunity to remain anonymous and were assured 
of the confidentiality of their responses. The study invitation letter, study information 
sheet and reminder letter can be found in Appendix Six. 
3.5 The Sample - interviews and questionaires  
Twenty patients, 10 men and 10 woman were interviewed. About half lived alone, 
others had a partner who required care. They were a diverse group with regards to 
occupation counting among them retired teachers, a vet, baker, barrister, van driver 
and architect as well as a still working solicitor and publican. For the interview, semi-
structured questions were used as a conversation starting point, and the patients 
were encouraged to talk freely. Exemplar transcripts of these conversations can be 
found in Appendix 15. Of note is that information pertinent to the study (such as age 
and reason for switching to DOAC) was provided by the anti-coagulation nurse 
rather than the patient. Therefore, some of the questions had to be rephrased or 
skipped in order to have a naturally flowing conversation.  
The sample size of 56 was dictated in part by the need for the minimum of 50 cases 
required for the questionnaires to be scientifically valid for analysis, but six 
additional patients asked to be included; all 56 patients completed scales at 3 time 
points. A minimum sample of 50 patients is based on the validation data for the 
SF36 instrument; according to Ware et al 2004, between 24 and 50 patients are 
needed as a sample size for the study findings to be statistically robust (Ware, 
2004). As further validation, a review over a period of 10 years and based on over 
9,800 publications, shows that 50 is the most common respondent sample size with 
this instrument (Turner-Bowker et al., 2002).  
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The patients’ perception of Quality of Life changes (QoL) were assessed using 3 
data points and two questionnaires as outlined in Table 3.2. 
 
   Patient    Questionnaires/sales: 
SF 36 and the PSS.  
Face-to-face Interview    
  
DOAC (switched Patients) 
Former Warfarin patients before 
switching, which is at the point of 
referral for switching. *    
     
56 patients subdivided by age 
group and sex.  
     
The scales were to be 
administered by the researcher.  
 
 20 of these 56 patients, subdivided 
by age group and sex, were also 
interviewed by the researcher 
(selected according to the 
availability of patients).  
    
Follow up (30 days)   Same 56 patients     
    
 
     
Follow up (90 days)   Same 56 patients     20 re-interviewed  
  
Table 3.2  
Research Sample outline  
 
 
The Perceived Stress Scale (PSS) and the Short Form 36 questionnaire were used 
at the baseline data collection point (before switch), and feeling of stress measured 
post switching, at 30 days, and 90 days later. After 90 days the patient’s prescription 
would be passed to the GP, and at this point the final scales were administered. This 
was not only to ascertain the patient’s views on the new medication but also to reveal 
whether they had had any adverse (e.g. bleeding) events associated with the new 
drugs. After the first administration of the scales the volunteers were given the option 
of completing the scales by face-to-face contact or by telephone/skype, though all 
preferred a clinical setting.  
  
3.6 Piloting the instruments   
The scales used in this study are established validated questionnaires that have 
been used in many studies worldwide, so it was not necessary to pilot them with 
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regards to content. However, the instruments were piloted for the purpose of 
establishing an estimated time-frame in which the patients would be able to 
comfortably complete the scales. They were piloted on colleagues in the clinic and 
with my two supervisors. Feedback about the ease of completing the questionnaires 
was also encouraged, no major changes were required.  Recent examples of SF-
36 studies include:  
1. ‘Satisfaction, quality of life and therapy adherence assessment in real life 
patients transitioning from vitamin K antagonists to direct oral anticoagulants’ 
(Serrao et al., 2020). 
2. Knowledge, Adherence, and Quality of Life among Warfarin Therapy Users 
(Matalqah et al., 2019). 
3. ‘Comparing quality of life and treatment satisfaction between patients on 
Warfarin and direct oral anticoagulants: a cross-sectional study’, (Ng et al., 
2019).  
 
3.7 Description of the Perceived Stress Scale (PSS)  
The Perceived Stress Scale (PSS) is an established psychological test used to 
measure an individual's perception of stress in his or her life. The instrument was 
originally developed in 1983 by Sheldon Cohen and is used to determine how different 
situations affect feelings, an individual’s overall stress levels, stress triggers and the 
perceived stress in a person’s life. It is a one-page scale and takes less than two 
minutes to complete. There are 10 questions enquiring about the feelings and 
thoughts of the person during the last month. Some of the questions are very similar 
to each other but with subtle differences. In such an elderly population there are likely 
to be psychological age related changes such as bereavement and loss, living alone, 
depression and loneliness (Bowling and Gabriel, 2004; Lane and Lip, 2009; Wenger, 
2002). These life factors may impact on the patient’s perception of their level of coping 
with medication. An example of the PSS questionnaire in use in this field is the work 
of Fumagalli et al., (2014) who explored the psychological effects of treatment with 
new oral anticoagulants in elderly patients with atrial fibrillation using the PSS scale 
to measure the level of stress. 
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Each scale item is rated on a 5-point range from ‘never’ (0) to ‘almost always’ (4). 
PSS-10 scores are obtained by reversing the scores on the four positive items, for 
example, 0=4, 1=3, 2=2, etc., and then summing across all 10 items. Items 4, 5, 7, 
and 8 are the positively stated items. The choices for the perceived stress scale 
questions include never, almost never, sometimes, fairly often, and very often. The 
PSS scale is shown in Appendix 11. Higher scores indicate greater perceived 
stress. Research has found that high stress groups usually have a stress score of 
around 20 points or greater.  High psychological stress is associated with high blood 
pressure, higher BMI, larger waist to hip ratio, shorter telomere length, higher 
cortisol levels, suppressed immune function, decreased sleep, and increased 
alcohol consumption. These are all important risk factors for cardiovascular disease. 
Although scores on the 14-item PSS tend to exhibit good reliability estimates across 
literature, four of the items tend to perform poorly when evaluated using factor 
analysis. As a result, the PSS is usually implemented using the 10-item version. 
Cohen et al., (1988) further reduced the PSS to a four item form for quick 
measurements; however, scores on the 4-item PSS tend to exhibit lower reliability 
estimates than researcher would like.  
Potentially stressful life events are thought to increase risk for disease since the 
demands these events impose tax or exceed a person’s adaptive capacity (Lazarus 
& Folkman, 1984). In turn, the perception of stress may influence the pathogenesis 
of physical disease by causing negative affective states (e.g., feelings of anxiety 
and depression), which then exert direct effects on physiological processes or 
behavioural patterns that influence disease risk (Cohen et al., 1983; Cohen et al., 
2007).  The Perceived Stress Scale (PSS) measures psychological stress 
associated with sex, age, education, income, employment status, and a number of 
other demographics. Before the development of the PSS, assessment of stress 
tended to focus on objective indicators (e.g., frequencies) of specific stressors (e.g., 
chronic illness, family loss, new family members). This tendency subsequently 
overlooks the influence an individual’s subjective interpretation of a stressor might 
have upon the experience of a stressor. Cohen et al., (1983) viewed the void of the 
subjective component in assessing stress as an unwanted quality and developed 
the PSS in response. Specifically, the PSS is based upon Lazarus’s original 
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transactional model of stress, which argues that the experience of a stressor is 
influenced by evaluations on the part of the person as to how well they can manage 
a stressor given their coping resources. The 14 items of the original PSS are 
purported to form a uni-dimensional scale of global perceived stress (Lazarus, 
2000). 
Data from the returned questionnaires were coded and entered into SPSS 25.0, 
which was then used to generate statistical analyses. The coding process and 
subsequent statistical analyses will now be described. The perceived stress scale 
and the Short Form 36 Medical Outcomes questionnaire were both structured and 
pre-coded for ease of analysis, it also included several questions with a binary or 
categorical response format. This involved pooling of data from UK quality of life 
studies which had used the SF-36. A non-probability sample was drawn which was 
considered appropriate because the research aims to explore the perceptions of the 
patients in this hospital ‘not to make statistical generalizations to any population 
beyond the sample’. (Neuman and Robson, 2012, p274). A quota sampling was 
used ‘with the aim of including representatives of the various elements of a 
population, usually in the relative proportions in which they occur in the population’. 
(Robson and McCartan, 2016) p274. In other words, people who were typical of the 
clinic population at the point of being ‘switched’.  
Age and sex are the categories, so patients fall into two groups: male (n=29) and 
female (n=27) each with three age subgroups: 65-74ys (n=19), 75-84ys (n=21), and 
>85 years, (n=16). The mean age was 79.5. All patients who were identified as 
meeting the inclusion criteria were invited to participate and continued to be 
approached until the quota – 12 or 13 cases in each group - was achieved. The age 
division is to explore whether over 75-year olds experience the treatment regime in 
a different way – more or different personal problems from those who are slightly 
younger. Likewise, male/female subgroups were identified to see if any difference 
in perception or experience exists between the sexes. See Appendix 15 table 16 for 
the SPSS calculations.  
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3.8 Perceived Stress Scale Scoring and analysis 
PSS scores are obtained by reversing the scores on the four positive items as 
described above, and then summing across all 10 items. Scores around 13 are 
considered average. Individual scores on the PSS can range from 0 to 40, with 
higher scores indicating higher perceived stress.  
• Scores ranging from 0-13 are considered low stress.  
• Scores ranging from 14-26 are considered moderate stress.  
• Scores ranging from 27-40 are considered high perceived stress.  
 Scoring the Perceived Stress Scale requires a simple calculation where a number 
value is assigned to each possible choice a respondent could choose. The numbers 
for the possible responses coincide with how much that particular response 
correlates to stress for the question. For example, an answer of ‘never’ would be 
assigned a score of four for the question ‘In the last month, how often have you felt 
confident about your ability to handle your personal problems’? However, for the 
question ‘In the last month, how often have you felt that things were going your 
way’? the ‘never’ response would be assigned a value of zero. By totalling the 
scores, researchers, psychiatrists, and other health care providers can get a relative 
idea of how stressed the individual feels in his daily life. This can help with diagnosis 
of physical and mental problems, since high levels of stress can contribute to high 
blood pressure, heart problems, appetite changes, depression, and many other 
mental and physical conditions. If an individual is highly stressed, treatment may 
include therapy or relaxation techniques to help lower the perception of stress and 
allow the body and brain to heal. Data from the returned PSS questionnaires was 
coded and entered into SPSS 25.0, which was then used to generate statistical 
analyses. The coding process and subsequent statistical analyses will now be 
described. The impact of the patient’s age and sex on the patient’s overall self-
perception of their health was assessed using one way ANOVA.   
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3.9 Description of the Short Form 36 Scale (SF-36), scoring and analysis.  
The SF-36 is an indicator of overall health status and is also well validated. This 
instrument addresses health concepts from the patient’s perspective. It is a 
structured, self-report questionnaire that a patient can complete with little or no 
counselling from an interviewer. SF-36, as provided by Ware et al., (2004) exists in 
various revised forms. Quality of Life studies, using the short form 36 (SF-36) 
instrument, have been published in over 41,000 surveys worldwide (Ware and 
Sherbourne, 1992; Dixon et al., 2019). The SF-36 questionnaire contains 36 items 
that assess patient’s health status and its impact on their lives:  
Physical Functioning (PF) 10 items; Physical Role limitations (RP) four items; Bodily 
Pain (BP), two items; General Health perceptions (GH) five items; Energy/Vitality 
(VT) four items; Social Functioning (SF) two items; Emotional Role limitations (RE) 
three items; and Mental Health (MH) five items. See Figure 2. 
Each scale is graded from 0–100 with 0 being the maximum disability, or in this case 
the least improvement of Quality of Life, with 100 being the best outcome. 
Therefore, higher scores indicate higher HRQoL. A scoring algorithm is used to 
convert the raw scores into the eight dimensions listed above. The scores are 
transformed to range from zero, where the respondent has the worst possible 
health, to 100 where the respondent is in the best possible health. All scales 
contribute in different proportions to the scoring of both PCS and MCS measures, 
which are composite QoL scores of mental and physical health. The correct 
calculation of SF-36 summary measures of PCS and MCS requires the use of 
special algorithms, which are strictly controlled by a private company (QualityMetric 
- OPTUM). 
 The two summary scores are derived from the Physical Component Summary 
(PCS) score and the Mental Component Summary (MCS) score. PCS and MCS 
scores are an aggregation of individual scores. The eight scaled scores are 
weighted sums of the questions in each section. Scores range from 0 - 100   
Lower scores = more disability, higher scores = less disability   
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Sections:   
• Physical functioning   
• Physical role functioning   
• Bodily pain  
• General health 
perceptions   
• Vitality  
• Social role functioning   
• Emotional role 
functioning   











Short Form 36 (SF-36) summary components  
  
As scores from the SF-36 are used to measure clinical outcomes, it is imperative 
that applicable normative data are used to judge effectiveness. In the last decade 
(2000–2010), 40 articles published in the BMJ have used SF-36 as an outcome 
measure, and of these papers 23% have potentially used inappropriate norms for 
calculating SF-36 scores, as samples were selected that extended beyond the 
boundaries of England (i.e. stated as UK wide), or encompassed England and 
Wales, or were located solely within Wales.  The analysis for the Short-form 36 
followed the process outlined by the authors of the scale. Different aspects of the 
patient’s well-being were scored for the patients who have switched, with a 
comparison of overall scores for SF-36 calculated at the three separate intervals 
(pre-switch, 30 days, and 90 days post switch). Then an individual comparison of 
each interval score was interpreted and trended to determine if the level of Quality 
of Life for patients who have switched has improved or decreased. The QoL model 
used is shown in Figure 3.3.  
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Figure 3.3   
Short Form 36 (SF-36 utility) 
http://www.sf-36.org/tools/SF36.shtml  
  
The data from the SF-36 for each patient was categorised into five groups: 65-74 
years, 75-84 years, >85 years and by M or F to identify if any these factors influence 
the views or problems encountered. Then, using a series of data queries with time, 
age and gender as independent factors, changes from baseline at timepoint 1 and 
timepoint 2 were captured and compared to the results at timepoint 3.     
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3.13 The analysis of the Interview Data.    
Thematic analysis was chosen as the method of data analysis because it is  widely 
used across the health sciences (Hoe, 2013) and suited the purpose of the study.  As 
the author was a novice researcher the literature was searched to identify a suitable 
model as a guide. Two approaches came to the forefront right away. The first was the 
‘Framework’ method developed by Jane Ritchie and Jane Lewis (2003). They 
provided a detailed process to follow for the development of themes and the 
construction of an index and how to develop a conceptual framework with which to 
guide the data analysis. However, it was rejected on the grounds the sample here 
was relatively small and the Framework approach can require a considerable amount 
of varied material to work with. The anticipated qualitative material here was to be 
quite tightly focused on a specific aspect of healthcare so would not need that level of 
organisation. The work of Braun and Clarke (2006) was then considered and agreed 
upon as the best method for this study. They provided a good overview of the role of 
qualitative research and a detailed explanation of the process of thematic analysis.  
Also attractive was that they took an educational stance – ‘that learning to properly 
undertake thematic analysis is a core skill of the new qualitative researcher’ (p4).  
While some social science commentators consider thematic analysis to be best used 
within other analytic traditions (such as Grounded theory) Braun and Clarke argue 
that ‘thematic analysis should be considered a method in its own right’ (p4).  
It was a relatively straightforward process and put and emphasis on all of the 
respondent’s voice being heard. ‘Through its theoretical freedom, thematic analysis 
provides a flexible and useful research tool, which can potentially provide a rich and 
detailed, yet complex account of data’ (Braun and Clarke, 2006, p5).  They stated that 
there were two levels of analysis at which themes could be identified. The first a 
relatively straightforward ‘semantic’ level where a surface (explicit) understanding is 
enough, or a ‘latent or interpretive level’ which offers more in-depth analysis (p13). 
This study, given the nature of the enquiry and the relatively short interview time, took 
a semantic level approach.  The statements provided by the patients were accepted 
at face value with patterns and themes forming as the amount of material grew. A six-
phase guide to data analysis was provided and followed here, this is how each stage 
was undertaken (Braun and Clarke, p18) 
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Phase One.  The researcher familiarises themselves with the interview material but 
also employs other sources such as early information gathered during the research 
problem formulation and any preliminary ideas emerging during the interviews. In this 
study, as the interviews were transcribed chronologically, they were read and re-read 
immersing the researcher in the material. Ideas for potential codes began to emerge 
from the start, such as reference to difficulties with diet while on Warfarin, and limited 
pain relief, which were also found in later interviews.  The transcripts were read in full, 
omitting no material, and they were checked against the original audio recording to 
ensure this.  
 
Phase Two. This phase sees the development of the initial codes, that is, the individual 
ideas that have been mentioned across many interviews. It is a process of clarifying, 
separating, and organising the material amassed in phase one into ideas and 
concepts that are discreet and distinct from each other. The codes were ‘data-driven’ 
– from the bottom up. They were arrived at manually; highlighter pens were used to 
colour-code the transcripts and ideas/codes were cut and pasted into groups. In order 
not to lose context – the whole human being behind the codes – each respondent’s 
transcripts was kept at hand to illuminate understanding.  
 
Phase Three.  In this phase, all the codes were allocated to large groups to form 
overarching themes, in order to structure and provide a deeper meaning of the 
sometimes factual statements and the subsequent codes expressed by the 
respondents. For example, stalwartness described the many codes referencing the 
role of the patients’ ‘resilience’ and ‘just getting on with things’.   Each code was found 
a home under one theme or another, some being reallocated on further consideration 
to get the best fit.  They were written onto post-it notes and hand sorted into groups, 
where necessary, some large groups were divided to produce a clearer theme. 
Supporting quotes from the text were numbered and colour coded to match the 
themes. 
 
Phase Four.  In this stage, with the help of a deeper knowledge of the material, the 
work of refining the themes and getting best fit for each code is continued.  The themes 
were considered against the whole person transcripts and some changed and refined. 
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Some early themes were reviewed and became two distinct themes allowing for more 
a more nuanced understanding of the material. By the end of this process, the overall 
picture of these patients’ experiences became clear. 
 
Phase five. This is when the themes were named and used to provide the broad brush 
strokes of the patients’ stories.  Effort was made to ensure that each theme was not 
too broad, failing to encapsulate a range of ideas or feelings at a level that was 
meaningful.  It should be noted here that although this study deals with human 
emotions related to this treatment programme, many of the codes and, therefore, 
subsequent themes lean towards the concrete, the practical, which sets it apart, to 
some extent, from a traditional qualitative study.   
 
Phase six. In this phase, writing the report, the researcher has drawn together all the 
material available and incorporated it into two findings chapters. She interpreted the 
material and drew conclusions, ending with recommendations which will inform more 
‘patient-centred’ future practice. 
 
3.14 Interviews with staff    
Anecdotal evidence from across the clinics concerned suggested that the clinicians 
(e.g. doctors, nurses) showed varying degrees of knowledge about of the social and 
personal impact the switch had on their patients. This may be related to the fact that 
little research had yet been undertaken, so the medium and long-term Quality of 
Life impacts were not commonly known for DOACs patients. Therefore, these 
interviews aimed to draw out the views of the clinicians and make a comparison 
with the information volunteered by the patients. For example, do both parties 
identify the same key issues or areas of improvement or concern? To draw upon 
the views and experiences as well as concerns of key staff involved in the care of 
lifelong anticoagulated patients, focus groups were first considered. But due to staff 
work commitments they proved impossible to arrange, so four staff members were 
interviewed individually. The group consisted of one doctor (the team consultant), a 
pharmacist and the two clinic nurses. (See Appendix Two for the interview 
schedule). The interview data generated was processed and analysed separately 
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from the patient’s interview data. The process again followed the Braun and Clarke 
model. A comparison was then made between the patient’s views and the data 
provided by the professional staff. Common and divergent views and levels of 
understanding were identified.  
 
3.15 Role of the researcher    
That the researcher took part in the interviews was considered a potential ethical 
issue as she was known to some of the group members. For example, they may not 
have wished to display a lack of knowledge about the topic in front of her (or indeed 
other colleagues). The researcher is, for this part of the research, an ‘insider’ 
researcher. The dilemma such researchers have was one of having ‘insider status’ 
as described by Corbin-Dwyer and Buckle (2009). ‘Insider research refers to when 
researchers conduct research with populations of which they are also members, so 
that the researcher shares an identity, language, and experiential base with the 
study participants (Asselin, 2003 and Shamloo et al., 2019). 
However, they argue that ‘the insider role status frequently allows researchers more 
rapid and more complete acceptance by their participants. Therefore, participants 
are typically more open with researchers so that there may be a greater depth to 
the data gathered’ (Asselin, 2003). It was anticipated that it would be the case here 
as the researcher was known to be an expert in the research topic although from 
only one clinical perspective. Asselin goes on to support the positive aspects of 
being an insider researcher. ‘Being a member of the group under investigation does 
not unduly influence the process in a negative way. Disciplined bracketing and 
detailed reflection on the subjective research process, with a close awareness of 
one’s own personal biases and perspectives, might well reduce the potential 
concerns associated with insider membership’. (Cracknell, 2010). To help mitigate 
this issue, the researcher undertook interviewer training at the University of 
Westminster. Interestingly, no resistance or issue was raised about researcher’s 
role, in fact the reverse was evident, Staff and patients expressed great interest in 
the research and were glad the subject was being studied.  
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This chapter outlined the research design and the methods employed detailing the 
mixed methods design, its origins, its relevance to this study and general 































Chapter 4 - Ethics and Governance  
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4.0 Ethical approval   
Ethical approval for the study was granted by the University of Westminster and the 
Integrated Research Application System (IRAS). In addition, the Imperial NHS Trust 
Research and Development Office were asked for and granted permission to 
conduct the research during anticoagulation clinic working hours on the Trust’s site. 
The participants were provided with a summary sheet of the study background, 
information about the study, and contact information in case of concerns emerged. 
A consent form for participating and a consent form to inform their General 
Practitioner (GP) of their involvement in the study were provided. See Appendix 13. 
The patients and staff will be provided with a summary of the findings in due course. 
The data and personal information were dealt with in a strictly confidential manner 
in accordance with the information governance rules set out by the trust, the 
university, and General Data Protection Regulation (GDPR) as it is applicable to 
NHS trusts in the UK. Respondents were assured that their names and other 
personal information would be dealt with in the strictest confidence. This aspect 
includes the principle of trust in which I assured the participants that their 
cooperation would not be exploited for personal gain or benefit, by deceiving or 
betraying them in the research route or its published outcomes. The principle of 
voluntary participation was explained, as was their right to withdraw from the study 
at any time. The principle of informed consent statement was attached to the 
questionnaires and verbally explained to the interviewees. Both principles entailed 
explaining the research process and its purposes to the participants.  
 
4.1 Data collection and storage    
This was a low risk study. All the scales used with the participants have been 
validated and are deemed to be reliable and widely used within the research 
community. The interview schedules were designed to be neutral and non-invasive. 
One factor, however, that needed to be considered was the risk of fatigue or the 
time burden to the patient. This was assessed on a case by case basis. The 
researcher looked for signs of tiredness or of the patient being uncomfortable. The 
purpose and duration of the study was explained verbally as well as with information 
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leaflets. The storage and use of personal information with regards to patient 
confidentially was also explained in the leaflets to the patients, who were given a 
copy of the patient information sheet (Appendix 6) and consent form (Appendix 8). 
The questionnaires were administered, and the interviews undertaken by the 
researcher. The data has been handled in accordance with the six Caldicott 
principles (Sinclair, 2013)  and the University of Westminster’s code of practice. The 
data collected was anonymised and given a key code number. The key code was 
held securely by the Director of Studies at Westminster University, Dr Patricia 
Maitland and kept separately from the data.  
The hard-copies and the transcribed reports from the patient interviews and group 
discussion were stored on a password protected recorder and on an encrypted 
memory stick, which was kept in a locked safety filing cabinet at the University. The 
information gathered using the memory stick, digital recorder and patient survey 
was electronically transcribed at the earliest opportunity using Dragon® auto 
transcription software. It was saved to a restricted drive on the University of 
Westminster’s secure server. This drive was viewable only by the researcher and 
will be kept for 5 years in accordance with the UK Data Protection Act of 1998, after 
which all data will be deleted from the drive. The hard copy of the raw data will be 
disposed of using confidential waste shredders.  
In formulating the Quality of Life survey questions for the patients, care was taken to 
consider the following:    
• Invasion of privacy    
• Sensitive questions    
• Voluntary participation    
• Informed consent    
• Benefits to patient    
• Risks to patient    
• Benefits to NHS Trust    
• Risk to NHS Trust    
• Patient confidentiality 
• Patient consent.  
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The standard complaints procedure was available to the participants if requested: 
they may contact the Ethics department at the University of Westminster. The 
Faculty Dean, Prof Annie Bligh, the University of Westminster sponsor, was the 
point of contact for any complaint. Alternatively, the Imperial College Healthcare 
NHS Trust patient advice and liaison service (PALS) or complaints team could also 
be contacted.  
As this research involves the elderly the researcher is mindful of any potential 
distress which might result from the study (Green and Thorogood, 2018). Should 
participants require follow-up support following the study, they would be referred to 
the anti-coagulation or cardiac arrhythmia team for clinical and social support. The 
team, which comprises medical staff, was best equipped to manage or change 
anticoagulation therapy if required by the participants.  
 
4.2 Project governance, management and support    
The Short Form 36 measurement scale (SF-36) is validated in the UK for use in QoL 
studies either in person or via telephone, in both paper and electronic formats. Dr 
Trudy Edginton and Dr Maria Woloshynowych (University of Westminster) acted as 
advisors for the administration and data analysis, likewise, the administration and 
analysis of the PSS and CFQ.  The researcher was granted Student Academic 
Research License by Optum, the company which publishes the scales, allowing 
access to the Short Form 36 instrument along with scoring materials. The 
identification of patients who are suitable for switching from Warfarin to DOACs is 
currently performed by the anticoagulation nurses and clinicians. All background 
investigations, such as checking patient clinical relevance to the study (age etc.) 
and data analysis was carried out by the researcher. Dr Patricia Maitland advised 
on the qualitative data collections and analysis. Dr Abdul Shlebak, Consultant 
Haematologist (General Haematology, Obstetric Haematology, Haemostasis and 
Thrombophilia) and Lead Laboratory Clinician at St Mary’s Hospital, Imperial NHS 
Trust, acted as a local research advisor. 
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Other occasional advisors were Dr Frances Akor, Consultant Pharmacist for 
Anticoagulation at the Imperial College Healthcare Trust, and Ms Jo Burke, Lead 
Anti-Coagulation Clinic Nurse. Any input to the research based on their area of 
expertise was ad hoc or on pre-scheduled dates, depending on their availability. 
Anticipated peripheral support for this study was provided by the University of 
Westminster’s Doctoral Researcher Development Programme. They include 
workshops on ethical issues, analysis of statistical data, academic writing, and the 
dissemination of findings.  
 
4.3 Dissemination of findings     
In the first instance, the findings will form part of a doctoral research degree and 
written up as a thesis for submission, and may be published on the University’s 
repository Westminster Researcher and on EThOS. As St Mary’s hospital is a 
stakeholder, summary findings of the report will be discussed with participating 
clinical staff and members of the steering group. The findings may then be used to 
inform clinical decisions with regard to patient anticoagulation care with DOACs, to 
revise policy on patient-centred care, and possibly on policies regarding self-
monitoring of oral anti-coagulation especially in the elderly (>65 years). Based on 
the findings of the report, a set of clinical recommendations will be produced to 
facilitate these clinical changes.  
As the targeted age group of the study is over the age of 65 years, a plain English 
summary, as opposed to an electronic version, was printed in leaflet/flyer format, and 
given to all participating patients. A summary of the findings may also be posted on 
‘The Source’, the Imperial Healthcare NHS Trust website, and submitted for publishing. 
The summary may reassure the patients that their on-going medical care is not just 
based on the risk/benefit of the new drug, but that the best clinical outcome (i.e. 
improvement in health and Quality of Life) is also considered.  
Publication of the findings in professional journals will also be considered.  
 













         
Chapter 5 - Findings Part One:  
    
The first patient interview at the time of the switch 
to a new drug regime.  
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5.0  Introduction - Participants and Procedure.  
As discussed above, this study is a mixed-method exploration of the views and 
experiences of older patients living with AF who have been on a long-term Warfarin 
treatment plan. This chapter reports the findings from the first interview with 20 of 
the 56 participants. The interviews were held at the time of the patient’s switch-over 
to a new drug regime. A second interview followed three months later and is 
reported in the next chapter. During the interviews, the Perceived Stress Scale and 
a general health measure were administered, both of which are fully reported in 
Chapter 7 but are also briefly referred to here. The four staff interviews are drawn 
on briefly when exploring the effectiveness of information and communication 
between staff and patients. To provide context, the patients’ general health and 
medications, apart from Warfarin, are first outlined. Their experience of life on 
Warfarin is next explored: how it impacted on their daily routine and implications for 
their family and social life, and how well they managed self-medication. Then their 
expectations, if any, of the new drug regime are explored. Finally, the effectiveness 
of information provision in its various forms is discussed.  
The data were analysed using the Clarke and Braun 2006 guidance for the 
development of themes emerging from the interview material. The full process has 
been set out in chapter three. To understand how the main themes were arrived at, 
see Appendix 14, tables 1 and 2 which show the main themes and supporting 
codes.  
5.1 Managing Complexity – living with multiple medical conditions while on 
Warfarin. 
Given the age of the sample it is not surprising that they were experiencing a wide 
range of medical conditions in addition to AF, including arthritis, high blood 
pressure, chest infections, high cholesterol, and asthma. It was reported frequently 
by the interviewees that one condition could pave the way for another; the older 
the patient the more medical conditions they disclosed. Importantly, treating their 
other conditions conflicted frequently with taking Warfarin. For example: 
‘I get these chest infections all the time, it’s horrible, and sometimes I’m 
up all night coughing. The antibiotics will get rid of the infection, but my 
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INR is up and down because of it. My wife is not very well either and we 
keep passing the chest infection back and forth, it’s like a vicious cycle’. 
MK, man 86ys.       
‘Every time I take antibiotics, my INR goes up, and I keep getting all these 
infections, especially when it’s cold like today’.  SS: woman 82 yrs.      
It is clear therefore, that AF is not the only medical issue that many have to manage. 
This needs to be kept in mind when exploring how they have coped to date and 
their responses to the new drug regime. It seems to be a balancing act:  
‘I take atorvastatin, tramadol, metformin, amlodipine and Salbutamol; 
Sometimes antibiotics and vitamins, but I have to be careful because my 
INR is always out of range’. GD, man 65ys.     
‘Hypertension, diabetes and epilepsy, and I was only recently diagnosed 
with ADHD as well. I have a grandson who is 7, he is so much like me, and 
my daughter told me that K has ADHD, so I went and got tested and imagine 
my surprise to be told at 64 that I have ADHD’.  BP, man 65ys.     
 
Despite the multiple illnesses, when asked about their current state of health, most 
interviewees declared that they were ‘fine’ or ‘okay’. In many cases it was only 
when direct questions were asked, often when completing the stress and health 
scales, that pain and other discomforts were disclosed. There was a tendency for 
many within this group to dismiss joint pain and body aches as part of ageing, to 
be coped with by self-medicating or quiet endurance.  
 
5.2 Stalwartness 
This reticence to complain, to be stalwart, emerged as a theme in both the first and 
second interviews and is explored more fully in chapter six. It is important to note 
that this overly-positive response cannot be regarded as ‘denial’ as such on behalf 
of the patient – they understood how ill they were – but rather a need not to dwell 
on their illness and not to bore other people by complaining. There is also a desire 
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to be normal – not always being seen as a patient and having a sense of control 
over their lives. However, once they began to talk freely multiple issues emerged, 
along with the difficulties encountered coping with them.    
The real life facing many of the interviewees was difficult and uncomfortable.  This 
man’s response was typical and tells of the impact of having several conditions:    
‘Oh yes, I have high blood pressure, high cholesterol and arthritis. I also 
have diabetes and every now and again I get these bad chest infections, 
especially when it’s cold or damp like today. I get all these ache and pains, 
so depending on what they give me, the INR can be sky high’. AB, man 91ys     
Two factors in particular emerged as prevalent and, at times, difficult to cope with: 
living with pain, and poor quality of sleep. Both tested the patient’s stalwartness. 
Pain was the most frequently occurring complaint with over half of the patients 
experienced it in varying degrees, and it had a direct impact on their quality of life. 
For some it was acute, the result of a recent operation, for others chronic pain 
accompanied arthritis. Typically, these patients complained of several pains: 
‘I have pains all down my back, in my hands and in my knees, I used to play 
rugby with my son as recent as 3 years ago, we used to go for a scrummage 
and that, but I can barely make it up the stairs most days’. BP, man 65ys.      
‘I had hip replacement surgery about 6 months ago, so I can now get to the 
shops up the road and back with my stick, but I have to stop when I feel the 
pain coming on…... I rest a bit then I carry on. It can take a while but it’s 
important to keep active’. OG, man 82ys.    
The degree of pain endured while on Warfarin is worth exploring because most 
pain relief medications have an adverse effect on the Warfarin patient’s INR. They 
were therefore underused, leaving the patients with little relief. Successful pain 
management become a more important factor after the switch.  
Another frequently raised factor, which strained their positive attitude to life, was poor 
quality sleep caused by constant pain. This was a typical comment:  
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‘I don’t sleep much these days. Sometimes I only sleep 3 or 4 hours a 
night, and even then, I have to sleep propped up by pillows in a sitting 
position, it’s very painful’.  MF, woman 65ys.     
The theme of stalwartness was reported by many but not all. Some, often the older 
patients, found life very trying indeed and felt little sense of control over their bodies.  
 
5.3  Loss of Control – the domino effect 
Contrary to the theme of stalwartness, a significant minority of patients said they 
were only barley coping. Physical illness was not the only factor of concern and for 
several not the most pressing. At points during the interviews some participants 
were quite emotional with a few revealing psychological issues of concern. 
Approximately a third reported feeling lonely or being down in spirits or depressed 
at times; social isolation, it transpired, was a major factor in the lives of several. 
Along with this was a feeling of a loss of control, not just over their physical pain 
but also their social life and a dislike of having to receive help with daily tasks. The 
resultant loneliness clearly had a profound impact on some. For example:   
 
‘I get upset, sometimes. I don’t think that I have much control. I feel so 
depressed all the time. I sit in all day and then go to bed cause I’m widowed 
you see. I don’t think that things are going my way, I don’t see a future 
actually. I just wish I had an answer to it all. Just so much going on’.  JW, 
woman 82ys. 
Others talked of the simple daily living activities being difficult to negotiate alone, at 
times physically and emotionally exhausting. For example:   
‘Ever since she [his wife] passed away, it’s been really hard, I find it hard just 
doing day to day stuff’. AB, man 86ys.  
Limited mobility was also mentioned by some as another cause of isolation and a major 
restriction on family interaction. This woman told of her plight:  
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‘I can’t walk very far, I need help getting dressed and all my relatives live so 
far away, and we never had kids. I get really lonely sometimes. I looked after 
my husband for 24 years before he passed away’.  SS, woman 82ys.  
All the participants, to some degree, felt restricted or not in full control, for example in 
eating, or rather in their choice of food being limited because of their medication. A kind 
of domino effect that they could not control was established – their life-saving 
medication led to major implications for their general health. Just under half stated that 
they experienced problems with food interaction and how ‘getting it wrong’ can impact 
their lives:    
‘Warfarin affects everything, from what pills I can take for my pains, to what 
type of vegetables I can have’. JW, woman 90 yrs.    
‘The hardest part is trying to co-ordinate the diet for taking Coumadin with a 
diet for diabetes’. ML, woman 89 yrs.    
A result of a restricted vegetable intake was, for several, the difficulty of maintaining 
a healthy weight. Patients who had embarking on a weight loss regime had to have 
their INR closely monitored at the clinic as their weight reduced. For example:   
 ‘The doctor told me that I had diabetes, he said that I am now at an even 
greater risk of a stroke. So, he suggested that lose some weight by gentle 
exercise and a change in my diet, but I noticed that kale, liver, and green tea 
would wreak havoc with my INR. It was later when I spoke to the nutritionist 
at Hammersmith that I was told that all the green leafy vegetables are a no 
go. That made dieting very difficult’. KS, woman 65ys.   
To compound matters for those who wished to lose weight, they said that if they 
exercised regularly they needed a higher Warfarin dose. Not being able to do even 
light exercises such as walking was reported as being one of the major daily 
problems because it hindered other health-promoting activities.  
The sense of reduced control extended to mild and serious physical reactions to 
Warfarin. One side effect, and one of the most unpleasant and embarrassing, was 
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the propensity to bruise without knowingly sustaining an injury. Several participants 
reported bruising even after a mild knock or even dental treatment:    
 ‘My face was really swollen and bruised after having dental work done while 
I was taking Warfarin. It really looked awful’. GA, man 68 yrs.     
It was not the discomfort that caused them anguish but having to explain the 
bruising to others, often healthcare professionals, and the questions that might 
follow.  A few wondered what people might think had happened to them; had they 
been a victim of domestic abuse perhaps. This could lead to a negative impact on 
their self-image:    
 ‘I was embarrassed and worried.  This was when M (his wife) was alive; 
we had a home visit to decide if she should go into care, and I had a black 
eye. I just get these bruises all the time. I was worried that she (the nurse), 
would think that M had hit me and take her (M) away…. She died a few 
months later, but at least she died at home, like she wanted’. FM, man 91 
ys 
Light-headedness caused by Warfarin was also a complaint by several patients. It 
could occur at any time, but most participants seemed to be aware of the danger 
points for their dizziness:    
‘……and just getting up quickly from the bed would make me lightheaded’. 
FM, man 91ys    
As well as bruising, cuts and bleeding are a constant fear of those taking Warfarin,  
more than half of these patients reported some form of bleeding. It could happen at any 
time without warning during regular activities such as a visit to the dentist.  For example:    
 ‘My only issue is my bleeding gums; the dentist says it’s related to Warfarin 
because I have healthy gums……usually when I brush my teeth, but they 
can start bleeding if I have any course or hard food, even toast can 
aggravate my gums’. AG, woman 71.    
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Fortunately, most cuts were dealt with without hospital admission, and this sample 
did not report many emergency hospital visits due to bleeding.   While not life 
threating in itself, bleeds caused considerable distress and discomfort.  
Two patients experienced less common side effects, but nonetheless distressing:       
‘I developed dermatitis since being on Warfarin, which affects my quality of 
life at this stage. I feel like people are always looking at me, I detest 
Warfarin’. GD, man 65ys.    
‘…. it’s called priapism (a persistent and painful erection of the penis), 
apparently it’s a rare side effect so I guess that makes me special 
(smiles)’. BP, man 65ys.    
It is clear from these interviews that life on Warfarin for a good number of patients 
can be difficult, with a range of physical and social consequences that, if not life 
threatening, make daily life uncomfortable and reduce their sense of control.  
 
5.4 Freedoms Lost – the impact on social and family life     
Further restrictions were cited by some patents. Leading a fully integrated social 
and family life was impacted negatively by their Warfarin regime.  
 ‘I used to play rugby with my son a lot, but because of all the pains in my 
joints, I can’t go up to the field much’, BP, man 65ys.    
In addition to participation in sports, travel was also affected. Simply taking a 
holiday became a major undertaking, particularly for long distance visits. Patients 
travelling to different time zones had to ask the clinic about the timing of their dose. 
Time differences of up to six hours were relatively easy to manage, they said, but 
travelling from London to New York (five hours behind London) as one man wanted 
to do, required him to calculate the time difference in order to take his medication 
on time. Some altered the timing of their doses gradually (e.g., two hours earlier or 
later each day) in the run up to their holiday and reversed it when returning home. 
Long range travel was curtailed, as for this man:    
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‘I mean it’s difficult to travel to see my family in Barbados, the GP says it’s 
too long a flight and I am at risk of a DVT’. RB, man 84 yrs.    
It is important to note that it is not only the medication itself that has an impact on their 
movement, but the whole clinical process proved burdensome for some:    
‘I’m a solicitor, so I could be called away in the middle of the night for a 
consult, so having to come to the clinics every other week sometimes gets 
in the way of trials or client visits. I usually have to plan my travel around the 
clinics or sometimes I miss the INR test at the clinic’. HM man 66 yrs.    
Importantly, it is worth noting that several patients expressed little difficulty with travel 
arrangements, for example:     
‘I’m sure that there are people worse off than me, I still travel every now and 
then and I’m not dead yet (laughs)’. GD, man 65 yrs.    
Another factor that impacted on the social life of a few was that mixing alcohol and 
Warfarin can be problematic. This woman seemed to know the risks but had a drink 
regardless:     
‘My INR is always up and down; I enjoy a tipple every now and again, which 
causes it to shoot up as well. This blooming Warfarin seems to shoot up for 
no reason, so I’m interested to see what happens with this new one’. MR, 
woman 65ys.    
For another woman, the occasional drink was hard to avoid given that she worked in 
a pub:     
‘Because I’m working in a pub, punters sometimes buy me a drink or two 
when they get the rounds in, but I know that I can’t drink like I used to 
because drinking causes the INR to be so out of control. I mean I have one 
here and there, but I do worry about it all the time, especially as I am getting 
older’. KS, woman 65ys.    
It was a risk, but one that some patients were prepared to take. Happily, there were no 
reports in this study of any serious side effects as a result of dose manipulation or 
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alcohol.  This is an indication of Warfarin’s long reach into people’s lives and that a 
domino effect can easily begin.   
 
The impact on families also needs to be noted here. They were often involved in the 
daily care of the patient, with emergency hospital visits from time to time in cases of 
a bleed, then nursing the patient while they recovered at home. However, the 
participants were sometimes not the only patient in the household:  
‘I take care of my wife, she has dementia, arthritis, diabetes, you name it. I 
used to miss a lot of the clinics and my Warfarin was all over the place…...it’s 
funny, she was always looking after me, I never even imagined that I would 
have to look after her………...39 years married this July’. JP, man, 73ys. 
Caring for his wife had a negative impact on his own health routine.  
 
5.5  Self-Reliance is Key – but within a partnership 
Despite the considerable medical and social difficulties faced by these patients, a 
culture of ‘you just have to get on with it’, of self-reliance, prevailed.  While each 
respondent had their own way of managing their medication, two factors became clear 
as key to their wellbeing: 1) being organised, and 2) the importance of the role of an 
efficient GP’s surgery to support their own efforts.   Being organised took several forms. 
Many respondents talked of their methods of self-medicating, with most integrating the 
Warfarin into a daily hygiene routine such as brushing their teeth:   
 
‘I have no difficulty taking Warfarin: the tablets are small and easy to 
swallow’. OG, woman 65ys.    
 
Mitigating against this sense of order, however, was forgetfulness, the most 
common reason for missing a dose. Sometimes it was what could be called 
‘medication fatigue’:    
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‘Sometimes I forget to take my Warfarin, I take 8 tablets a day, some before 
meals, some in the morning and some last thing at night. It can be annoying 
trying to keep up with which ones to take’. MF, man 73ys.     
Other patients took the possibility of forgetfulness into account and were well organised 
taking their Warfarin regularly. This lady did have help however:     
‘Yes, I have a pill box that my husband always checks and stocks up. He is 
a bit younger than me and is registered as my care-giver. He comes with me 
every week to my appointments’. AB, woman 91ys.    
Being organised included knowing their condition well enough to be able to 
successfully manipulate their table dose. Almost all admitted to changing the dose 
of their medication without medical intervention or advice: 
‘If I’ve been out drinking, I sometimes don’t take the whole tablet, I will break it in half. 
I’ve had this heart problem and been on Warfarin for so long, that I feel confident to 
swap and change, it’s always all over the place anyway….’. GD, man 65ys.    
The clinic check-up was generally viewed in the same light, as just a small 
inconvenience worth putting up with if planned well:     
‘I usually have my blood test on the way to work, it only takes fifteen 
minutes and they give you a little pin prick and they give you the results 
straight away’. GA, man 65ys.   
 
5.6 Partnership in care – having a good GP.    
The need for good organisation went beyond the patient’s own sphere of control to 
the medical support offed by the NHS.  Self-reliance could take them only so far; a 
good, easily accessible, well equipped, GP surgery was also essential. One much 
approved of organisational feature was the increased use of technology. An older 
respondent praised the new machine at his GP’s surgery which tested his blood 
with a finger prick test, and provided immediate results so that his doctor could 
adjust his levels of Warfarin if necessary:     
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‘It is so much easier than the old one [machine]. You had to wait for them to 
warm up and check the machines which took ages, but these ones are just 
like my diabetes one at home. They put your blood on a little strip thing and 
you get the result, amazing’.  GB, man 81ys.    
Interestingly, the smooth running of their medication regimens is not, it seems, 
according to these interviewees, depended on age. Both the older and younger 
participants talked of the need of being well organised. The main difference was 
that with the older patients they were generally organised by others.  
 
5.7 Responses by sex and age   
As well as whole group responses as set out above, the interview data were 
examined by age and sex to see if any difference in views between the sub-groups 
could be identified. Some small differences were seen. Patients aged 75 years or 
over were more likely to show openness to being switched from Warfarin to DOACs, 
but the reason for this finding is unclear.  It is possible that Warfarin-related food 
restrictions are more of a burden for elderly patients who may prefer traditional 
green leafy vegetables, so the switch was made more attractive to this group.  
However, several patients under the age of 75 were also open to change, so it is 
important not to make too much of this finding.   
When it came to identifying the differences across the age groups with regards to 
the main themes discussed above, a few findings are noteworthy.  The views and 
issues could be found across the whole group, though with some patterns forming 
between groups. All patients, but with varying degrees of enthusiasm, said they 
were ‘fine’ until more detailed questions were asked. The culture of stalwartness 
was true for the older and younger patients alike. However, when the interview 
revealed personal distress or sadness, it was noticeable that the patients who were 
in the 65-74 age group made fewer references to symptoms of anxiety or 
depression than those over 75yrs in similar circumstances.  It was also noted that 
patients over the age of 85, as would be expected, more frequently reported poor 
functional status. Life was more difficult all round; mobility difficulties were more 
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pronounced, pain was often present, and more in this age group tended to live on 
their own increasing their sense of isolation:    
 ‘I have so much pain all over, I don’t get much sleep ever since my hip 
operation. If I stay on Warfarin, the cardiologists said I will not be allowed to 
have Naproxen, which really helped me before I was on Warfarin’. JW, 
woman 90 years.  
 ‘Bingo on a Thursday, but not much else since my husband died, I don’t 
always get to go as well. My only daughter moved away when she got 
married’. AB, woman 68ys.   
A sense of freedoms lost because of the medication was slightly more pronounced 
in the younger group, as they also reported more activities, they had wished to do 
but were prevented from doing so. They also seemed to have more questions for the 
nurse and consultant, the older patients being more accepting that a switch would be 
in their best interest.   
  
No clear pattern of differing views between the sexes was identified, however some 
small tendencies emerged. For example, men more often reported being socially 
active than women, so felt marginally more restricted by the Warfarin regime. 
Conversely, the woman more frequently raised the issue of being alone a significant 
amount of the time. This was most commonly noted in those who had lost a partner 
or other social support. Importantly, more women revealed concerns about a decline 
in mental health and wellbeing, linking with a feeling of not being in control of their 
own body. The men detailed more negative impact from the Warfarin regimen than 
the women. This may be related to their more active lifestyle, and wishing to 
undertake even more activity but feeling prevented from doing so. Interestingly, 
there was no division between the sexes when it came to concerns about the new 
medication. In particular the often voiced concern, ‘how will I know if it is working’? 
was evenly spread across the sample. While small differences can be identified 
across the ages and sexes related to some themes, it needs to be remembered that 
this is a small sample and, like all interviews, is dependent on how the participant 
was feeling on the day.   
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5.8 The provision of information  
One goal of this study is to improve, where needed, the patient-facing services 
provided by the haematology clinic. To this end, questions were asked about the 
amount, method of delivery and appropriateness of the information available about 
AF, about the switch-over, and about the new drugs prescribed. The topic was raised 
at the time of the switch and again at 90 days. To avoid repetition, this analysis 
combines material from both first and second interviews. In addition, material from 
the clinical staff’s interviews is included to provide a rounded picture.  
  
Most of the participants voiced at least a minimal understanding of their medical 
condition (AF) which necessitated their being on Warfarin, and several were well 
informed. Many had lived with AF for a long time and knew the condition well, 
including the possible health crises that they were susceptible to:     
  
‘I have been taking Warfarin every day for 15 years to reduce my risk of 
stroke and am very pleased to say that I have never had one’.  BP, woman 
77ys.    
In general, the patients showed a good understanding of the medical care required 
to keep them stable although, importantly, there was a leaning toward the younger 
patients being better informed.  Three themes emerged related to the provision and 
source of their information: that the material was current; was age appropriate 
(method and clarity); and a culture of ‘learn as you go’ prevailed.  First, it became 
clear that that for several patients their original information, provided when they 
were first prescribed Warfarin, which for some was over 15 years ago, was now old 
and had not been updated. Unless they asked staff about something, specific little 
or no ‘refresher’ material was forthcoming; the habit of just asking the nurses about 
any emerging issue was well established. There appeared to be a general 
assumption among patients and staff that they knew ‘all about it’ by now.  
Secondly, age appeared to impact the level and depth of knowledge and an 
understanding of the benefits and risks associated with Warfarin and the new 
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drugs. The older patients, 75+, demonstrated poorer knowledge than their younger 
counterparts; indeed, the knowledge level among older participants appeared to 
be quite superficial and fragmented.  Many could not explain with any degree of 
precision the rationale for taking Warfarin and the associated risks. Some were 
reliant on others for help:  
 
‘My daughter is a nurse, so she has told me a lot about it’. OG, woman 84ys.      
 
The younger participants, under 75ys, were more knowledgeable, and a small 
group was very well informed, talking of their use of the internet and having read 
widely on the subject.  
  
The third theme, common across the group, was that, in their view, the best source 
of information was experience, not only their own but that of others. Being in the 
older age range of the general population increased the likelihood their of knowing 
other people in their daily life who were also on Warfarin and experiences were 
shared. Some patients had become skilled in self-monitoring, developing a reliable 
sensitivity to their own wellbeing: 
  
‘Over the years, you learn more from other patients and the clinic. I learn as I 
go as well. Sometimes I know the dose change before the nurse tells me’. AC, 
man 82ys.    
  
However, informal information sources had risks. One lady, who had been on Warfarin 
for years was made unnecessarily anxious:    
  
‘What’s worrying me is that lots of my friends and people I’ve met tell me 
that they would never take Warfarin as they’ve heard terrible things about it. 
I’ve heard rumours that it’s been used as rat poison or could cause me to 
bleed to death. It seems a very unpopular drug’. AM, woman 85 ys.    
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 It was understood from these interviews that formal information, regardless of the 
source, had its limits in keeping patients safe – personal vigilance was always required:   
  
 ‘I was told to watch out for major bleeding from my stomach or bowel, 
which is a potential complication of taking Warfarin, but luckily I have never 
suffered anything like that’.  SC, woman 82ys.   
  
5.9 The Switch Itself – the level of perceived understanding of the reason for a 
switch and the process   
These patients had good recall about why they had switched drugs. Several listed 
the following reasons: poor compliance with Warfarin, pain that could not be relived 
with other medication, problems with food interfering with the Warfarin, bleeding, 
and bruising. Most participants agreed with the doctors that a switch was required, 
but some without much enthusiasm based on not really seeing a problem. However, 
overall, there was a general expectation voiced that they thought things would 
improve for them over the next few months as a result of the switch.    
Regarding information provided about the switch-over there was generally an 
expression of satisfaction across the group regardless of age, sex, or state of health. 
The information had taken the form of discussions with their GP, consultant, and 
nurses at the clinic, but the delivery varied in effectiveness.  Some professionals, it 
was said, explained things better – in more detail – than others.  In addition, there 
were leaflets for the patient to read at home and share with family members. 
Importantly, it appeared that the speed of delivery (too fast) and the amount of 
information (too much) impacted, for some, on the comfort and effectiveness of the 
experience:    
‘It was all explained to me at the time by the nurse at the clinic. I’m not 100% 
with all the information and leaflets and stuff, but it all seems ok so far’. ML, 
woman 89ys.   
‘Like I said, it was the clinic that explained it all to me. The GP didn’t explain 
it as well as the nurse. I came last month for my check up and she (the nurse), 
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took her time and made sure that I know not to skip a dose or take two if I 
forgot’.  DF, woman, 84ys.  
 
5.10 The clinical staffs’ view of information provided.  
Each week the staff saw dozens of Warfarin patients and between four and eight 
on DOACs. Their own information sources about the administration and use of 
Warfarin and the new medications came primarily from brochures and factsheets 
supplied by the pharmaceutical companies concerned and a booklet prepared by 
the Trust. The doctor kept his knowledge updated by reading journal articles on the 
topic and consulting the NICE guidelines.  On-line information, which they said was 
plentiful, was also consulted.  Interestingly, no one reported being on a training 
course or expressed a need for more information; they felt sufficiently well informed. 
The team’s lead nurse had also prepared an information pack for the patients. The 
staff confirmed the patients’ accounts of the process of information delivery: that 
conversations were had in the weeks before the switch, and written information 
given to the patients at each stage.   
 
5.11 Trust is the key to understanding  
Importantly, despite the abundance of information in various paper and electronic 
forms, the key to good information exchange, claimed the staff, was trust, namely 
their relationship with the patient which had been built up over the years. The trust 
between patient and nurse was crucial, they argued, in the patient agreeing that 
something was going wrong with their existing programme, and so considering a 
new drug, and then going ahead with the different treatment.  Reading about the 
medications was not enough; patients needed to be able to ask questions, 
sometimes repeatedly. Without the human interface the information exchange 
would have been much more problematic.   
5.12 Summary   
Warfarin as a lifelong medication has a long reach into people’s lives.  As well as the 
cardiac therapeutic impact, themes emerged from these interviews indicating that it 
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can profoundly affect many aspects of the patient’s daily routine, their comfort and 
their sense of wellbeing. The interviews reveal the high degree of comorbidity among 
these patients, and how one condition often triggered another.  Despite this, there 
was a culture of stalwartness across the group, and a high degree of trust in the 
medical staff who cared for them. Living with Warfarin meant a constant alertness for 
harm, and a degree of loss of control over their bodies and their lives. This extended 
beyond family life to relationships in the outside world, where they thought that the 
occasional results of treatment, bruising and bleeds might draw unwanted concern 
from others.   
  
Self-reliance was a major theme, but just as frequently raised was the need of a good 
GP to confide in and for clinical support.  The provision of information was reported 
as good but variable, and to some extent depended on when the patients had been 
put on Warfarin, with the more recent cases tending to be better informed. There is 
a need however, for age-appropriate information (e.g. large font and layman’s terms) 
to be available.   There are just a few differences between the men and women with 
regards to the main themes. Some are related to age, but none were unexpected. 
There was no difference between the sexes or age groups when it came to concerns 
about the new medication, which ran through the whole group. The concerns focused 
on the monitoring of the effectiveness of the new medication.  
 
These patients indicated that to be effective and to keep their anxiety to a minimum, 
the information needed to be detailed, with questions anticipated and answered in 
simple language; unrushed with time to answer questions, and repeated at several 
sessions. That is, conducted through face-to-face conversations with both clinicians 
and nurses, on more than one occasion, and with opportunities to ask questions, 
even extending for some time after the switch. Communication also needed to be in 
both a verbal and written format.  Plain language leaflets were required for the patient 
and, just as importantly, for their family to read and retain.   
  
The next chapter reports on the second patient interview at 90 days, and the emergent 
themes between the two sets of interviews are compared.  
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Chapter 6 - Findings: two  
    
The second patient interviews 90 days after the switch,  










 6.0 Participants and Procedure 
At the heart of this chapter are the patient’s observations about their lives during the 
first twelve weeks after switching medication, and how this compared with life on 
Warfarin.  The first interviews, at the time of the switch, were reported in the previous 
chapter and surfaced several key themes which dominated their thinking. Three 
months later additional themes had emerged. This analysis is followed by an 
exploration of the clinic staff interview data and continues from the previous chapter.  
A decision was made to integrate the staff material within the body of the patients’ 
findings in order to make comparisons and to avoid the repetition of themes within 
the thesis.  
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As stated in the methods chapter, the same twenty patients participated in a second 
interview.  During the first interview, as part of the consent process, the patients 
provided their contact information, also giving permission to be contacted at 30 days 
(for the questionnaire to be administered) and 90 days (for interview and 
questionnaires) to explore their experience of the new medication. Since some of the 
patients were not due to return to the clinic at the 90 day point, eight of the 20 were 
interviewed by telephone. As this was the third time the researcher and patient had 
talked on this subject it was considered that the relationship was strong enough for a 
telephone interview to produce good information. This proved to be the case, and no 
patient expressed reservations about a telephone interview. The interview began with 
a personal reintroduction by the researcher, and a summary of the purpose of the 
interview and research aims. In addition to the interview, the patients were given an 
appointment by the clinic staff to attend the anticoagulation outpatients’ department 
at St Mary’s Hospital in order to answer any clinical questions they might have. The 
perceived impact that switching to a new drug regime had had on the patient’s health 
and their life in general was discussed, as was their satisfaction with the service 
provision from the anticoagulation team at the St. Mary’s Hospital. The interview 
material is initially reported as whole group responses; then by sex and age (65-74ys, 
75-84ys and 85+).  
 
6.2 General health after the switch.  
As expected, the range of age-related medical conditions listed at time one 
remained unchanged: diabetes, high blood pressure, arthritis, general pain, 
recurrent chest infections, high cholesterol, and asthma. However, it is important to 
note that several conditions were reported as being less severe. The reasons why 
this was the case was not always clear, but several signs and symptoms were 
reported as being, in the patients’ view, positively impacted by the switch to the new 
drugs.   
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6.3 Stalwartness – a continuing theme 
In the previous chapter it was reported that the patients, when asked how they were, 
often replied ‘I’m fine’ but on further probing reported discomfort or had a range of 
other medically related worries. This was also evident throughout the second 
interviews; a culture of ‘keep calm and carry on’ was expressed by all ages and both 
sexes. Stalwartness continued to pervade the conversations. For some, this took 
the form of not complaining to the clinical staff about their personal or social issues. 
Interestingly, no interviewee stated that the healthcare staff were unhelpful, but 
rather that they had sense of stoicism and did not want to bother them.   
However, some concerns were raised by the patients, but these were about the 
‘system’, for example, too long a wait to receive a GP appointment.  This initial 
positive response when asked about their health was, however, undermined 
somewhat when they began to talk in more detail about their chronic medical 
conditions. This reticence to complain to staff was not always in the patient’s 
interest, for during one or two interviews comments made were so concerning to 
the interviewer that referrals were made to clinical staff for further investigation.  This 
theme of outward stalwartness is important here as it can in mask a patient’s real 
situation and lull their clinicians into believing that all is well, and only when the 
patient’s test results are of concern is there a fuller conversation with the patient. 
This tendency for some patients to underplay their complaints is known in 
healthcare research, and was one reason for including scale questionnaires in this 
study. These provided an additional data source to complete the picture, and were 
gained obliquely so did not suggest that the participants were complaining about 
their lot.  The scales also acted as useful prompts during the interview, thus 
capturing additional rich data.  
 
6.4 A leap of faith – responsibility for own wellbeing and a reduction in 
dependence on healthcare professionals  
Possibly the most important feature of the new regime was that the patients no 
longer needed to attend clinic regularly for a check-up. The responsibly for their 
welfare was, therefore, now moved onto the patients themselves.  For some this 
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was a significant change, while in the majority of cases the routine of self-
medication was reported as presenting no problems once it had been established. 
Those who lived alone felt the burden more acutely; that it was very much up to 
them to get the tablet taking ‘right’, as there was no one to support or remind them. 
While this had been the case when they were on the old Warfarin routine, the 
clinical check-up had always been there as a backup.  The lack of regular clinic 
check-ups added a new level of anxiety.  ‘How will I know if I am ok?’ was repeated 
by the majority of participants of all ages. For example: 
 ‘Yeah, I feel fine, but I was really worried at first, …. I’m not sure if they [the 
new drugs] are working? It was really a leap of faith, after being on Warfarin 
so long, but it’s no different to the blood pressure ones, cause they don’t test 
for those ones. (laughs)…. It’s all fine, I am getting used to them’. BP, man 
65ys.  
For others is will take a little longer to feel confident: 
‘I understand a lot more about the new tablets now, but I am still not used to 
them. I guess it will take time. The clinic nurse said that I can come in or call 
if I have any questions. That helps, but I still get anxious cause I’m not sure 
it’s working’. JW, woman 82ys.  
 
Despite these worries they adapted and kept going:  
‘So far so good, thank God. No, I haven’t been back to the hospital since the 
last time. It’s getting a bit warmer so the pains in my hands are not too bad 
now. I can take the naproxen now too, I had to stop it for a while, but the GP 
has put me back on it. So, it’s all good thanks’. VP, woman 89ys.    
One new responsibility raised as a concern by several was that for the medication 
to be effective, it needed to be taken at the same time each day. It was mostly the 
older participants who mentioned it, and their main concern was poor memory – 
forgetting to take the tablet or taking two by mistake. Some patients had, therefore, 
developed techniques to help themselves:  
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‘I take so many tablets, some before meals and some after meals, I tend to 
try and keep my tablets in a set order on the kitchen counter, but if someone 
tidies up and moves things around, I can get a bit muddled….’. FM, man 
91ys.    
It is important to note that having to keep to a strict timetable was not enough of a 
problem that they reported regretting the switch. The earlier theme of being well 
organised remains as important as ever. 
 
6.5 Liberation – regaining control  
The majority of these patients talked enthusiastically of a newfound freedom now 
that they were liberated from attending regular healthcare appointments. Most were 
very happy with the greater flexibility provided by the new regime. With the weight 
of the old restrictions lifted many took up opportunities to visit friends and relatives 
in other parts of the country, or to just be a tourist: 
 ‘It’s made a difference; not going to the clinics, I can actually make plans’. 
BP, man 65ys.  
 ‘My holiday to Turkey is booked for next week, this is such a big deal! I’ve 
wanted to go for a really long time. I’m still worried about getting sick on 
holiday, but I don’t have to worry about travelling. I am so excited. I think it’s 
been more than 15 years…...since I went abroad’. HM, man 66ys.  
Each of these improvements, small as they might seem to an outsider, represents 
a new freedom and opportunity to enlarge their lives. The loss of control over their 
movement which emerged as an issue in the first interview was reversing - choice 
had been restored: 
‘…...France, Ireland, back to London for 2 weeks, then I’m back to France 
again for my nephew’s wedding…...yes, it’s been a great few months’. CO, 
man 67ys. 
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It is important to note that those who reported increased liberation were those who 
had already experienced a good deal of independent living. For many who had 
reported living relatively isolated lives, the older patients, their situation had 
changed little. The new liberation of movement was absorbed into the lives of these 
participants in differing degrees; some were better able to benefit than others.   
The situation was slightly different when it came to enjoying relief from the side 
effects of their old medication as the benefits appeared to be more evenly spread 
across the sample. Many patients talked of their improved wellbeing as a result of 
fewer negative interactions with other medicines.  Recurring pain had been the most 
reported issue at time one, therefore the wider range of pain relief medication now 
available to them was embraced. This new ability to control their pain is a significant 
finding and is one that impacts on almost half of the participants. This is no small 
achievement, as many first reported living lives in quiet but substantial discomfort 
and, for some, in distressing levels of pain:   
 ‘…. By the time the pain comes on it can be too late to take anything. But at 
least now I can take some really strong stuff that I couldn’t before…...no it 
doesn’t happen as much, cause I tend to take the Naproxen, but when it does 
happen it’s pretty painful’. VP, woman 89ys.  
The pain reduction led, in some cases, to improved mobility and to a much 
welcomed greater social interaction:  
‘I had so much pain in my knees and hips before, and I would get very stiff 
joints in the mornings. I still have some pain, but no way like it was before. 
I’ve started walking to the shops on the Highstreet, it’s about 100 yards away, 
it was near impossible before’. OG, man 82ys. 
Others were freed from the dietary restrictions that Warfarin had required. Their food 
choices had opened up, and for some this was a life changing freedom as well as 
the pleasure of more varied meals: 
‘My diet is going ok; it’s amazing all the things that I can eat now. I’ve lost 
almost a stone’.  ML, woman 89ys.     
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Closely linked to diet was the added benefit of now being able to drink alcohol. 
Again, it went beyond the simple enjoyment of wine or beer, but it helped with a 
newfound confidence in social situations, and the opportunity for companionship in 
an expanding social circle. They were becoming normal again:  
‘I even had a tipple on the weekend. I went to my mate’s pub and had a gin 
or two……no I still used to have a glass of gin before, but it would completely 
mess up my INR for about 2 days. It’s good to be a enjoy a drink now’. GD, 
man 65ys.    
These are just a few examples of how the reduction of side effects offered broad 
benefits. In the first interview patients talked of a domino effect; one illness 
impacting on others; and one negative effect of Warfarin leading to other issues, so 
decreasing their ability to be comfortable and mobile. So, life, they felt, was closing 
in on them. A reverse domino effect was now reported, with one symptom reduction 
leading to an opening up of parts of their lives which they thought they had lost.  An 
example of this is the improved sleep patterns for some:  
‘The night sweats still happen, but I’m not dripping in sweat like I used to the 
nurse said to keep an eye on it, but it seems to be getting better. At least I 
can get more sleep now’. AB, woman 91ys  
It was not made explicit why their sleep had improved, but since many were now 
undertaking more exercise that may have played a role. Leading on from this, 
several patients reported improvements in their sense of wellbeing and how life 
was, for several, simply more comfortable – even if they had no major health 
improvements. For example, one woman was delighted that there was a significant 
improvement in her appearance – her hair had begun to grow back:   
 ‘…...it’s only a few millimetres but my hair has started to grow back’. MR, 
woman, 65ys.    
What may appear to be small changes can have huge implications for these 
patients. This can be easily missed by the clinician whose primary concern is 
managing the patient’s major, even life-threatening condition.   
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6.6 New beginnings   
Small liberations led some patients to report quite complex pathways to better 
health, with the removal of the perceived barrier, real or imagined, created by the 
need to take Warfarin. Some were now able to face up to other health issues for the 
first time in many years. It appeared that improvement in one area of life raised their 
spirits to such a degree that they were prompted to review other areas that had 
been burdensome. The impact seemed to be cheering for a significant number, and 
a new start seemed to be offered. For example, this woman talked of reversing old 
bad habits:  
  
‘I think I used my health problems as an excuse for a long time. I ate poorly, 
and I never really worked out. But I think it’s time for a change. I was talking 
to my GP about all the green foods that I can eat now, and she suggested a 
whole lifestyle change to help control my diabetes. So far so good’. KS 
woman, 65ys.  
This man was also very clear about the positive impact:  
  
‘I’m not sure how much weight I’ve lost now, but my trousers are definitely 
looser. I’m really surprised, cause its literally just been a short walk to the 
shops and a few light exercises once a week at the gym. I can’t really do too 
much. But yes, I’m really pleased’. MK, male 68ys.  
  
Two virtuous circles seem to be at work here. One is that better access to pain 
relief is leading to increased mobility and better quality sleep. 
  
‘I can walk to the shops now (new pain relief) and take my time shopping, I 
used to have to be aware of what foods to get so I just had a routine of 
getting the same things every time. But I can take my time now and buy 
different things’. GA, woman 69ys.     
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A second circle relates to the wider availability of healthy foods, weight loss, 
improved appearance, and subsequent growth in confidence: 
    
‘My (blood) pressure for the most part is ok, and I still have some pains from 
the arthritis, but I am eating more greens now which I couldn’t do before, so 
my cholesterol has gone down…...yeah I have noticed a difference’. AB, 
man 91ys.   
 
6.7 Liberation for some was a loss for others.  
It is important to note here that a few patients were less enthusiastic about the 
switch, claiming that they had not been unhappy on Warfarin. However, it became 
clear that the loss of Warfarin was not the problem, rather it was the change of the 
health care process. While heralded as a great improvement for many, the absence 
of the weekly clinical check-up was major loss to others. It had become clear during 
the first interviews that several patients lived relatively isolated lives, and while not 
the main purpose of the weekly check-up at clinic it was, for some, an important 
social event.  It is important to note that these patients did not report any physical 
difficulties associated with the switch, but this does not diminish the importance of 
the missed social experience for this small group of patients. The loss of the clinic 
would have been noted less but for the isolation experienced by several patients:  
‘I feel like I do nothing all day. I have no kids and I’m widowed, so I don’t 
really have much to do, or people to visit. It can get very lonely’. SS, woman 
82ys.  
‘Every other Thursday they send the bus to pick me and take me to the clinic. 
It’s nice because I get to catch up with the other patients on the round. We 
have a good chat. We talk about knitting, our aches and pains and things like 
that. Mary used to be a nurse, so sometimes we badger her with questions. 
Poor Mary, she’s a good sport’. GA, woman 69ys.     
The following case illustrates many of the concerns voiced by this group: 
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‘I really preferred to be on Warfarin, the old system, it’s a reassurance to 
know what your INR is’. MP, woman 85ys.  
It is noteworthy that her switch did not occur after a period of discussion, but 
suddenly as a decision by the consultant three days before a knee operation in 
order to minimise the risk of haemorrhaging during or after the operation. This was 
standard practice for patients on Warfarin. The consultant used this opportunity to 
switch the medication rather than resume Warfarin post-operatively. The patient, a 
woman of 85ys, had been on Warfarin for 17 years and had been more than 75% 
outside of her Warfarin therapeutic range for the past 12 months.  
MP reported that she was very unhappy with the switch to DOACs. She lived alone 
with no children or family and, as well as AF, suffered from diabetes, high blood 
pressure and rheumatoid arthritis. MP had recently had both knees replaced due to 
severe pain from her rheumatoid arthritis in her joints. She was also taking multiple 
medications for her complex range of illnesses. It was therefore predicted that there 
might be interactions between the Warfarin tablets and the pain medications.  While 
she understood the reason for the switch, she said that she missed the contact with 
the nurses she has known for a long time and trusted., She complained that she 
had had pains and had to wait 15 days for a doctor’s appointment instead of talking 
to ‘her nurse’. She said that she was constantly unsure of whether the new 
medication was working and had no one to tell her it was ok.  It was not just the lack 
of reassurance of a friendly figure that troubled her, she said that she was very 
lonely and missed the interaction on the NHS transportation bus, which took her to 
her weekly appointments at the anticoagulation clinic. The bus journey with the 
other patients with whom she had forged a friendship over the past 17 years was a 
chance to catch up with her friends, some of whom were also elderly and house-
bound, and to share her experiences of being ill. Essentially, she now considered 
herself a shut-in and had become very sad.  MP still suffered some discomfort in 
her knees but, on a more positive note, said that felt she was getting stronger all 
the time 
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6.8 Responses by age and sex.  
The themes reported here were broadly true for all the participants irrespective of 
their age or sex; however, there were notable variations between some groups. For 
example, the much-voiced concern about the lack of regular monitoring was a 
greater concern of the over 75s of both sexes, although the difference is slight, as 
several 65-70 year olds also voiced concern. As might be expected, the loss of the 
bus trip to the clinic was more often voiced by the older participants who were also 
more likely to live alone. But again, this is not hard and fast, as some younger 
participants also felt the loss.  
 
6.9 Overall satisfaction with the switch. 
In order to gain a group perspective on the level of overall satisfaction with the switch, 
the second interview schedule (90 days) included one scale item asking the patient 
to score themselves as: 1 = very unhappy - 7= very happy. The data was analysed 
by both age and sex and the response was overwhelmingly positive on both counts. 
See Figure 6.1. Almost all of these patients rated themselves as happy and a few as 
very happy, there was little difference when analysed by age and sex. This overall 
positive view is in accord with the interview material. 
 
Figure 6.1 
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6.10 Comparison of findings from Time One and Two.  
While the themes emerging during the second interview were similar in many 
respects to the pre-switch conversations, they took on a new and, overall, more 
positive perspective. One theme remained unchanged, however, that of 
‘stalwartness’. The participants sense of ‘carrying on no matter what’ remained just 
as evident three months later. This appears to be both a benefit as they step into 
the unknown of a new medication regime, presenting a potential problem if taken 
too far and difficulties are not expressed to their clinical staff.  The theme of ‘loss of 
control’ voiced at Time One was, for many, reversed, with a feeling of regained 
control over their own bodies and parts of their lives.  Overall, the patients reported 
improved wellbeing, mainly resulting from their new drugs, and a reduced area of 
conflict with a range of food stuff and medication. For some, it felt like a new start 
to take back more control over their lives. This resulted for many in a freeing up of 
their time to allow travel and make plans away from home.  
However, the very change that liberated many patients created a problem for others. 
The old routine of clinic visits had clearly supported many somewhat isolated 
patients, but the gap left by the new regime for some patients’ lives could not be 
filled by the clinic. Rather, it could be argued, this fell in the domain of their GPs’ 
responsibilities. The improvement of service in one area, with the reduced need to 
visit a clinic, also created a need for services (not necessarily provided by the NHS) 
in another aspect of the patients’ lives for some patients.   
This research suggests that the strongest influencer on the patient’s wellbeing is not 
a single factor standing alone, for example now being able to eat a wider range of 
vegetables, but rather the interaction or combination of several factors – a positive 
domino effect.  However, underpinning all of this are the patient’s personal domestic 
circumstances which so often determine the level of support they could expect.  
This next section reports on the data gathered from the four staff interviews.   
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6.11 Staff interviews  
The staff interviews were conducted by the researcher at the Anticoagulant Clinic 
at St Mary’s, Paddington. As mentioned in Chapter 3, a focus group was originally 
planned, but due to difficulties with the staff rotas the interviews were carried out 
individually. It was originally hoped the eight staff would be interviewed but, for the 
same reason, only four were available. The aim was to explore how the staff 
received information about the new DOACs, any concerns that they may hold about 
the treatment plan, and their perception of the patients’ responses to the new 
medication. Their views about the provision of information were discussed in the 
previous chapter. In addition, the interviews aimed to explore any concerns they 
might have about patients switching from Warfarin with regard to wider health issues 
and any emerging social implications. The interviewees had considerable 
experience of working with DOAC patients – between 3 and 8 years. Two were 
anticoagulant nurses, one a pharmacist, and the fourth a consultant haematology 
doctor. Two were men and two were women. Each week they saw between four 
and eight DOAC patients.  
At each clinic visit, the patient’s compliance (blood test) with the Warfarin regime is 
recorded electronically. Following this, the computer will then provide an alert if the 
patient shows difficulty in compliance.  The nurse then talks with them about their 
difficulties with the treatment and can refer them to the consultant for further 
discussion and a decision.  (It was claimed that often the nurse, who may have 
known the patient for many years, could tell without the aid of the computer that the 
patients were not coping on Warfarin and would refer them to the consultant.) This 
process would take place a few weeks before the switch. Written information would 
be given to the patient at each stage, and a time offered to come into the clinic with 
any questions.  Their GP would also be made aware of the switch, and would also 
be offered information if required when they take on responsibility for the 
prescribing.  With regard to the decision to switch to DOACs, the staff made it clear 
that it would be made on clinical grounds, with the patient’s personal life only being 
considered if it was deemed to be the cause of their poor compliance – for example 
the patient’s poor drug time keeping, or a medical emergency occurring.   
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6.12 Awareness of the impact of the new medication on the patients.  
At the time of the switch staff reported that the psychological or social impact on the 
patient as a result of the change was not generally taken into account. The clinical 
data was all that mattered:  
‘Not as much as would like, you tend to get to know the patients over a course 
of several years, but I tend to assess the patient’s clinical need for the 
medication …… and whether or not they qualify under the rules and 
guidelines for switching to the new medication’.  Consultant.  
However, on reflection, as a result of their growing experience with these patients, 
the team thought that wider considerations should be made relating to the patient’s 
domestic circumstances. But these considerations were unlikely, unless extreme, 
to override the person’s clinical needs. Despite the small role that social factors 
played in the decision, the team were aware of several factors, the foremost of which 
was the lack of future clinic monitoring sessions and the anxiety it generated – for 
both staff and patient. The lack of regular check-ups generated four areas of 
concern. The first was the team not being aware of a patient’s non-compliance 
(adherence), and so other medical issues could follow:  
 ‘Accidently overdosing or their missing doses is my biggest fear’.  Nurse.   
Linked to this issue of over or under-dosing is the lack of reversal for the new 
medication which could be a problem although only in an emergency. Bleeds 
resulting in a need for emergency treatment were generally considered by staff to 
be a result of overdosing, so timely tablet taking was key to success. However, 
small domestic mishaps such as a cut with a potato peeler could also create an 
emergency situation. Despite this, these drugs were considered to be relatively low 
risk:  
‘Mostly in an emergency, but it’s a pretty stable drug. The medication should 
be out of the system in just over four hours’.  Nurse.  
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While the risk was low risk, it was still a risk. The consultant had a more general 
concern for his older patients:  
‘Older patients are prone to falls and can get quite nasty cuts and bruises, so 
particularly for those and trauma patients, the lack of reversal may be an 
issue’.  Consultant.  
The risks did not, in the view of this team, outweigh the benefits. It was more a 
matter of the patient getting used to a new routine and being alert enough to 
maintain it.  
The second concern was the patient being anxious about knowing if the medication 
was working. While the staff felt confident that the majority of the patients were 
coping well with the change, it was acknowledged that other issues might weigh on 
the patients’ minds. The nurses had some sympathy with their anxiety. The third 
concern was that potential warning signs of distress, not all of them medical, could 
now easily be missed until their GP may picked it up: 
 ‘Sometimes I find bruises on the patients or find out information during the 
chats that I would have missed otherwise. Sometimes it’s nothing to do with 
the Warfarin, these patients may be experiencing abuse or loneliness, these 
are the signs that may be missed without a clinic’. Nurse.  
While not frequent, it happened often enough to be raised as a concern.  Finally, 
the withdrawal of a social support provided by the clinic visits concerned the nurses. 
It was not simply the medical consideration of no regular check-ups, but the team 
recognising the social role the visits fulfilled:   
 ‘The older patients struggle with not coming to the clinic. Some are widowed 
or shut-ins – so they complain about not having the clinics’.  Nurse.   
‘To be honest most of the issues are social problems, but there are issues 
such as the reduced access to the medical team that can cause some 
patients to be overly anxious’.  Nurse.  
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The complexity of settling down to a new medication programme was well 
understood by the consultant:  
‘It often depends on a whole host of extenuating circumstances such as other 
medical conditions, as well as the social and psychological condition of the 
patients. …persistent pain, or loneliness… all of these a can have an impact 
on how the patient responds to changes in their routine, not just to changes 
in their medications’.  Consultant.  
   
6.13 Positive aspects of the switch  
The clinical team were clear that the switch had several benefits for the patients, 
and they were the same as those reported by the patients. For example, the patients 
having more time to themselves, and not being restricted by clinic visits, was 
considered a major benefit for most patients. This was linked with a keen awareness 
that this is an older population, who were relatively isolated at home and they liked 
the social interaction of the hospital trip. Possibly the most positive impact 
recognised by the staff, because of the multiplier effect of additional positive 
implications, was that the new medication had fewer issues around interference with 
other medicines and types of food: 
‘I think the fact that DOACS are more stable is a high plus for these patients’. 
Nurse.   
The full implications were understood as the Consultant said:  
‘The patients now have a wider selection of medication and diet options that 
they were previously excluded from.  Especially the patients that suffer from 
chronic pain, they can now have access to stronger more effective pain relief 
that was not allowed to be taken with Warfarin’.  Consultant.  
It is interesting to note that while this benefit is acknowledged and given its huge 
implications for the patients, it did not come top of their list of benefits.  
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6.14 Could the trust do more?  
It was clear from the team’s responses above that they understood the patients’ 
needs for on-going support, particularly among the over 80s. But, importantly, they 
considered that such support needed to be easy to access and located in the 
community rather than with them. In reality, this support was currently, as far as 
they were aware, sporadic, and dependent on the patient’s GP practice or 
community nurses:   
‘There is of course always more that the Trust should be doing, but the reality 
is that there is insufficient funding to ensure patients in the community are 
compliant with their medication’.  Consultant.    
Given that the issues for limited community care were often financial, one nurse 
offered a solution: that the reduced clinic time due to these patients not coming in 
for regular check-ups would generate a financial saving which could be redirected:   
‘I think that some of the savings gained from switching to these new drugs 
should be spent on community nurses to check up on these patients. I think 
that there is such a post code lottery when it comes to access to social care. 
The trust should consider more community based care. Patients may even 
do better being cared for in their own homes and free up much needed bed 
space’.  Nurse.  
One practical suggestion was offered – that the patients could be reached by 
telephone, not necessarily by the Trust, but perhaps from the community:  
‘Maybe check up on them more after the switch or have a team of admin staff 
that call them routinely to see how they are getting on. It would be interesting 
to see how they are doing six months, a year or two later. For younger 
patients I think they will be ok, but the older ones should be checked on. 
Definitely worth doing’.  Nurse.   
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6.15 How the staff and patients’ perceptions compared  
There was a good deal of commonality between the views of the clinical staff and 
their patients, which was to be expected given the long relationship. The 
fundamental benefits of the new medication were understood by both groups, as 
were the patients’ reservations about the new responsibility of unsupported 
compliance with the treatment.  The patients, understandably, provided more 
detailed and nuanced information about life after the switch than the staff. The one 
area where a gap in perception was evident was in the breadth and depth of the 
impact on personal achievements enabled by the new medication’s lack of conflict 
with many formerly incompatible foods and medicines. According to the patients, 
some outcomes were life-changing and had a positive impact on wider health 
issues. However, this information could not routinely be made known to the staff 
given the time constraints of their clinic interview. 
In the next chapter the findings from the questionnaires (PPS and SF-36 scales) 
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Chapter 7 – Findings three:  









7.0 Introduction  
The responses from the patient interviews reported in the previous chapter allowed 
for important themes associated with living with the new medication to emerge. 
Patients spoke openly and sometimes in an unreserved way which allowed the 
issues to be explored thoroughly at an individual level. However, it was considered 
important that this idiographic (personal) material should be supported with 
nomothetic data (general statements) in order to gain a fuller picture of the patients’ 
perceptions towards their medication routine and their general health.  
This chapter reports on the findings of the two questionnaires used as survey 
instruments for this study: The Perceived Stress Scale and the Short Form 36 (SF-
36) Health Survey. The two scales were administered to the 56 participants (29 men 
and 27 women) three times: at the switch over, then at one and three month time 
points.  
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7.1 Findings – Perceived Stress Scale (PSS)  
As discussed in the methods chapter, the aim of using the PSS scale was to 
ascertain the level of stress these patients considered themselves to be under 
before and after changing to the new medication. The scale is a short one, just 10 
items, and produces one overall score. It does not subdivide the score into smaller 
units, so the findings are relatively straightforward to present. The findings of the 
PSS scale show that, overall, the perceived stress of all 56 participants reduced 
between Time1 and Time 3, - ninety days later. Of importance to note is that the 
greatest reduction was between Time 1, at the switch, and Time 2, four weeks later. 
See Figure 7.1. The decrease in score was quite marked. The reported reduction 
in anxiety happened quickly, within the first four weeks, and stayed down, but with 





Figure 7.1  
Mean PSS Scores 
 
 
In order to compare the data at each time-point and determine how much the three 
groups differ, statistical analysis of the average PSS scores at each of the three data 
time-points using one way anova was undertaken. The results are shown in 
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than the F value between the groups. Because the calculated value of F from the 
PSS data is larger than the value in the F table, there is proven variance between 
the populations being explored to a 95% confidence. This indicates that the results 
are robust, and not random or due to chance.  
 
The F crit value represents the point of intersection of the data, and the F value 
represents the ratio of variance (should be close to 1.0). A one way ANOVA was 
conducted to compare the mean PSS scores at each time point and showed a 
significant difference, F (2,110) = 13.79, p < .001 - See Appendix 15, Table 2. 
Therefore, as seen in Table 7.1 the mean of the total scores for each time point 
shows that there was a general consensus among patients of feeling less stressed 
90 days after switching from Warfarin to DOACs, and that this was statistically 
significant, not arrived at simply by chance.   
  
7.2 Age and Stress Scores  
Figure 7.2 shows that the observed changes are maintained across all age groups 
at the point of the switch, at week four (T2) and at 12 weeks later (T3) (See Appendix 
15, Table 3). 
 
Figure 7.2  
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In all groups the most marked change is within four weeks of the switch. 
Interestingly, the 85-94year age group recorded the lowest stress scores at all 
points, though the difference is minimal between groups. There was an overall 
decrease in the stress scores by approximately 5%, which is significant (See 
Appendix 15 Table 3).  
  
The patient’s self-reported outcomes may be related to a perception of life in general 
being less stressful anyway. Given the small sample size it is important not to read 
too much into this small difference between the age groups.  The fact that the 
patient’s stress level is determined by a spectrum of confounding factors may 
contribute to this result, not simply their change of medication.  
7.3 Sex and stress scores  
Figure 7.3 shows that across the time points there was only a marginal difference 
between the total stress scores in males and females. And as was reported for age, 
both sexes responded in a similar way across the time points; that is, the biggest 
change was within the first four weeks.  
 
 
Figure 7.3  
 Male and female scores for 3 time points  
 
In Figure 7.4 the picture is broadly the same when the data is analysed across age 
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changes in their stress reduction after week four, women aged between 85-94 
continue to reduce their stress over the 12 week period. Interestingly, the men in 
that older group show a slight increase of stress at time three.  
  
 
Figure 7.4  
Scores by age and sex  
 
It is worth noting that based on the analysis of the overall data from the switch over 
point compared to day 90, there were no significant changes in the responses for any 
individual each PSS scale item when analysed by both age and sex together. The 
factors of age and sex do not appear to have a significant effect on these patients’ 
perception of their overall level of stress.   
 
7.4 Short Form 36 (SF-36) Health Survey  
Turning now to the second questionnaire administered at the same three time 
points, the Short Form F36 (SF-36), which is an indicator of self-reported overall 
health status. The scale divides into two sections: the physical component scores 
(PCS) 18 items, and the mental component scores (MCS) 19 items, each with 
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7.5 Results  - whole group 
Matched-pairs t-tests were calculated for both the PCS scores and the MCS scores. 
The results are presented below in Table 7.2. Noticeable were the reductions in the 
mean PCS and MCS, but the difference between the total group scores (times 1, 2 
& 3) groups was not significant.   
 
Component   Difference   t-value   P-value   
PCS   1.80   1.877   0.063   
MCS   0.73   0.789   0.437   
Table 7.2 
Results of matched-pairs t-tests 
PCS = physical component scores, MCS = mental component scores 
 
 
The combined scores for the SF-36 for each participant at each of the 3 time points 
(n=169), 51 (91%) of the 56 described their health as moderate. Figure 7.5. This is 
consistent with the number of participants who first expressed views of satisfaction 
with their overall health then later expressed dissatisfaction with some aspects of 
their health and social circumstances. See Appendix 15, Table 6. 
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Figure 7.5  
Mean SF 36 scores for overall health – the whole group  
  
7.7 Results by age and sex 
Older patents in the study, 85 years and over, showed a greater satisfaction with 
taking the old medication Warfarin (p<0.008), with fewer reported Warfarin-related 
issues (p<0.001). This may be associated with comorbidities, social or other 
reported psychological issues relating to loneliness and isolation and a liking for the 
regular clinic visits required for Warfarin therapy.  This age group of Atrial Fibrillation 
patients (>85 years), interestingly also had a decreased perception of potential 
benefits from switching from Warfarin to Direct Oral Anticoagulants (p < 0.001), and 
also showed markedly less interest in potential side effects or safety-related issues 
of DOACs (p < 0.001). Perhaps there were used to living with risk. 
The men and women had very similar reactions to each other, with very close mean 
SF-36 scores. Females, however, scored very slightly higher, that is more positively, 
for both the MCS (mental health) and PCS (physical health) domains. This was 
supported by data generated from the ProCore® software, which compared the results 
from this study, to other studies conducted on Atrial Fibrillation patient populations of 
the same age, using the same SF-36 questionnaire (Hayes, et al., 1995). In this study, 
females (n =27) scored an average of 40.8 for physical health issues and 37.7 for 
their mental health. The males (n=29) scored an average of 39.9 for physical and 
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Figure 7.6   
Mean PCS & MSC scores combined time points  
– Male and female  
  
 
There was no significant difference between men and women with the mean overall 
therapy switch satisfaction (p = 0.624). Of note is that the women reported a greater 
number of problems associated with their Warfarin therapy than men (p = 0.047, 
Mann–Whitney U test). Conversely, the women were significantly more concerned 
about the switch (side effects, monitoring, etc.) than men (p < 0.001). The potential 
benefits associated with the switch from Warfarin to Direct Oral Anticoagulants in 
both men and women were remarkably similar (p = 0.276). 
Bodily pain was the most reported domain of this scale, with almost 50% of all 
participants across all age groups reported having either a chronic or acute pain. 
Consistent with the results from the Perceived Stress Scales, a mean of 27% of all 
participants reported being emotionally affected by events that had happened in the 
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Figure 7.7  
SF 36 Domains at 3 time points  
PCS, physical component summary; MCS, mental component summary; PF, physical functioning; RP, role physical; 





7.8 Duration of Warfarin therapy and quality of life 
The patients who had been taking Warfarin for more than 10 years were reportedly 
less accepting of the adverse side effects it brought, for example,  interactions with 
other medications, their diet and pain relief restrictions. Therefore, it was considered 
of value to explore this further here.  On the SF-36 scale, a ‘p’ value of 1.0 is the 
maximum score achievable for a patient satisfied with being on Warfarin. It was 
noted that the longer the patient had been on Warfarin therapy, the lower their 
satisfaction with it (p = 0.026).  
Interestingly, whilst there was more apprehension around switching to a new 
medication in the >85 year group, there was no direct correlation noted, between 
years on Warfarin and the patient’s satisfaction with the new medication they were 
switched to. The apprehension appeared to be linked to ‘a change’ rather than ‘the 
change’. This is further substantiated by the fact that the overall satisfaction of the 
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overall understanding of the new DOAC therapy, gave a ‘p’ value of p = 0.879, with 
is a positive finding. See Appendix 15, Tables 9a & 9b. 
 
7.9 The total SF-36 score by sex and employment status.   
During the first interview the employment status of the participants was discussed, 
the sample was then divided into ‘retired’ and ‘working’. Along with ‘male’ and 
‘female’ these subgroups were analysed by each patient’s total SF-36 score 
(satisfaction score). The satisfaction score directly correlates to the Quality of Life 
of the participant. The findings showed that retired men had a better overall 
satisfaction score compared to non-retired men, but this association was not 
observed among the women. Men living in cohabitations or in mixed arrangements 
also had a higher score and therefore a better quality of life, than those who lived 
alone. Interestingly, women who lived alone had a median score and did not show 
a clear overall satisfaction or dissatisfaction with the SF-36 scores. With regards to 
their self-reported level of physical activity, the men and women who stated they did 
not practice regular physical activity tended to have lower overall score. Women 
who reported good physical and psychosocial health were more likely to have a 
higher total score then those who did not. For men, the highest total score was 
associated with those with higher socioeconomic conditions (e.g. income, 
education, occupation, and neighbourhood). 
Gratifyingly, the most commonly reported overall patient perception was a positive 
response, as 30 of the 56 participants (54%), noted that there were fewer food, 
drink, and concomitant medication interactions to contend with. They also noted that 
they could be prescribed a wider spectrum of medications post switching than when 
they were on Warfarin. Most commonly, these were prescriptions relating to arthritis, 
general pain, and recurrent infection (usually antibiotics).  
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Figure 7.8  




The findings from both sets of scales are consistent. The Perceived Stress Scale 
shows a notable positive impact, a reduction in stress levels, right at the start of the 
new treatment that was sustained for at least three months. This pattern held true 
even when the data was analysed by sex and age. Interestingly, there was slight 
tendency for the older female participants (85+) to show lower stress levels at the 
start and a greater reduction in stress at time points two and three.  
The findings from the SF-36 questionnaire indicate that the participants were, 
overall, reasonably positive about their state of health, with most rating themselves 
as ‘moderately healthy’.  Slightly more declared themselves to be in ‘excellent 
health’ than those who claimed to be experiencing ‘poor health’. This was despite 
about half the group experiencing bodily pain at the time of the study. These findings 
were largely unchanged when analysed by sex and age. These results are 
supported by the work of Chiong and Cheung (2013), whose results confirmed no 
significant difference between the sexes. Concerns about mental health were less 
frequently reported as troublesome than physical illnesses. These findings are 
supported by similar studies, for example Campos et al (2014) who found a direct 
link between physical activity and the quality of life in the elderly, with particular 
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reference to the impact on the following domains: ‘autonomy; past, present and 
future activities; death and dying; intimacy; mental health; vitality; and 
psychological’.  These interesting findings support the decision here to include 
scales as a research tool; they have provided statistically sound evidence of a 
perceived positive change after the switch which supports the interview material.   
The discussion and conclusion chapter which follows will combine the findings from 
the interview materials and scales, and will draw conclusions about the participants’ 
perceptions of life on their old and new medication. This is followed by 
recommendations for the future care of patients switching from Warfarin to new 








































8.0 Introduction    
This study explored the perceptions of 56 AF patients who switched from Warfarin 
medication to one of the new DOACs. In this chapter the findings are discussed in 
relation to other research on the subject, and to current NHS policy on the long term 
care of these and other AF patients. Recommendations are made with the aim of 
helping translate the findings into practical support for all such patients. Finally, the 
limitations of the study are discussed. The aim of the study was to undertake a 
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qualitative exploration of the perspective of a sample of patients who were required 
to switch from a life-long treatment plan on Warfarin to a new drug regime on one 
of three of the Direct Oral Anticoagulants (Apixaban, Rivaroxiban or Dabigatran). 
The aims and objectives were achieved, with several key themes emerging from 
the data which will inform healthcare professionals of their patients’ views, and 
which will aid them significantly in providing a more patient-centred treatment plan.  
 
8.1 Context  
At the time of the first interviews the majority of this sample had multiple co-
morbidities, with many concomitant medications, and these did not change over the 
three month duration of the study. Often patients had to juggle their medication; 
each tablet had its own requirements (for example, to be taken pre-meal, post meal, 
twice a day, four times and a day, first thing in the morning or last thing at night). 
This presented the patients with a complex schedule of medication to maintain, 
which for many became a struggle. Adherence to long-term Warfarin therapy 
remains challenging due to the risks of anticoagulant-associated complications and 
the burden of monitoring. The patients here expressed a variety of reasons for 
having missed doses, including forgetting to take their tablets, self-adjusting their 
dosage in order to consume alcohol, or missing a dose because of personal 
circumstances such as travel. A few patients reported missing a dose of Warfarin 
deliberately in order to allay the side effects of Warfarin. Adherence was measured 
by the clinic staff by asking the patient whether they thought they were excellent, 
moderate, or poor in taking their medication, and why. Poor adherence leads to 
poor anticoagulation, which is reflected in the patient’s blood test results. Among 
this sample, the anticoagulation team anecdotally noted that adherence was one of 
the most common reason for poor INR results. 
These participants stated that various factors affect adherence, possibly related to 
cognition (poor memory) and also to physical, functional, and psychological status 
plus outside influences. Horstmann (2019) undertook a European study and 
showed that of 94% of patients were receiving oral anticoagulants for 12 months 
following a stroke. Unexpectedly, physical, and functional problems, more than 
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cognitive performance, were associated with discontinuation of anticoagulant 
therapy at 12 months; adherence tended to be better with DOACs than under 
Warfarin. That finding is very different from the sample reported in this study who 
did not show any signs of needing to discontinue their oral anticoagulants. Were 
they just lucky or were there other factors involved? It is difficult to assess 
adherence objectively; there may have been a selection bias in the present study, 
as patients with a cognitive disorder were excluded for reasons of feasibility (ability 
to complete the questionnaires). 
The patient’s satisfaction with their pharmacological treatment should be considered 
as an important factor in clinical practice. This is because satisfaction with, and 
preference for, a given drug regimen may have a significant impact on medication 
adherence. In similar clinical studies a higher medication satisfaction in patients is 
associated with better anticoagulation control (Choi et al., 2014). Therefore, patient 
satisfaction with their anticoagulant therapy should be considered an important 
factor in encouraging optimal medication adherence.  
8.2 The broad research objectives and findings:  
To explore the participants’ perceptions and understanding of the new 
treatment and its impact before and after the switch using a qualitative 
approach, with a sample of 20 patients, who will be interviewed at the time 
of the switch and 90 days afterwards.  
To ascertain the impact of switching for 50 patients by assessing quality of 
life and the perceived stress at three points: baseline (immediately before the 
switch), then at 30 and 90 days into the new treatment regime, using 
standardised scales.  
The objectives were achieved, and, in addition, a further informal conversation 
accompanied the administration of the scales at the 30 day point. The requests for 
interviews were met with enthusiasm, indeed several people said how good it was 
to have the chance to voice their feelings on the subject of their treatment. This 
produced rich data.  
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8.3 The emerging themes: 
I’m fine – coping with multiple conditions   
A theme which permeated all these interviews was that of stalwartness, self-reliance 
and, importantly, ‘learning as you go’. Early in the analysis this culture of ‘carry on 
no matter what’ was regarded as peripheral to this research, and simply an 
interesting cultural phenomenon of older people, some of whom could remember 
WW2 and the depravations that followed. They saw themselves as resilient. It was 
perceived as merely providing a cultural context to the other findings. However, it 
soon became clear when considering the current NHS plans for managing chronic 
and long term conditions that resilience is an important and necessary personal 
attribute to hold. The Department of Health in fact declares its aim to cultivate such 
feelings of resilience and independence in order to deliver more cost-effective 
treatment in the future.  
The NHS report Long Term Conditions Compendium of Information (2012) provides 
an overview of the situation at present regarding the numbers and treatment of 
patients in the UK with a long term condition (LTC). A key observation is that the 
population at large, with or without and long term conditions but particularly those 
in middle age, must take greater responsibility for their health. This can be achieved, 
the report argues, if the onset of any long term condition can be delayed for as long 
as possible thought public heath interventions such as exercise and other healthy 
living programmes. This would appear to support the views of many in this sample, 
who relished their newfound ability to self-medicate after the switch and to take 
more responsibility for themselves, but with the caveat that they should not be left 
to cope alone. They wanted to have on-going contact with the NHS at times of need, 
and simply for reassurance. The findings reported here go some way to support the 
conclusions drawn by the NHS report that patients with long term conditions want 
the following:   
• to be involved in decisions about their care – they want to be listened to. 
• to have access to information to help them make those decisions.  
• to receive support in understanding their condition and confidence to 
manage it. 
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• to receive support for joined-up, seamless, self-care services (NHS 
England, Annual Report, 2012, p4). 
The authors of the report’s claim that the best way forward for the older population 
is to delay the onset of any chronic condition would be sympathetic with this sample. 
Many patients talked of a ‘new start’ health-wise, and the all-round improvement to 
their health after the switch from Warfarin. Some chronic conditions were reversed 
slightly, such as increased mobility and reduction in pain. Others were slowly 
improving their health through weight loss, hence decreasing the likelihood of 
developing diabetes and lowering their blood pressure, and so reducing the 
chances of suffering a stroke.  
They were in fact, through their own sense of wellbeing, delaying the onset of a new 
long term condition. Foot et al., (2014) argue that this cannot be achieved by the 
patients alone and that they need to be supported in their self-management claims. 
They also report on patents retaining control of their own health care. The key 
factors to successfully assisting patients are to have a personalised care plan, 
structured education for staff and patients alike and, importantly, peer support. 
(p25). Each of these goals would be supported by these patients.  
Concern about welfare of elderly patients within the NHS and the wider society is 
regularly reported in the headline news, and many research papers are emerging 
to discuss elderly care (NHS Safeguarding, 2018). Studies such as the one by 
Pillemer et al., (2016) show the problem of neglect and abuse of the elderly to be a 
worldwide phenomenon. Understandably, most studies are organisational reviews 
at the level of actual abuse, not at sub-optimal care or at the point where older 
people find themselves in potentially difficult circumstances.  
The NHS’s safeguarding report (2018) confirms this. They list over eight types of 
abuse and neglect, though reporting is retrospective; little has been written about 
the inadequate, though not culpably bad, care offered to the elderly. There is no 
suggestion that the patients in this study are not treated with genuine care and 
professionalism by the clinic staff. However, both patients and staff identified a 
potentially problematic area for the elderly patients after the switch: that of missed 
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doses and lack of self-care (medicine wise) for those who live alone (Callewaert 
and Callewaert, 2011; Pillemer et al., 2016).  
8.4 A leap of faith  
This theme of trust in the judgment of clinical staff was true for the whole sample – 
they were taking a leap of faith with regards to trusting the new medication. Anxiety 
about the new venture at the point of the switch was very real, however, and only 
thinly disguised if at all. The anxiety voiced by this sample about not knowing 
whether the new medication would work, and would continue to work, is not 
unexpected or unusual. Brosschot et al., (2016), who undertook an evolutionary 
theoretical research perspective to study anxiety, concluded that to feel anxious and 
concerned in the face of uncertainty, the unknown, is the ‘default’ position for all 
humans. It is not ‘generated’ by the stress producing factor but rather ‘uncovered’ 
as it is our natural, risk adverse response to threat.  
It is not surprising, therefore, that the whole sample here expressed some degree 
of concern at the new treatment. Brosschot’s theory might also account for the swift 
reduction of anxiety, as recorded in the questionnaire data, that during the first few 
weeks of treatment the previously unknown medication became commonplace in 
their lives. The interviews echoed this, with nearly all expressing satisfaction with 
the new medication, some almost immediately, while for others it took a week or 
two. 
The presence of anxiety is all too often regarded as par for the course and not 
always addressed by heath care staff. Mohlman (2013) reports that it is not only 
medical staff working with older people who may miss signs of anxiety, but 
psychologists who have been slow to recognise the frequency of anxiety and its 
impact on the elderly. Even mild anxiety, according to a report by the National 
Institute of Mental Health (2019), can have a knock-on effect, inducing, in some 
people, feelings of fatigue, poor sleep or simply feeling restless (Mohlman et al., 
2013). The anxiety reported by this sample at the start of their new treatment, 
although brief in some cases, should not be dismissed as inconsequential, and 
steps need to be taken to provide reassurance at the outset of the process.  
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Attempts have been made to reduce a patient’s anxiety by offering technology-
assisted self-testing for anticoagulant patients at home, with some positive results. 
Kuljis et al., (2017) interviewed 17 patients who were using self-testing at home to 
monitor their dosage. They were concerned with the lack of information about the 
patient’s perspective regarding low clinical engagement and the reliance of 
education programmes, rather than asking the patients themselves how things were 
going. While the self-testing was valued by the patients, they also valued the clinic 
time for the same reasons given here: trust, reassurance, and the human contact. 
For self-testing by patients to be taken up in any numbers by the patients, the 
researchers argued that support needs to be the clinic as well. The role of the 
patient taking more responsibility for their own health was understood and valued 
but it must be performed within a framework of support.  
8.5 A new start for many but not all  
A theme of better times ahead or a ‘new start’ for many of the patients in the lower 
age range is echoed, although to a more limited extent, in the older participants’ 
responses. This was, to a major extent, due to the reduction of pain resulting in the 
now wider availability of improved pain relief. More than half the patients lived with 
varying levels of pain, which inevitably would have a direct impact on their wellbeing, 
particularly in mobility and quality of sleep.  
Twenty percent reported a recent operation, whilst others were experiencing 
physical pain due to other medical conditions such as arthritic joint pains and lower 
back pain. Untreated pain can become chronic and greatly diminish their quality of 
a patient’s life (Cracknell, 2010). This sample is typical for this age group across the 
general population, with arthritis as one of the most common causes of pain in the 
elderly; results from a study reported musculoskeletal disease causing joint pain, 
inflammation, and stiffness (Bowling and Gabriel, 2004). Patients who initially rated 
themselves on the scales as having chronic or acute severe pain, also reported 
being limited in their ability to perform daily tasks such as walking 50 meters, 
carrying a small bag of groceries, doing household chores (particularly vacuuming) 
and the ability to wash themselves. This reduction in the ability to perform daily 
activities accounted for just over a third of the participants. The patients’ general 
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outlook on life before the switch, for those who experienced chronic pain, was lower 
than those who did not have pain related limitations, as indicated by the SF-36 
Health Survey scores. The ability to perform even moderate physical exercise: 
walking, performing domestic chores, participating in social activities, and 
maintaining an independent lifestyle had the biggest impact on the patients’ general 
outlook on life.  
This sample was not alone in their responses; Dueñas et al., (2016) found links 
between pain intensity and a patient’s perception of wellbeing. Patients in this study 
also reported a poorer quality of life than patients with moderate and less frequent 
pain. Their pain had a greater impact on the physical dimensions than on the mental 
ones. The researchers also found that in relation to pain intensity, symptoms of 
anxiety or depression and emotion-focused coping strategies are the variables that 
most affected the wellbeing of patients – all of which was voiced by the participants 
of this study. Sleep disorders, often linked to pain, may increase levels of stress 
and, accordingly, such disturbances can made it difficult for patients to perform 
simple tasks. They may even impair their cognitive ability, in turn affecting everyday 
activities in the workplace and at home (Dueñas et al., 2016). The new freedom 
from much of their pain was a major benefit for these patients, and the impact was 
life-changing in some cases. Importantly, this may also help the patients delay the 
onset of other conditions due to their increased mobility and subsequently decrease 
in pain, allowing them to seek out and extend social contact. Improved quality of 
sleep also enabled them to lead a fuller life despite their complex conditions.  
8.6 Sex and age - differences in perspective.  
The interview and questionnaire data and the scales data were examined by age 
and sex to ascertain if any observable patterns emerged. This met the requirement 
of the fourth objective: ‘To explore any effects of gender and age on measures of 
quality of life and perceived stress before and after the switch’. Interestingly, very 
few authors have published research relevant to this topic that report observed 
differences by age or sex in treatment, or responses to switching medication. The 
elderly, as far as this area of research is concerned, seem to be regarded as a 
homogenous group. While it is acknowledged that the interview sample was rather 
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small to identify any major differences between the sexes or across the ages it was 
worthwhile exploring to identify if any patterns emerged.  
Some difference could be identified, mostly related to age; more of those over 75 
voiced greater concern about the lack of monitoring after the switch. Importantly, 
key to their complaint was the loss of the social aspects of the bus trip to the clinic. 
This loss increased their sense of isolation, which was particularly hard for those 
who lived alone. It also reduced their opportunities for obtaining medical advice. It 
is important to note that anxiety, related to the cancelation of clinic visits as 
discussed above, was prevalent across all age groups. There were only small 
differences between the sexes on any issue, and none that could be regarded as a 
clear pattern, suggesting that other factors such as living alone, general health, and 
level of pain may be better variables by which to examine any further qualitative 
research material.  
With regards to the scale data, however, the picture was a little more interesting. 
This was supported by data generated from the ProCore® software, which 
compared to the results from this study to other studies conducted on Atrial 
Fibrillation patient populations of the same age, using the same SF-36 
questionnaire (Hayes et al., 1995). The Perceived Stress Scale showed a reduction 
is stress levels as soon as the new treatment began, which lasted for at least 90 
days. Neither the patient’s sex nor age changed this outcome; it was true for the 
whole sample. It is interesting that the older women (85+) not only showed lower 
initial stress levels but also recorded a reduction at one and three months. Despite 
having several medical conditions, the SF-36 questionnaire shows that they were 
reasonably happy with their sate of health, and this is in line with their stalwart 
attitude emerging from the interviews. Interestingly, as a group they were less 
concerned about the state of their mental health than their physical complaints. 
 
8.7 Other work in this area.   
When this research study began over seven years ago there were no published 
research papers exploring the perception of patients in this older age group who 
have switched to DOACs. However, during the research period a few papers have 
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been published, although none focused on the switch over itself and their methods 
were more restricted, being mostly short surveys not supported by interviews. 
Therefore, this study has further original knowledge to offer. The outcome is that 
this current research and that of others has now paved the way towards a practical 
understanding of the implications and impact on patients of being on anticoagulants 
and switching medication.  
A number of studies on the topic of new anticoagulants, which are gradually replacing 
Warfarin, are now beginning to appear. Monz et al., (2013) assessed the impact of 
Dabigatran and Warfarin on health-related quality of life factors of 1435 patients with 
AF.  Using a utility and Visual Analogue Scale consisting of five areas: mobility, usual 
activities, self-care, pain/discomfort, and anxiety/depression at three time points up to 
12 months. Interestingly, the findings were a little different from those reported here. 
For example, there was no significant difference between the Warfarin or Dabigatran 
groups across any the five health dimensions at the three points including levels of 
anxiety.  Also, of interest is that contrary to the finding here, their Dabigatran group 
did not report better pain control.  However, as the two research methods were 
different it is difficult to make a direct comparison of the findings.  Interestingly, one 
factor did appear to be consistent across the two research populations - that which 
this study calls stalwartness is also expressed in Monz’s sample in the higher than 
might be expected HRQoL scores considering the number of comorbidities reported. 
Fumagalli et al., (2014) used PSS scales to study the psychological effects of life 
on anticoagulants when comparing groups of elderly, atrial fibrillation patients on 
DOSCs with those on Warfarin.  They argued that DOACs could be used more 
extensively with elderly patients and set out ‘to determine whether new oral 
anticoagulants have greater psychological tolerability than Warfarin’. Their sample 
was smaller (15 on Warfarin and 15 on DOACs) and older (81+ys) than the study 
reported here and did not interview the patients.  But their PSS scales reported 
findings similar to those observed here, that the DOASs group expressed, among 
other things, less stress than the Warfarin group. ‘They concluded that NOA have a 
positive psychological impact when compared with Warfarin in elderly patients’ 
(p99). Patel et al., (2015) reports a longitudinal study at Kings Collage Hospital, 
London, where they studied the dosage and monitoring level of compliance of AF 
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patients. Some of the findings resonate here. The Kings College team highlighted 
the discovery of the following health care issue:  
 ‘We were surprised that an individualized dosing strategy was not 
recommended for these new anticoagulants when they were introduced into 
clinical practice. Although the dosing strategy adopted was based on data 
from large clinical trials, clinical trial populations do not necessarily 
represent real world populations, especially older and frail people who 
commonly use these agents’. (p1)  
The relative lack of understanding and the lack of action taken to address the needs 
of older patients would appear to be widespread. That they may require more 
sensitive person-centred treatment was also noted by Patel and colleagues. This 
supports the findings here which show that, even in the most caring of clinical 
environments, older patients need more help than younger ones if they are to 
successfully manage their own medication programme.  
A study close to the aim here was undertaken by Bartoli-Abdo et al., in 2016 (of 
which Patel was a team member) but it differed considerably in methodology and in 
some outcomes. With a research team from Kings Collage, London they involved 
32 people, fifty per cent each of AF and venous thromboembolism (VTE) patients 
in order to monitor their responses to switching from Warfarin to a new 
anticoagulant. The patients had, however, already been on the new medication for 
several months by the time they joined the study. Four focus groups were held, 
lasting 90 minutes, at two anticoagulation clinics: at King's College Hospital NHS 
Foundation Trust, London, Denmark Hill and Princess Royal University Hospital, 
south London. These patients were paid £30 each for their time. (It is noteworthy 
that the current study did not offer an inducement.) The focus of the group interviews 
was the value patients placed on VTE against other treatments, their experiences 
with the new medication, how well they managed it and their level of satisfaction 
with the new treatment  (Auyeung et al., 2016; Mabley et al., 2019, p63). The 
patients were seen once only and always in a group.  
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The results for the Kings College team were, in some ways, similar to those reported 
here, but did not go as far in fully exploring the life-changing impact of the switch on 
various aspects of their patients’ lives. In common is that the patients had all 
successfully incorporated their anticoagulant drugs into their wider array of 
medications and saw no major difficulties in adhering to the treatment plan. Some 
similar small difficulties were reported, such as clinical appointments for monitoring 
getting in the way of work and travel. Both samples reported anxieties about how 
they would know if things were ‘all right’ without regular testing. They also reported 
a high level of trust in the care staff to keep them safe from harm. (Also reported by 
Patel et al., 2016, p65).  Like the sample here, they reported a high level of 
compliance after the switch with just a few stating they manipulated the doses to 
help manage life events.  
Their findings also supported the view of the current sample, that of desiring more 
long-term support even if in-clinic testing was not required. Telephone helplines and 
occasional meetings were put forward as options. Bartoli-Abdo et al., acknowledge 
that while many of the experiences regarding this type of therapy are known about 
‘…. they nonetheless deserve attention….’ if a better service is to be delivered (Patel 
et al., 2019, p66). The Kings sample was small and acknowledged as a limitation, as 
was the fact that the participants were self-referring and so may not be representative. 
In addition, there was no attempt to further analyse their findings by age or sex. While 
the findings of Patel et al., may support many of the findings of the study reported 
here, the St Mary’s study aimed to and was successful in gathering more soft, 
personal material that underpinned the lives of these patients. Patel et al., (2019) 
member of the Kings College research team, returned to the data set and published 
more findings but they were restricted to clinical issues.  
Bajorek et al., (2018) explored patient’s preference for Warfarin versus newer 
anticoagulants, using vignettes and interviews with a group of patients on the old and 
new treatments. Both samples of patients professed satisfaction with their current 
medication but mostly, it was thought, due to familiarity and not wanting to try 
something new. Interestingly, similar themes emerged to those reported here, 
patients claimed that they ‘just accepted that things were as there were, nothing you 
can do about it’.  In addition, it was also found that the regularity of the blood testing 
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was a comfort for those on Warfarin and those on one of the DOACs talked of liking 
the simplicity of the new regime and the reduction of the Warfarin side effects, but  
some missed the comfort of the clinic visits.   
Most recently, Ng, et al., (2019) compared the quality of life and treatment satisfaction 
between patients on Warfarin and direct oral anticoagulants in a cross-sectional 
study. Their findings showed no significant difference between the two groups on 
physical and mental satisfaction but, despite this, the DOACs group reported being 
more satisfied with their treatment than the Warfarin patients.  Perhaps related to this 
was the Warfarin patients significantly higher hospitalisation rate due to adverse 
events. This last finding of higher satisfaction with the new regimen resonates with 
the findings reported here.  
While research studies in this field are still few, notice is now being taken of the 
patients’ perceptions of the old and new treatment programmes.  There would seem 
to be a consensus that this group of older patients show personal resilience in the 
face of comorbidities, but some do miss the comfort of clinic visits. Importantly, there 
would appear to be growing evidence that they are generally happier with their new 
anticoagulant programme than on Warfarin.  
 
8.8 Staff perceptions of on-going care for older AF patients.    
These findings are the result of meeting the second research objective:  
‘To interview the medical and nursing staff to explore their level of knowledge 
relating to issues faced by the patients with regards to safety and compliance, 
as well as their awareness of the social implications of switching patients to 
DOACs’.    
Pirmohamed (2006) said that due to the frequency of contact between the patient 
and the nurses in the specialist anticoagulation clinics based in a primary care NHS 
hospital, they are able, through building a trusting relationship, to effectively and 
safely manage anticoagulation patients who require a multi-disciplinary or 
multifunctional approach.  It would appear that the frequency of contact with the 
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same staff and subsequent trust is key to patient’s continued health then and now. 
Trust of course requires stability, such as the same team with low staff turnover 
within the clinic team in order for trust to build. It was clear from their interviews that 
the staff at St Mary’s anticoagulant clinic cared very much about their patient’s 
welfare. Though this was in the best interest of and at the heart of each patient’s 
treatment plan, it was, however, necessarily limited to clinical concerns. Noticeably, 
concerns relating to bleeding were not often mentioned by the patients and have 
not been directly linked to improvement of patient satisfaction in this study. 
However, it is worth noting that concerns of bleeding play a role in deciding the 
prescription given to AF patients for the primary prevention of stroke.  
The staff were aware of some of the personal, non-medical consequences related 
to the switch, but were less alert to the wider implications which sometimes lasted 
for the rest of the patient’s life. The increased sense of personal responsibility the 
patients voiced after the switch was acknowledge by the staff, and some concerns 
were shared, particularly those of not knowing if all was well with their medication. 
However, it was left more at the level of voicing concern than of having a strategy 
in place to help them. To be fair to the staff there is no easy answer, as the only 
plan was that the patient should keep in contact with their GP. A similar finding was 
discussed by Glasziou el al., (2013) when exploring the rise in diagnosis and decline 
(as they saw it) in ‘care’. They state that we need to get better at working with the 
patient, to sharing knowledge of the risks of treatment as well as the benefits, so 
that the care plan can be shared. This is in line with the tone of the already cited 
NHS report on long term care:   
 ‘Patients universally say that they wish to be treated as a whole person and 
for the NHS to act as one team. Despite this, those people who have more 
than one condition, particularly older people, face an increasingly fragmented 
and ‘specialised’ response’. (NHS England Annual Report, 2012) p3.  
It could be said that the staff did appreciate the patient’s difficulties, but it could be 
argued that they did not fully understand the sometimes positive impact of the switch 
on many aspects of the patients’ lives. The impact of Warfarin into people’s lives 
was not always fully understood, nor was the new freedom of the new medication.  
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The provision of information to the patient is linked to the roll of the staff. The 
patients reported being quite satisfied with the amount and format of the information 
provided but some room for improvement was noted. The information provided was 
generally paper-based but a link to a website was also given. Elsewhere, more 
sophisticated methods have been tested with similar patients. Denizard-Thompson 
et al., (2012) worked with 91 patients in America who were educated about good 
anticoagulant compliance via handheld personal computers during clinic visits. The 
computer-assisted strategy was received positively by patients and staff and they 
claimed that the learning was sustained over time. It was cost-effective with regards 
to clinic time and resources, with the patients undertaking all three modules with 
little assistance from the staff.  
One factor that the St Mary’s participants tell us is important to them but is not raised 
in Denizard-Thompson’s study, is a face-to-face relationship which led to the 
building of trust. In addition, the patients here required repeated ‘top ups’ of 
information over time to keep them reassured. It would be difficult to see how the 
older patients in this study would cope with a much high level of technology 
assistance despite the attractive elements of the technological approach regarding 
cost and freeing up of resources (NHS England Annual Report, 2012).  
8.9 Should more people be switched?      
Given the positive response of the majority of these respondents to the new 
medication, what might the future hold of other AF patients?  Martin Cowie, (2012), 
Professor of Cardiology at Imperial College London (Royal Brompton Hospital) and 
colleagues from other leading institutions, reported on the progress of the new DOACs 
(NOAC innovation in anticoagulation report. 2014). Their concern was that many 
people who could benefit from appropriate anticoagulation medication were not 
receiving this treatment. The general tone of their paper was that more people could 
be helped and so avoid the high attendant cost of their required monitoring while on 
Warfarin:   
‘Routine anticoagulation monitoring adds significantly to the cost of Warfarin 
treatment. Treatment with NOAC therapies means that routine anticoagulation 
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monitoring is not required, and therefore, NOACs may present a release of 
capacity opportunity for local health services’ (p 29).  
It should be noted that the report was commissioned and sponsored by the 
pharmaceutical industry.  
The findings here might support Cowie’s conclusions, in particular in the light of current 
thinking about patient-centred healthcare. As the overall response of this sample to 
has been positive in both practical and psychological ways, perhaps there is room for 
a discussion within the NHS about switching over more patients. These additional 
switchers might be selected by their Consultant or GP, but the decision to switch them 
could now beneficially be based on personal issues and well as clinical factors. Taking 
this idea further, patients might be allowed to self-select into a DOACs programme 
based on their being well informed about the impacts of Warfarin and the new DOACs.  
The choice might also be offered to newly diagnosed AF patients. The cost for this 
change would, of course, have to be a consideration, as the newer medicine is more 
expensive than Warfarin. To date, however, there are no firm figures on the costs 
of such a move that go beyond the cost of the medications. A study needs to be 
conducted that takes into consideration the reduced cost of the patient no longer 
requiring weekly monitoring and the reduced incidences of emergency admissions. 
More research is also required into UK patients’ perspectives of the medication 
change-over.  
The calculation of the financial benefit to patients switching from Warfarin to DOAC 
as recommended by NICE takes into account the Quality Adjusted Life Years 
(QALY) of each individual patient. The QALY combines both quantity and health 
related quality of life (QoL) into a single measure of health gain in years. This was 
scored using ‘perfect health’ as 1 and death as 0. This Figure was then used to 
calculate the QALY-ICER which is the Incremental Cost effectiveness ratio. The 
QALY is the recommended measure of the national institute for clinical excellence 
(NICE) to measure the cost-effectiveness of treatments for patients, especially in 
life-long conditions such as AF. It also allows for benefit versus harm analysis as 
well as allowing for a broader comparison between patient groups. The expected 
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QALY for patients switching from Warfarin to DOAC according to NICE 2012 is 
shown in Figure 8.1 below.  
 
  
Figure 8.1  
QALY of switching to Anticoagulation Drugs 
Adapted from (NICE, 2012)   
 
Research has begun elsewhere on this topic, for example Elewa et.al., (2014), 
surveyed 260 patients in Georgia, USA to ascertain their level of satisfaction with 
Warfarin and their views on switching to Dabigatran. The study was a short 
questionnaire-based study administered to outpatients. No interviews were carried 
out. The findings report that although the majority of patients claimed to be satisfied 
with Warfarin most said they would be willing to move to the new medication. Fewer 
follow-up appointments was cited by patients as the main attraction, but they would 
also welcome the reduced negative interaction effects with other medications and 
with some foods which would normally have an impact on the effect of Warfarin. It 
is interesting to note that Elewa et al., respondents would forgo the comfort of the 
staff interaction during routine monitoring in order to have the freedom of choosing 
a greater variety of foodstuff, which is similar to those reported here. Unlike the 
patients in the current study, these American patients had an additional barrier to 
overcome before they could change medication, that of cost. The new medication 
was almost three times more expensive than Warfarin, so some patients, despite 
wishing to switch, did not do so for financial reasons.  
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The switch is not without complications, particularly for the elderly; Elewa et al., also 
quotes Eikelboom et al., (2011) who reports an increase in bleeds in older patients. 
This is not an issue that emerged in the St Mary’s sample. However, if they had 
been studied for longer that the 90 days, it is possible more incidences of bleeds 
might have been reported.  
 
Real life has intervened here in a somewhat dramatic way. This thesis was at the 
point of completion when the COVID-19 virus was at its height in March and April 
2020. This impacted immediately by curtailing all patients’ visits to UK hospital 
clinics for INR monitoring. Several clinics in London moved into the community but 
the decision was also made to switch many patients from Warfarin to one of the new 
DOACs which require no clinic visits. The high cost of such a switch becoming 
secondary to patient and staff safety. This may herald the increased use of DOACs 
in the future. 
 
8.10 Conclusion    
The findings show a clear overall positive response to the switch to the new 
medication, and that the patients felt a considerable reduction in their stress levels 
almost as soon as the switch was achieved. This was true across both sexes and 
ages groups. The findings show an overall satisfaction with the care they received 
at St Mary’s and a high level of trust between staff and patient. It is clear that the 
anticoagulant clinic at St Mary’s is performing well in supporting their patients who 
switched from Warfarin to a DOAC. However, more consideration could be made 
with regards to the patients’ dietary preferences and/or restrictions before starting 
anticoagulant therapy, as well as to their age-related needs, comorbidities, and 
domestic circumstances. With all these in mind a fuller care-plan could be 
developed that would help the patients adhere to the new medication.  
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8.11 Recommendations   
Any change in healthcare practice will often require a reallocation of resources or 
an increase of funding, or both. Some of the recommendations set out below could 
be achieved with small changes to practice, given the goodwill of staff concerned. 
However, others would require the cooperation of other parts of the NHS, 
necessitating considerable management time and multi-discipline involvement. 
Cross-discipline cooperation can be very hard to achieve, and will require a strong 
case to be made for the added expense of time and effort. With regards to funding, 
some savings will be made within the anticoagulant team budget due to the reduced 
number of clinic appointments required for the switched patients. However, the risk 
is that that money will be re-absorbed into the general budget. A way needs to be 
found for it to be protected for the use of switch patients.  
A key finding is that patients differ in their care needs depending on their age and 
complexity of comorbidities, and that happily this is now being more widely 
recognized within other health care professions. A recent overview of the care 
received by anticoagulant patients is Excellence in anticoagulant care (2016), 
published by The NHS London Clinical Networks. Its overriding theme is that:   
‘An excellent anticoagulation service should be built around the needs of its 
patient population, and commissioners should actively involve patients and 
carers in the design and improvement of services’. (p7)  
Components of an excellent patient-centred anticoagulation service would include, 
as the report stated: convenient services close to home, good GP services, and 
rapid access to expert support when needed. Clinical staff should be innovative 
when designing communication channels with their patients, including greater use 
of telephone contact to save time and travel. More ‘one stop’ provision to help the 
patient, especially the old and frail, and more convenient appointment 
arrangements were also called for. Finally, a clear ‘care pathway’ should be 
developed for each patient. All of these factors have also emerged from the current 
study.  
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However, it is important to note that despite the good intentions of the London 
Clinical Networks report, the practice on the ground currently remains traditional 
and not particularly patient centred (Gbadamosi et al., 2015). In the light of many 
NHS reports on good governance and many publications of improving practice, it 
might be worthwhile before setting out the recommendations, to consider that many 
patient care systems and departments, such as the link between the NHS and the 
council (which supports the patient outside of the hospital), are not linked up in a 
way which enhances good value for the patient.  Gbadamosi talked about the 
difficulties the NHS faces when implementing change, listing ten common reasons 
why bottom-up change, even small changes, are so often thwarted. In order to be 
able to discuss let alone implement even the smallest of changes outlined in these 
recommendations Gbadamosi’s ideas need to be considered. One in particular is 
the stifling of innovation by the system itself:  
‘Senior leaders are trapped in inflexible processes. We fail to embrace ways 
of taking part in low coat, low risk experiments to test ideas. We must utilize 
the diverse experiences of stakeholders - our patients’.   
  
Likewise, Alderwick and Ham, (2017) reported on quality improvement in the NHS. 
They listed lesson for leaders which focused on relationships and culture, in 
particular the involvement of patients and their carers, and that stated their care 
package should work as a whole system (Alderwick and Ham, 2017).  
In the study reported here, the supposed greater ease of use of DOACs reflected in 
greater satisfaction in this sample but did not always improve adherence or quality 
of life for everyone. The introduction of DOACs, intended to simplify follow-up for 
the physician, may have had the collateral effect of making the prescription of oral 
anticoagulants more complicated by reducing contact with healthcare professionals. 
The findings are clear, that good adherence to any medication routine is complex 
even for the most cognitively aware and robust patient. It is recommended that a 
series of discussions among healthcare professionals within the Trust be held and 
focus on the way in which elderly patients, particularly those who are frail or house-
bound, are monitored following the switch to DOACs. To facilitate this there follows 
a number of recommendations.  
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These recommendations are based on patient and staff concerns and the 
researcher’s interpretation of the evidence generated here. For clarity, the 
recommendations have been divided into three areas:   
• Local research   
• Local anticoagulant clinical practices  
• Implications for the NHS   
While at this stage these first recommendations are regarded as local, but it is 
anticipated that some could be used to inform the healthcare process of similar 
patients across the NHS. In the first instance, they will be used to inform the patient-
centred pathway already in place at St Mary’s, and the two hospitals in Lewisham 
where the researcher works.  
8.12 Local research.  
The first recommendation involves making use of this sample of patients’ preference 
for informal learning, many participants talked of learning so much from each other, 
for example, on the bus ride to the clinic, this knowledge base should be unitised. It 
is important for the medical team to draw on the years of unique experience that 
these patients have to offer from living on either Warfarin or the newer 
anticoagulants. This study has gone some way to inform us of the impact of the 
switch, and has provided insights into how some patients cope with their medication 
treatment plan. Importantly, their coping mechanisms sometimes include methods 
of self-management which are not what the doctors would recommend or even 
approve of, though the patients continue to employ them all the same. For example, 
awareness of how, when, and exactly why they manipulate their medication dosage 
to suit their daily activities might be very useful information for the clinical staff to 
know – and enable them to prepare for. The difficulties of taking the correct dose at 
the right time when faced with work or travel arrangements or simple forgetfulness 
are unique to each patient. However, it may be that a pattern of behaviour is 
discernible across a particular group. Each patient in this study has worked out a 
way to survive their medication without too many mishaps. How they do this, and 
the risks involved, is well worth exploring further.  
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This is a small study and limited to patients over the age of 65, therefore, it is 
recommended that a research study be set up with older AF patients to meet in a 
series of group discussions. The focus groups should be divided into sub-groups: 
men and women; age 65/74, 75/84, 85+ and, if possible, a group of patients who 
live alone and another for those who live with another; also, if possible, groups of 
people with different types and numbers of co-morbidities. The reason for these 
subgroups is to gain a wider and deeper understanding of some of the key themes 
identified here. A group facilitator would encourage them to talk about their personal 
coping methods and to ask questions. It should be a ‘safe’ environment, so the 
patients can talk freely without sensing any disapproval or concern from the group 
organiser. They should be encouraged to talk openly about any of what might be 
called ‘rule breaking’ or ‘work-arounds’ that they need to employ for their medication 
to meet their personal needs. A second line of discussion would be the gathering of 
any hints or tips about how to manage one’s life which on such medication. For 
example, tips with regards to eating, exercise and travel would be invaluable. It is 
anticipated that the patients would have insights that could be incorporated in the 
preparation of a booklet for patients living with this type of long term medication. 
After approval by health care professionals, it could be distributed to existing and 
newly diagnosed AF patients. It is hoped that a patients’ groups at the researcher’s 
NHS Trust in south London will be set up in the near future. 
8.13 Local clinic-based recommendations.  
Longer switch over patient consultations are recommended. When a switch to new 
medication is under consideration, a series of conversations should be held with the 
patient about the clinical necessity of the change and also about their domestic 
circumstance. How they will achieve treatment compliance should be explored. The 
clinician should not assume that the patient has a clear idea of what is involved. For 
example: 
• What process will the patient use in order to remember to take their 
medication? 
• What difficulties does the patient think may emerge and how will they cope with 
them?  
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A personalized healthcare/anti-coagulation plan based on personal circumstances 
could then be developed.  
8.14 Development of a global/national DOAC registry  
Currently, INR results for Warfarin patients are monitored and trended on popular 
hospital databases such as the INRstar® or DAWN® software. Additionally, these 
patients are issued with a record book (‘yellow book’) in which patients can keep a 
contemporaneous record of their INR, taken at home or in a hospital or clinic. The 
record book can be transferable between various hospitals and clinics. However, 
patients who have been switched from Warfarin do not have a log or record keeping 
method. As there is an increased interest in the use of direct oral anticoagulants as 
an alternative to Warfarin therapy, it is therefore a recommendation that a global or 
national database for DOAC patients be introduced to the NHS. The need for such 
a registry is evidenced by the introduction of the Dresden DOAC registry in 
Germany, which has been cited as ‘an invaluable source of information in 
emergency situations’ (Beyer-Westendorf et al., 2014).  
As this research was conducted within Imperial NHS trust, which is a world-
renowned teaching hospital and innovator in technological and medicinal advances, 
it may be prudent to approach specialists in anticoagulation who work at the trust 
such as Dr Shlebak, a specialist consultant in haemostasis and thrombosis, and 
who kindly assisted with this study, Dr Mike Laffan (Professor of Haemostasis and 
Thrombosis), or Professor Martin Crowie, a Consultant Cardiologist, for assistance 
with setting up such a registry.  
8.15 Assistive technology   
It is recommended that research be undertaken into a method of assistive 
technology, such as a handheld device, that will allow patients to self-monitor direct 
oral anticoagulants at home and so reduce their anxiety. When identified it might 
well be of support to some of the participants, such as the ones who are overly 
concerned with the loss of the Warfarin testing, though not to all (NICE, 2014b). 
Given the advanced years of many of the participants, some would not be able to 
cope with the technology but undoubtedly some would. Additionally, according to 
research elsewhere, clinicians working in an emergency or trauma setting would 
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welcome the ability to rapidly detect the presence of DOACs when deciding 
pathways of treatment (Ebner et al., 2017). This, however, is a difficult task. While 
there are guidelines for medical staff to help support and train patients in self-
monitoring who are on Warfarin, such as the London Clinical Networks, there is no 
equivalent for patients on the new anticoagulants. This results from the issue of 
anticoagulation being complex, and made even more difficult by the nature of the 
DOACs, whereby they are licensed for use without monitoring. This may be due to 
the fact that each DOAC dose has a targeted mode of action within the coagulation 
pathway, is rapid in onset, and has a predictable removal time from the body via the 
kidney, usually 2-4 hours. However, according to Padrini (2019) it is possible for 
patients to inadvertently overdose DOACS, particularly those patients who have 
impaired renal function. Padrini revealed that 43% of patients with atrial fibrillation 
and renal impairment were at an increased risk of overdose and haemorrhages. A 
handheld device with the capability of detecting and quantifying DOACs would 
therefore be of benefit to a population of over a quarter of DOAC users (Padrini, 
2019). 
8.16 Better information.  
It is recommended that printed information leaflets and web sources are made 
available to both new switchers and those remaining on Warfarin, as their existing 
information may well be out-dated. These should contain information about the AF 
condition as well as the medication. A further leaflet should also be provided for the 
patient to give to their carer or any other person close to them the aim being to inform 
the non-patient about the condition and implications of the medication. The 
information would be similar to the patient leaflet, but would be addressed directly to 
the patient’s supporter/friend/family so that they feel the information is specifically for 
them. Both should be written in an appropriate way to help with understanding, such 
as using plain language, perhaps using larger lettering, and with easy references. 
8.17 Linked up working – reaching out to patients 
It is recommended that the help of Community nurses is enlisted because they are 
familiar with treating patients with similar personal and medical circumstances. 
DOAC patients could be added to their list of medical patients requiring home visits 
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for follow-up or simply just to check on. This would be independent of whether the 
patients had other conditions. It is also recommended that a service of dedicated 
anti-coagulation healthcare workers routinely phone DOAC patients once a month 
for at least a year post switch. These callers could be medically trained personnel 
or other healthcare staff who have had training to identify at-risk patients or those 
in need of a home visit or referral.  
It is recommended that a dedicated hotline for patients who have questions or 
concerns regarding their anticoagulation therapy be set up. Patients should also be 
able to receive advice or referrals on non-anti-coagulation issues such as 
loneliness, transportation access, medical personnel access, entitlement to 
benefits, weight loss, or age-relevant local social activities. This would necessarily 
need to serve as a referral resource as well as an immediate source of reassurance.   
It is recommended that an intervention to support patients who are newly switched 
from long-term anticoagulants (e.g. Warfarin) to long-term DOACs be set up that 
offers face to face contact delivered within a social setting. Suitable locations would 
be in a recreational/non-clinical community setting such as a local fire station, 
hospital, church or school, that elderly people could attend weekly for tea/coffee 
and sandwiches and a chat with people of the same age group and circumstances, 
and so develop a more community-like sense of belonging. This would also be a 
point of contact for those who are coping on their medications, but are dealing with 
non-prescriptive issues such as loneliness and depression.  
Patient-led support groups have been a feature of NHS life for many years. 
However, to date there are no community based support groups for AF patients in 
South London.  Worrall et al., (2018) undertook a review of the research on self-
help groups of patients with mental health problems and found many positive 
outcomes (Seebohm et al., 2013). There was good scientific evidence, they argued, 
to support the view that support groups were successful. They cited researchers 
who found that groups could help people develop an improved sense of personal 
value and belonging and improve their social networks (Worrall, et al., 2018). They 
also enhanced feelings of control and resilience (Seebohm et al., 2013).  
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8.19 Reversal of DOACs  
Within the medical community, the uptake of the use of some DOACs, despite their 
many benefits compared to Warfarin, has been slow. As discussed in earlier 
chapters, one of the most commonly cited reasons for this is the unavailability of an 
approved reversal method or antidote for these particular DOACs. In May 2019, the 
first reversal for Rivaroxaban and Apixaban (Andexxa®), was proposed to the 
National Institute of clinical excellence as a possible reversal but was declined 
because: 
‘there is insufficient information on the rationale for scoping the use of Andexxa®’. 
(NICE, 2019).  
It is therefore the recommendation of the author that future pharmaceutical research 
be centred on expanding the development of suitable reversal of DOACs, as well 
as increasing the information accessible to clinicians on the scope and benefits of 
DOAC reversals.  
8.20 Limitations of the study  
The patients were seen on three occasions over a three month period, a relatively 
short time given that their medication plan was lifelong. With more resources, it 
would be desirable and beneficial to visit them again at 12 and 24 months to learn 
how those who claimed they were experiencing a new lease of life had actually 
fared over a longer time period, and how the older patients were coping in the face 
of reduced clinical support. Finally, an alternative research methodology, but again 
depended on increased resources, would have been a case study approach which 
would gain a deeper understanding of some of the profound changes that the new 
medication brought to the lives of these patients. Notwithstanding these limitations 
the study has generated new and valuable information and clearly demonstrates 
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Chapter 9 - Self-Reflection  
  














9.0 The start of the journey 
This chapter presents my personal reflection of completing this Professional 
Doctorate, charting my personal development and growth as a researcher. I am 
really pleased to have reached the conclusion of this thesis; this is an enormous 
achievement for my entire family who have been supportive whilst I pursued this 
self-funded study. I am a wife, mother of three and have worked full time as a 
Specialist Biomedical Scientist in haematology for the last 17 years.  
The progression of this thesis has been a journey. At times it was very difficult, 
frustrating and tear inducing, but also gave me the joy of discovery and hugely 
increased my knowledge of the subject researched. I have always been an ‘adapt as 
you go’ kind of person, and not always good at forward planning. However, over the 
last six years I have come to realise the value in getting to know my personal and 
professional potential. David A. Kolb in 1984 said: ‘Learning is the process whereby 
knowledge is created through the transformation of experience’. How right he was!  
Being the eldest child and grandchild to a very large and extended family has its 
challenges. I often feel as if I have a lot of responsibilities in maintaining   
communication with all the siblings and relatives. My main priority has always been 
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to make sure that my husband and children are cared for, however, I also have 
routine financial obligations to several relatives. This has not always been easy, 
especially as this course was almost all self-funded for 6 years. For years, I have 
worked two jobs in excess of 50 hours a week as a routine, to accommodate my 
responsibilities. What I learned from that was the need to plan, right down to the last 
detail, and to cooperate with those who can offer support.  
At the start of my studies, I worked in the NHS as a Junior Biomedical Scientist, my 
husband worked full time as a Metropolitan Police Officer, and we had two children. 
While my employer was positive about my research plans, they could not fund them. 
At the time, my husband and I were required to participate in a work shift pattern 
which includes day and night shifts during the weekday and on weekends. My 
university attendance for the first two years was often before or following a 12 hour 
night shift.  
Two years into the studies and whilst on maternity leave with my third son, I was 
promoted to Senior Scientist in the NHS, a role I kept for two years. This new role 
helped me develop skills which were also useful in my studies: conflict resolution, 
working with various IT platforms, managing a budget, people, and time 
management and most important of all - multitasking. Again, my employer was 
enthusiastic about my research which led to some fruitful discussions. Later I left 
the NHS and joined a private medical laboratory on Harley St (HCA). This laboratory 
offered shift patterns which, most importantly, allowed me to attend the NHS 
anticoagulation clinics at St Mary’s to collect data for this study. Work at HCA also 
taught me the value of communication and engaging with the users of the service, 
producing efficient and quality results. All of which I have been able to apply to my 
studies. They also offered some funding for my studies.  
In 2018 my husband joined the Ministry of Defence as an Armed Police Officer, 
which is a really big achievement and had a positive impact on the whole family in 
part due to the more regular hours and increased ability to time manage. In 
December 2018, I returned to a new job in the NHS and was promoted to the senior 
role of Blood Transfusion Laboratory Manager for two NHS Hospital laboratories 
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(Queen Elizabeth Woolwich and University Hospital Lewisham), with a total 
rotational staff responsibility of 28 scientists.  
It is worth noting here that during my interview for the job, my research was 
discussed and recognised as important and received informal support with a 
request for me to share the findings with the Trusts. Most usefully, I have been the 
master of my own time schedule during this last vital year of study. Looking back, I 
am pleased that I was persuasive enough about my research to bring all my 
employers along with me, in spirit at least.  
9.1 Looking to the future, the role of research in my profession  
The importance of research intelligence has always been important in healthcare to 
determine strategy formulation as well as patient care management policies. In 
recent years, the importance of research has become far greater than previously as 
part of the decision making process for all aspects of patient care. At the start of my 
studies I had ambitions around self-progression as well as helping my patients, but 
also, I wanted to promote my profession. This, in my view still needs doing. For 
example, the results generated by biomedical scientists influence 75% of all clinical 
diagnosis in the UK, however there are very few people who are aware of who we 
are and the work that we do and as a result, the pool of applicants for the profession 
each year is declining which will in turn impacts on standards. Often patients are 
asked to list the staff involved in their care and only 5% would list the scientists, the 
laboratory or even the results. It was, therefore, a dream of mine as a junior scientist 
to be able to have a platform from which I could promote this section of healthcare 
and also increase awareness of Biomedical Science as a career option in young 
people entering university.  
Now that I have progressed to the level of management, I would like to apply lessons 
learnt from this doctorate journey such as critical analysis and review of data, time 
management skills, the ability to prioritise the order of deadlines, to my new role as 
Blood Transfusion Manager and hopefully promote the profession as a career 
choice.  
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9.2 My academic learning  
Before engaging in this research programme, I had only basic research skills gained 
during my Master’s degree but had a desire to find out what happens to vulnerable 
members of the community who have reduced access to medical/healthcare 
professionals following a change in their life-long medication regimen.  The taught 
modules, which made up the early part of doctoral programme, improved my 
academic learning and raised my confidence in many ways including an 
understanding of the importance of how to undertake qualitative research and how 
to manage a research project over a long time period. I was new to the process of 
critically reviewing the research of others but now find it a valuable skill.  
I have also found it useful to learn from the experiences of others and I have been 
very lucky to have formed a bond with the other students in the class. I have learnt 
various perspectives and approaches to problem solving and critical thinking. 
Conducting this research using validated questionnaires has introduced me to some 
of the most popular qualitative and quantitative research tools and methods. I 
therefore gained practical experience whilst administering questionnaires, as well 
as data analysis skills.  
I was very concerned about the possibility of not completing this course due to time 
constraints, work and family commitments and the financial pressure. However, 
early into the course (second year), I was encouraged to perform a SWOT analysis 
as part of the Professional Development module. This later proved to be invaluable, 
as it quickly emerged that some of my ordinarily routine tasks would have to be 
curtailed, postponed, or delegated in order to complete this study. I needed to get 
structure and routine into my daily activities, so I implemented forward planning, 
Figured out what changes can be made in my work and home life, As much as 
possible, I have maintained links with family and friends who were my support team 
for the duration of the course and tried to maintain a healthy balance of diet and 
exercise as well, although not always successfully.  
I was under no illusions that this course was going to be an easy one, far from it. I 
remember in my first year during a Q&A session following a lecture with Dr Patricia 
Maitland, who later became my project supervisor, she said ‘Completing a PhD or 




Student ID: W10503030 v5 20.07.2020 
Prof Doc is a test of endurance and perseverance as well a love of learning’. Six 
years in and my work-life balance has been greatly impacted as well by the time I 
have set aside for studying, researching, and writing. I made monthly schedules to 
include all work and family related events, these are posted on the family fridge.  
A copy of the schedule is also given to my child-minder. Additionally, I synchronized 
the iPhone calendar time-table for my husband and I, in order to better manage the 
pick-up and drop-offs of the various activities of the kids such as scouts and 
swimming etc. This introduction of my new organisation skills has greatly improved 
the routine running of the day to day tasks and work hours and has gone some way 
to reducing stress in the household. I have learned the art of delegation, a skill that 
will no doubt become invaluable in the future in my role as a Blood Transfusion 
Manager.  
I am happy to conclude that I am generally a happy and grateful person but now also 
a more questing one. I stand back and think more critically about published research 
papers, asking are they valid and useful? Along with this is a greater appreciation of 
the research (and researchers) undertaken within the health care sector as I know first-
hand just how much goes into it. This DProf has undoubtedly been one of the hardest 
things I have ever done so. I will end with a quote from Cicely Tyson:   
‘Challenges make you discover things about yourself that   
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APPENDIX 1 - Gantt Chart  
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APPENDIX 2 - Question Guide for Clinicians and Biomedical Scientists 
Interviews.  
Introductions and explanation about the aims of the research  
Topic: Your experience of working with DOACS - as a group warm up 
covering:  
Q 1. How long have you each worked with DOACS? (1a) In what capacity?  
Q 2. Approximately, how many DOAC patients per week/month do    you see?  
Q 3. What information do you have available about the dosage, side effects, 
and other information relating to DOACs to help you?  
Topic:  DOACS itself – information provision.  
Q 4. How and when is the need for a switch of medication first discussed with 
the patients?  
Q 5. After the decision is made, how is the DOAC information generally 
passed to patients?  
  5a Do you think it is the right/ enough information?  
    5b How else might it be given?  
Topic: The impact of the new medication  
Q 6. What issues have you observed the patients encounter at the point of the 
switch?  
Q 7. What do you know about the personal and social impact the switch has 
on the patients?  
Q 8. What is the biggest impact you envisage that these drugs will have on 
the life of these (DOAC) patients?  
Q .9 Do you think that the lack of monitoring of these DOACs could be an 
issue for these patients?  
  
Q .10 Do you think the lack of reversal of these DOACs could be an issue for 
patients? If so, in what way?  
  
Q 11. Is the social impact on the patient considered before the prescribing 
DOACs?  
Q 12. What are the main concerns of patients being on DOACs?  
Q 13. Do you feel that there is more that the Trust or coagulation department 
could do for these patients? Close  
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APPENDIX 3 - Question guide for the first patient interview.  
 Welcome given and the researcher repeats the explanation about the research 
that the patient was given at the time of recruitment. The information and consent 
form are then read by the patient and completed.  
The patient’s scale scores will be read by the interviewer before the qualitative 
part of the interview begins just to see if any areas of particular interest or concern 
can be identified.  
Topic: Living with Warfarin   
Q 1. You have been on Warfarin for some time now, can you tell me what that is like? 
For example, how does it impact your day?  
o Prompt for examples  
Q 2. Does having a drug regimen interfere or enhance with your lifestyle in any way?  
Q 3. How do you get on with self-medicating – giving the medicine to your- self?  
Topic: Information provision  
Q 4. Thinking back to when you first started on Warfarin, how much information were 
you given?  
4a  How  was  the  information  provided? 
(leaflets/conversion/website).  
4b Did you understand the information easily?  
       
   4c Were you give any more information after that time?  
  
Topic: Current health self-assessment and expectations  
Q 5. How much do you know about the condition (AF) that Warfarin helps you with?  
Q 6. How many other medications do you take? Do you think you can name them?  
Q 7. Do you know why your medicine is being changed?  
Q 8. Do you think that switching to drug (DOAC) will change anything for you?  
Q 9. What benefits are you expecting from the new drug, if any?  
  
Q 10. Do you have any concerns about taking the new drug?  
Prompt only if necessary:   
reversal/antidote/adverse events/returning to Warfarin.  
  
Q 11. Have you had any unexpected experiences or events since using Warfarin?  
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And finally   
Q 12. Is there anything else you would like to tell me about being on Warfarin or your 
feelings about the change to a different medicine.  
  
Thank you for giving your time to take part in this study, we will hopefully 
meet again in three months’ time to see how the change of medicine has been 
for you.  
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APPENDIX 4 - Question guide for the second patient interview.   (90 days post 
switch)  
Welcome and a recap the first interview and any issues raised with be included in the 
discussion.  
Topic: The switch over.  
Q 1. How was the switch over for you at the time?  
Q 2. Did you understand the reason for it?  
Q 3. How long did it take to get used to taking the new medicine?  
Topic:  Living with the new medication.  
Q 4. Now that you have been on your new medication for three months, how are things 
going for you?  
Q 5. How are you getting on with the routine of self-medicating?  
Q 6. How do you think switching to drug (DOAC) has impacted on your life?  
Q 7. Have you had any unexpected experiences or events have you had since 
switching to DOAC?  
Q 8. Are you glad you switched?  
Topic: Expectations  
Q 9. Are there any expectations that you had initially that have/haven’t been met? If 
so, what are they?  
Topic: Overall Satisfaction  
Q 10. In broad terms, how happy are you that you made the switch to this new 
medication.  
Very unhappy. 1     2  3  4   5  6  7   Very happy  
Q 11. Is there any way the hospital could make your medication regimen better for 
you or others with the same condition?  
Thank you for giving you time to take part in this study.  
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Rights Reserved. SF-36® is a registered trademark of Medical Outcomes Trust.  (SF-36 Standard, US Version 1.0)   
9. These questions are about how you feel and how things have been with you during the past 4 weeks. For each question, please give the one 
answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks...?  
  All of  Most  A good  Some  A little  None   the 
of the bit of the of the of the   time the time       time  
     
a    Did you feel full of pep?.....................  1 ....... 2 ....... 3 ....... 4 ........ 
5 ........  6 b Have you been a very nervous     
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 person? ...................................................... 1 ....... 2 ....... 3 ....... 4 ........ 5 ........ 6 c 
Have you felt so down in the         
  dumps that nothing could cheer             
 you up? ..................................................... 1 ....... 2 ....... 3 ....... 4 ........ 5 ........ 6 d 
Have you felt calm and peaceful?............. 1 ....... 2 ....... 3 ....... 4 ........ 5 ........ 6 e Did 
you have a lot of energy? ................... 1 ....... 2 ....... 3 ....... 4 ........ 5 ........ 6 f Have 
you felt downhearted        
 and blue? ...................................................  1 ....... 2 ....... 3 ....... 4 ........ 
5 ........  6 g Did you feel worn out? .............................  1 ....... 2 .......
 3 ....... 4 ........ 5 ........  6 h Have you been a happy person? 
...............  1 ....... 2 ....... 3 ....... 4 ........ 5 ........  6 i Did you 








SFSF-36® Health Survey 1988, 2002 by Medical Outcomes Trust and QualityMetric Incorporated. All Rights Reserved. SF -36® is a registered trademark of Medical Outcomes Trust.    
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APPENDIX 6 - Information sheet for patient participants  
 A study of the impact of substituting Warfarin with Direct oral 
Anticoagulants (DOAC), in Atrial Fibrillation (AF) patients over 65 years old: the 
patient’s and clinician’s perspectives.  
Information sheet for study volunteers who will complete the scales and be 
interviewed  
Chief Investigator: Patricia Richards  
You are being invited to take part in a research study. Before you decide whether 
or not you wish to take part, it is important that you understand why the research 
is being done and what it will involve. Please read this information carefully and 
discuss with others if you wish. If you would like to ask questions about the 
research you can contact the study researcher, Patricia Richards without any 
obligation to participate. Please take time to decide whether or not you wish to 
take part.  
What is the purpose of the study?  
This study will look at the short term impact on the quality of life of 50 patients 
who are 65 and over and switching to the new Warfarin alternatives, DOACs. It 
will help us understand, from the patient’s point of view, what it is like living on 
Warfarin and then switching to a new medication. This information will help us 
work better with patients in the future, so your assistance will be of value to many 
other patients in years to come. This research is being undertaken as part of the 
researcher’s studies for Professional Doctorate in Health Sciences at the 
University of Westminster. It is being carried out at the Imperial NHS trust at St 
Marys, St Charles, and Hammersmith Hospital and Queens Park sites.  
Why have I been chosen?  
You have been invited to take part in this study as you are 65 or over and have been 
switched from Warfarin to DOAC.  
  
Do I have to take part?  
No, it is up to you to decide if you want to take part or not. If you decide to take 
part Patricia will explain the study to you and you will need to sign a consent form. 
If you start the study then change your mind that is ok, you are free to withdraw 
at any time without needing to give a reason. If you wish to withdraw you can 
request that any data, we collected from you is destroyed.  
What will happen to me if I take part?  
If you wish to take part in the study, you will be asked to complete an informed 
consent form. Patricia will then talk to you about your experience of switched from 
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Warfarin and ask you to compete some short questionnaires/scales about how 
you feel at the moment with regards to your general wellbeing and any stresses 
or anxieties you may have. It will take about 30/45 minutes.  
A month later you will be asked to complete the questionnaires again which will 
take about ten minutes. Finally, in three months’ time, Patricia will talk with you 
again when you can discuss how life has been on the new drug and you will 
complete the scales for the last time. Asking you to fill in the 
questionnaires/scales three times and talk with Patricia twice gives us some idea 
of any changes that you may experience over first three months of your new drug 
programme. Participants will be provided with a copy of their signed consent form  
  
 What do I need to do if I want to take part?  
If you would like to take part in the study please tell the researcher, Patricia 
Richards, or email on patricia.richards@imperial.nhs.uk or by telephone (0203 312 
1132).  
  
What are the possible benefits of taking part?  
You will have some private time to talk to someone who understands the drugs 
you are on and to discuss with them how you are getting on with the drugs - if 
they change anything you do socially and how they make you feel within yourself.  
When the study is finished all the research volunteers will be able to read about 
the results on the hospital website.  
   
What are the possible risks and disadvantages of taking part?  
They are no risks to you as the research only involves talking with the researcher. 
Nothing about your treatment will change.  
  
What will happen if I don’t want to carry on with the study?  
If you decide to withdraw from the study, data obtained from you may be used to 
contribute to study results. If you do not want this to happen, you can request 
data that belong to you to be destroyed. However, once data has been 
anonymised and included in a dataset it is impossible to remove this data as we 
have no means of identifying which is, specifically yours.  
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Complaints  
Any complaints you might have for this study will be fully investigated. If you have 
any concerns about study procedures you can speak to the primary researcher, 
Patricia Richard who will answer your questions. If you remain unhappy and wish 
to complain formally, you can contact Dr Annie Bligh, t Westminster University. 
A.Bligh@westminster.ac.uk  on +44 20 7911 5000 ext. 65038   
  
If you have any issues or concerns, please contact the patient advice and liaison 
service (PALS) or complaints team. Patient Ground floor of the  
Queen Elizabeth the Queen Mother (QEQM) building, St Mary’s Hospital, South 
Wharf Road, London W2 1N. Phone: 020 3313 0088, Monday to Friday, 09.30-
17.00. Email: IMPERIAL.PALS@NHS.NET:   
  
Will my taking part in the study be kept confidential?  
Yes, anything you say during the interviews will be kept strictly confidential. No one 
will be able to identify you at any time.  
The University of Westminster has a standard confidentiality procedure for 
participants involved in research that adheres to the Data Protection Act. This 
stipulates how personal information is collected, used, stored, and disposed of 
during and following completion of research projects. Files will be encrypted, and 
password protected. Any information that is collected about you during the course 
of the study will be kept strictly confidential and secured within restricted areas 
and/or electronic files on computers that have restricted access. Each participant 
is assigned a unique code that is used on all data collected during the research. 
This code is then used to identify data in place of personal information. Only the 
researcher will have access to personal identifying data information.  
No one will be identifiable from the collect data, written report of the research, or 
publications arising from it.  
 
What will happen to the results?  
Your interview material will be combined with that from the other volunteers and 
it will all be analysed as a group. The results will for part of my doctoral research 
for the University of Westminster. The findings will be used to help other patients. 
In certain exceptional circumstances where you or others may be at significant 
risk of harm, the researcher may need to report this to an appropriate authority, 
in accordance with the UK Data Protection Act 1998. This would usually be 
discussed with you first.  
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APPENDIX 7 – Staff Information Sheet 
A study of the impact of substituting Warfarin with Direct oral Anticoagulants 
(DOAC), in Atrial Fibrillation (AF) patients over 65 years old: the patients’ and 
clinicians’ perspectives.  
Information sheet for staff / study volunteers who will complete the scales only.  
Chief Investigator: Patricia Richards  
You are being invited to take part in a research study. Before you decide whether 
or not you wish to take part, it is important that you understand why the research 
is being done and what it will involve. Please read this information carefully and 
discuss with others if you wish. If you would like to ask questions about the 
research you can contact the study researcher, Patricia Richards without any 
obligation to participate. Please take time to decide whether or not you wish to 
take part.  
What is the purpose of the study?  
Generally elderly patients on Warfarin are routinely monitored in a clinic setting. 
The level of Warfarin, which is referred to as the International Normalised Ratio 
(INR) is used to determine whether the patient is being effectively anti-coagulated. 
Due to the many side effects of Warfarin, its documented interactivity with other 
drugs being taken by the patient as well as other reasons, patients are being 
switched from Warfarin to new Direct Oral Anticoagulants (DOACs). These drugs 
do not require monitoring and as such the patients are not seen routinely (once 
prescribed DOACs).  
This study aims to look at the social changes in the quality of life of patients over 
65 who have been switched, both from the patient’s and clinical perspective. You 
are invited to be a part of focus group of NHS staff participants from a medical, 
clinical, pharmaceutical and scientific background, to discuss your experiences 
(anecdotal and otherwise), of patients who have switched, your level of interaction 
that you have with the patient post DOAC prescription, as well as any perceptions 
you may have on the quality of life of these patients.  
 
Why have I been chosen?  
You are an NHS staff member involved in the prescription, dispensing, care of, or 
testing of patients who have switched from Warfarin to DOACs.  
 
Do I have to take part?  
No, it is up to you to decide if you want to take part or not. If you decide to take 
part Patricia will explain the study to you and you will need to sign a consent form. 
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If you start the study then change your mind that is ok, you are free to withdraw 
at any time without needing to give a reason. If you wish to withdraw you can 
request that any data, we collected from you is destroyed.  
 
What will happen to me if I take part?  
If you wish to take part in the study, you will be given a staff participant information 
sheet which detailed how the focus group will be undertaken as well as the contact 
information for the research student Patricia. You will also be asked to complete 
an informed consent form, which will include permission for the research student 
to audio record the focus group discussion. Participants will be provided with a 
copy of their signed consent form  
Please note that quotations from the transcribed audio recording may be used in 
the in written submission of the research to illustrate the findings of the patient 
study or supplement the final discussion/conclusions.  
  
 What do I need to do if I want to take part?  
If you would like to take part in the study please tell the researcher, Patricia 
Richards, or email on patricia.richards@imperial.nhs.uk or by telephone (0203 312 
1132).  
  
What are the possible benefits of taking part?  
You will be a part of an interesting discussion which may go on to inform NHS 
policies on the social effects of switching patients to Direct Oral anticoagulants as 
well as potentially help to improve the lives of the elderly patients seen by the 
Imperial NHS Trust. This study also forms part of a doctoral study for the research 
student; therefore, you will be assisting the researcher in completing her study. 
This study may form the framework for a larger future project looking at the social 
impact of life-long anticoagulants of the elderly, which is not possible to be done 
as part of this study due to time constraints.  
 What are the possible risks and disadvantages of taking part?  
They are no perceived risks to you as this research only involves talking with the 
researcher.  
What will happen if I don’t want to carry on with the study?  
If you decide to withdraw from the study, data obtained from you may be used to 
contribute to study results. If you do not want this to happen, you can request 
data that belong to you to be destroyed.  
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Complaints  
Any complaints you might have for this study will be fully investigated. If you have 
any concerns about study procedures you can speak to the primary researcher, 
Patricia Richards who will answer your questions. If you remain unhappy and 
wish to complain formally, you can contact Dr Annie Bligh, t Westminster 
University.  
A.Bligh@westminster.ac.uk. You may also contact the Patient Advice and 
Liaison Service (PALS) or complaints team on the Ground floor of the Queen 
Elizabeth the  
Queen Mother (QEQM) building, St Mary’s Hospital, South Wharf Road, London 
W2 1N. Phone: 020 3313 0088, Monday to Friday, 09.30-17.00. Email: 
IMPERIAL.PALS@NHS.NET:  
 
Will my taking part in the study be kept confidential?  
Yes. The University of Westminster has a standard confidentiality procedure for 
participants involved in research that adheres to the Data Protection Act. This 
stipulates how personal information is collected, used, stored, and disposed of 
during and following completion of research projects. Files will be encrypted, and 
password protected. Any information that is collected from you during the course 
of the study will be kept strictly confidential and secured within restricted areas 
and/or electronic files on computers that have restricted access.  
 
What will happen to the results?  
Your interview material (audio recording), will be analysed thematically, with the 
results used to supplement the findings, discussions and conclusions drawn from 
the patient interviews. The results will for part of my doctoral research for the 
University of Westminster. The findings will be used to help other patients. In 
certain exceptional circumstances where you or others may be at significant risk 
of harm, the researcher may need to report this to an appropriate authority, in 
accordance with the UK Data Protection Act 1998. This would usually be 
discussed with you first.  
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Title of Study:  A Quality of Life study of the impact of substituting Warfarin with Direct 
Oral Anticoagulants (DOAC), in atrial fibrillation patients over 65 years old, at Imperial 
NHS Trust.  
Lead researcher:        Patricia Richards                     Please initial  
  
I confirm that I have read and understand the information sheet dated …………...... (V2) 
for the above study and have had the opportunity to ask questions.  
  
   ------    
I have had an opportunity to ask any questions and I am satisfied with the answers given.  
  
   ------    
I understand I have a right to withdraw from the research at any time and I do not have to 
provide a reason.  
  
  ------    
I understand that if I withdraw from the research any data included in the results will be 
removed if that is practicable (Once anonymised, data that has been collated into other 
datasets may not be possible to remove).  
I consent to my general practitioner being informed of my study participation and results. 
       
  
  ------  
I give the researcher permission to contact me on 2 future occasions                             ------    
  
I would like to receive information relating to the results from this study.  
  
       
  ------   
I understood what will happen in the event of disclosure of sensitive   information.  
  
    
   ------  
I give permission for my interviews to be audio recorded.  
  
   ------    
I confirm I am willing to be a participant in the above research study.  
  
   ------    
  
I note the data collected may be retained in an archive and I am happy for my data to be 
reused as part of future research activities.  
  
  ------    
  
  
I understand that my anonymised words may be used as quotes in the final     
research report or publications.      ------  
 
Participant’s Name__________________   Contact number _______________  
Signature:      ____________________________ Date:  _______________  
Researcher’s Name:  _Patricia Richards_          Signature:  ____________Date: __________  
 If you have any issues or concerns, please contact the patient advice and liaison service (PALS) or 
complaints team. Patient Ground floor of the Queen Elizabeth the Queen Mother (QEQM) building, St Mary’s Hospital, South 
Wharf Road, London W2 1N. Phone: 020 3313 0088, Monday to Friday, 09.30-17.00. Email: IMPERIAL.PALS@NHS.NET: 
   
APPENDIX 9 - CONSENT FORM Staff participants   
 Participant’s key code __ __ __  
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Title of Study:  A Quality of Life study of the impact of substituting Warfarin with Direct Oral 
Anticoagulants (DOAC), in atrial fibrillation patients over 65 years old, at Imperial NHS Trust.  
Lead researcher:  Patricia Richards                            Please initial  
  
I have been given the Participation Information Sheet and/or had its contents 
explained to me.  
  
------    
I have had an opportunity to ask any questions and I am satisfied with the answers 
given.  
  
------    
I understand I have a right to withdraw from the research at any time and I do not 
have to provide a reason.  
  
-------    
I understand that if I withdraw from the research any data included in the results 
will be removed if that is practicable (I understand that once anonymised data 
has been collated into other datasets it may not be possible to remove that data).  
  
-------    
I would like to receive information relating to the results from this study.  
  
-------    
I give permission for my focus group discussion to be audio recorded.  
  
------    
I confirm I am willing to be a participant in the above research study.  
  
------    
I note the data collected may be retained in an archive and I am happy for my data 
to be reused as part of future research activities.  
------    
  
I understand that my anonymised words may be used as quotes in the final    ---   
research report or publications.  
  
Participant’s Name:    ____________________________  
  
Participant’s contact number _______________________  
Signature:      ____________________________ Date:  _______________  
  
I confirm I have been provided a copy of the Participant Information Sheet approved by the 
Research Ethics Committee for use by staff and colleagues and its contents have been fully 
explained. I have been given an opportunity to ask questions, which have been answered.  
  
Researcher’s Name:  ____________________________    
Signature:      ____________________________ Date:  _______________  
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APPENDIX 10 - CHA2DS2VASc and HAS-BLED Scores Index  
  
Lip GYH, Halperin JL. Am J Med 2010; 123:484  
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 APPENDIX 12 - Comparison of Warfarin and DOACs  
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 APPENDIX 13 – GP Referral letter exemplar  
                REC ref: 17/LO/0290   
IRAS project ID: 196397 
<GP name and address>  
  
<Date>               
Dear Dr, <GP name>  
Re: Title of Study:  A Quality of Life study of the impact of substituting Warfarin 
with Direct Oral Anticoagulants (DOAC), in atrial fibrillation patients over 65 
years old, at Imperial NHS Trust.  
Your patient <Participant’s name and surname>, DOB <DOB>, <Participant’s 
address>, has volunteered to take part in a research study at St Mary’s Hospital, 
imperial NHS trust. <He/She> has given us permission to contact you.  
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The study is designed to look at the short term impact on the quality of life of 50 patients 
who are 65 and over and switching to the new Warfarin alternatives, DOACs. It will 
help us understand, from the patient’s point of view, what it is like living on Warfarin 
and then switching to a new medication. This information will help us work better with 
patients in the future; the data will be of value to many other patients in years to come.  
This research is being undertaken as part of the researcher’s studies for Professional 
Doctorate in Health Sciences at the University of Westminster. For more information, 
see the attached participant information sheet.  
We have selected men and women, aged over 65 years. With the exception of 
participants excluded on medical grounds, all AF patients who are switching from 
Warfarin to DOAC, regardless of sex, race, or disability, will be included in the study 
and approached for participation.  
At the end of the study, a copy of your patient’s results letter regarding the 
measurements performed as part of the study; any abnormal readings will be sent to 
you.  
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If you feel that there is a medical reason that prevents your patient’s continued 
participation in this study, or if you need further details, please contact the study 
consultant Dr Abdul Shlebak, Consultant Haematologist (General Haematology, 
Obstetric Haematology, Haemostasis and Thrombophilia) and Lead Laboratory 
Clinician at St Mary’s Hospital, Imperial NHS Trust on 020 3312 6666 Secretary: 020 
3312 6806.  
Kind regards,  
Patricia Richards BSc. MSc CSci MIBMS  
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APPENDIX 14 – Interview Transcript samples 
 
Coding the Qualitative Material. 
These two tables provide an example of how the main themes were developed by 
combinations of the smaller codes elicited from the transcripts. Four transcripts then 
follow which are from younger and older patients whose words have been coded 
according to the themes shown in these tables. It is noteworthy that, generally, the 
second interviews were shorter and less full then the first as most of the personal 
information has already been discussed. Nevertheless, they provide valuable 
information about the patients coping strategies and responses to the change of 
medication. 
Table one: The main themes and supporting codes elicited from the first interview at 
the time of the switch. 
 
First patient interviews before switching 




• Coping with different illnesses and their impact on 
taking Warfarin correctly and feelings of wellbeing.  
• Findings ways to cope with so many different tablets 
to be taken throughout the day. 
• Organisation of domestic life, getting help with pill 
taking routine. 





• A tendency to dismissing personal discomfort 
resulting from their other illnesses as normal, just to 
be tolerated. 
• A desire to make no fuss. 
• It’s a normal part of aging – nothing to be done.   
• Pain and limitation of pain relief due to Warfarin.  
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Loss of control – the 
domino effect   
  
• Social isolation leading to loneliness and anxiety 
about health.  
• Coping alone – even just the small things are hard. 
• One thing leads to another: the burden of food 
restriction due to medication and impact on exercise.  
• Fear of getting it wrong – errors with dosages can lead 
to an emergency admission to hospital. 
• One medication side effect leads to another problem. 
 
 
Freedoms lost  
• Family activates curtailed – sport for example. 
• Travel restricted to short trips as need to attend 
appointments. 
• The health care process as a Restriction - the time it 
takes to get to the clinic. 
• Pleasure denied - drinking alcohol - an educated risk. 
  
Self-reliance - within a 
partnership 
 
• Self- organize life or fail. 
• The importance of a good GP.  
 
Appendix 14 Table 1 
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First interview - at time of switch.         
                                               75 – 84 St Lucia 
15/04/2018 
Patient 8 – SS, 82/F 
 
Topic: Living with Warfarin   
Q 1. You have been on Warfarin for some time now, can you tell me what that 
is like? For example, how does it impact your day?  
 
SS: It’s bleeding awful, I have problems swallowing pills, always have done. so, I hate 
it.  12 or 13 years ago, I had a stroke, 2 days after my 70th birthday! Can you believe 
it? Just my luck… if it were going to happen to anyone it would be me. I later found 
out that I had this AF condition and have done for years, but I had no idea. I kept 
telling the GP that I was lightheaded and faint and that my chest felt funny. It was 
never picked up. Now I have to take 2 tablets twice a day. Oh, just awful……. My 
health has gotten worst over the years, especially after my husband died 20 years 
ago… of a stroke and I don’t have much help.  I can’t walk very far, I need help getting 
dressed and all my relatives live so far away, and we never had kids. I get really 
lonely sometimes. I looked after my husband for 24 years before he passed away. 
He was very ill towards the end. 
 
Q 2. Does having a drug regimen interfere or enhance with your lifestyle in any 
way?  
 
SS: Enhance? Enhance? I really wouldn’t say so. I keep thinking, today is going to 
be the day I can be done with it, but It never ends. I don’t mind coming to the clinics 
every few weeks to get tested. It is so hard to get a GP appointment in Ladbroke 
Grove. The bus is sometimes late to take me here though, I have complained. The 
driver said that he was new, then he said he not familiar with area and now he doesn’t 
say much. 
Q 3. How do you get on with self-medicating – giving the medicine to your- 
self?  
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SS: It’s difficult, in the morning, I have the Warfarin, then the citalopram and then the 
insulin. I was on antibiotics back in December, but I finished that last course of 
amoxicillin in January. I get really fed up. I have asked about syrups or dissolvable 
tablets…... I did have some dissolvable pain killers, those were very strong, but they 
tasted so awful. I usually keep all my pills in the kitchen near the door, just in case. 
The last few times the ambulance came to my house, the box was right there at the 
kitchen door which was handy…… I come in and out and in and out, I may as well 
move into St Marys! I tell yah, I have not been very well.   
 
Topic: Information provision.  This section was not coded and themed in the 
same way because the information was generally factual. But a some key 
factors did emerge and are reported in Chapter Five.  
Q 4. Thinking back to when you first started on Warfarin, how much 
information were you given?  
 
SS: ohhh, probably not much, everyone is so busy these days, everything is online, 
and I don’t have a computer………... I knew about it before the stroke because J*** 
was on it after his heart operation for years. I do know its rat poison; did you know 
that.... I does go through my mind sometimes. NO wonder patients who take it has 
all these problems. 
 
4a How was the information provided? (leaflets/conversion/website). 
 
SS: I can’t really remember, probably a conversation. I think they waste so much 
paper these days printing things. Most young people these days don’t even read. 
 
4b Did you understand the information easily?  
 
SS: I don’t know. I was in hospital at the time. After the stroke, I was in ITU for 2 
weeks, felt like there was an elephant sitting on my chest. Very painful and 
uncomfortable. Even if they had told me, I was probably not in a position at the time 
to take it all in. 
       
4c Were you give any more information after that time?  
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SS: The GP and the clinic has always been good and telling me any new bits that I 
need to know. You don’t know what you don’t know, so I probably don’t know enough, 
or should know more than I do but how would I know what I don’t know? 
 
  
Topic: Current health self-assessment and expectations  
Q 5. How much do you know about the condition (AF) that Warfarin helps you 
with?  
 
SS: I know that it is a very dangerous condition and that it is very serious. I worry all 
the time about AF episodes coming on, they can be quite distressing. I worry about 
the long-term effects. I worry about serious heart damage because of it. It’s been a 
constant worry, I could have a cardiac arrest, stroke. Every time I have the slighted 
murmur or chest pain, I think, is this it? Am I having a heart attack or a stroke? It 
never leaves your mind. It’s like a constant that I’m going to die. You only get one 
heart you know. Sometimes I worry that my other medication is working because of 
the Warfarin, or even the Warfarin not working because of the other tablets…... 
absolute constant torture. I feel anxious right now. 
 
Q 6. How many other medications do you take? Do you think you can name 
them?  
 
SS: 3 – citalopram, insulin, and Warfarin…...sometimes ibuprofen for my pain, some 
vitamin c and sometimes I have a bit of cod liver oil. But mostly just the 3. 
 
Q 7. Do you know why your medicine is being changed?  
 
SS: Well, I am not doing very well. I hear this new one… Apixaban is better than the 
Warfarin, we will have to wait and see. When I spoke to my cardiologist last week, I 
told him that I was so worried about the whole thing. I think I will still phone the 
Warfarin clinic to speak to the ladies here…...yes, I know they are not testing 
anymore, but just in case I have any questions; I think I will call here (clinic). 
 
Q 8. Do you think that switching to drug (DOAC) will change anything for you?  
 
SS: It can’t get much worse, so it can only get better. 
   
    
198  
 Student ID: W10503030 v8 – 05/08/2020 
 
Q 9. What benefits are you expecting from the new drug, if any?  
 
SS: Hopefully, I won’t always be lightheaded and get lots of nose bleeds and bleeding 
gums. I really hope that I can have some normality really. Day to day life on Warfarin 
can be really unpredictable, I’m getting old now. I don’t want to have all these worries 
about fainting on the stairs…. I would love a Stena stair lift, but they are so expensive, 
so in the meantime, I really don’t want to fall off the stairs again, that was painful last 
time. 
 
Q 10. Do you have any concerns about taking the new drug?  
 
SS: Lots, I don’t really know how it works or if it works, well I assume it works or they 
wouldn’t give it to me, but I thought that with Warfarin and that was bloody awful. I 
think that because I have had such a tough time with the other meds, I really don’t 
have much hope for this new one. 
 
Q 11. Have you had any unexpected experiences or events since using 
Warfarin?  
 
SS: Oh, do we have enough time? So many, as I said, I’ve had bleeding gums, 
headaches, dizziness, nose bleeds, fainting spells, palpitations, you name it. 
 
And finally   
Q 12. Is there anything else you would like to tell me about being on Warfarin 
or your feelings about the change to a different medicine.  
 
SS: I know it’s odd, but as bad as it is being on Warfarin, I don’t really want to change. 
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First interview 
        65 - 74 England 
05/03/18 
Patient 10 – MC, 65/M 
 
Topic: Living with Warfarin   
Q 1. You have been on Warfarin for some time now, can you tell me what that 
is like? For example, how does it impact your day?  
 
MC: 15 years now.  It is very difficult to plan trips away, I have struggled for years to 
keep within range - but it’s always something (to go wrong). I take a few other 
medications, which affects it, and my diet affects it, even if I have a drink at the local 
it affects it. 
 
Q 2. Does having a drug regimen interfere or enhance with your lifestyle in any 
way?  
 
MC: I wouldn’t say enhance but definitely interfere. I mean, touch wood I haven’t had 
a stroke, (this is good) but no I don’t think Warfarin enhances my lifestyle it’s a 
hinderance if anything. 
 
Q 3. How do you get on with self-medicating – giving the medicine to your- 
self?  
 
MC: I am pretty good, unless I have had a good night out. If I am travelling then the 
time difference tends to throw me off, but I am generally quite good. 
 
 
Topic: Information provision.   Not colour themed - see Chapter five 
paragraph?? for analysis. 
Q 4. Thinking back to when you first started on Warfarin, how much 
information were you given?  
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MC: Aaahh……… not much to be honest. I have had heart problems since I was 
young and take one medication or the other all the time, so I know quite a bit now. 
But I think back then the condition was explained, and the medication or ‘fix’ was 
given - I was told it was life long, but I really don’t think I had a lengthy conversation 
about Warfarin. 
 
4a How was the information provided? (leaflets/conversion/website). 
MC: at a consultation with the cardiac consultant, I can’t remember when. 
 
4b Did you understand the information easily?  
 
 MC: Yeah 
       
4c Were you give any more information after that time?  
 
MC: Oh of course, several papers and articles and conversations with my GP. The 
nurses in the clinic are pretty good, here and at Hammersmith. 
  
 
Topic: Current health self-assessment and expectations  
Q 5. How much do you know about the condition (AF) that Warfarin helps you 
with?  
 
MC: Quite a bit, I am in a support group with the AF association, they put on events 
and things and they send out information packs from time to time. 
 
Q 6. How many other medications do you take? Do you think you can name 
them?  
 
MC: 4 or 5, a lot’s going on, but I take it in my stride. 
 
Q 7. Do you know why your medicine is being changed?  
 
MC: Yes, it was my TTR, it was in the time range? Basically, it means that my INR is 
not within range sufficiently, it’s really poorly managed not because I don’t take the 
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blessed thing, because I do, it’s just so unpredictable and it stops me from having a 
tipple. 
 
Q 8. Do you think that switching to drug (DOAC) will change anything for you?  
 
MC: Well no more clinics for a start. I am here sometimes every week or every other 
week. Very tiresome. I was told there is better control and less interactions but no 
antidote - that’s concerning. 
 
Q 9. What benefits are you expecting from the new drug, if any?  
 
MC: Better control of my INR, well it’s not INR anymore, but better blood thinner 
control. I went to Cornwall last week; I hadn’t been in a long time. 
  
Q 10. Do you have any concerns about taking the new drug?  
MC: Just the reversal issue. Sometimes my INR is 10 or 11, very high, not 
sure what happens if the Apixaban is very high. 
 
Q 11. Have you had any unexpected experiences or events since using 
Warfarin?  
MC: I have had several bleeds, sometimes I get really bad headaches and joint 
pains, hence why I take all these other pills, but I’m generally ok. 
Q 12. Is there anything else you would like to tell me about being on Warfarin 
or your feelings about the change to a different medicine.  
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Table two:  the main themes and supporting codes from the second interviw 
held at 90 days.  
Table two: The main themes and supporting codes elicited from the first interview at 
90 days post switch. 
Themes  Supporting codes 
  
Stalwartness – a continuing theme 
• All is well on the face of it.  
• Not always a good thing, patients tend 
to mask difficulties from healthcare 
staff. 
• The system can be frustrating not the 
people who run it. 
 
 
A leap of faith - increased patient 
responsibility  
• How will I know if the new medication 
works?  
• Total trust in the medical staff’s 
decision that they can cope alone. 
• Increased responsibility for own health.  




Liberation – reigning control 
• No more clinic - more time to self  
• Freedom to travel longer distances and 
for longer periods of time. 
• Medical freedoms - reduction in pain 
due to better pain relief. 
• Wider choice of food stuffs so better 
health 
 
Fewer Tablets – Simpler regime 
 
• Less tablets taken per day 
• Fewer regimens to remember (i.e. to be 




•   The switch enabling a life review.   
• Virtuous circles begin – one thing leads 
to another 
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Liberation – but a loss for some 
• Missing the clinic visit and the 
reassurance it brought. 
• Missing the company of other patients 
at the clinic. 
• Raised anxiety for some. 
Appendix 14 Table 2 
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Day 90         75 – 84 St Lucia 
16/07/2018 
Patient 8 – SS, 82/F 
 
Topic: The switch over.  
Q 1. How was the switch over for you at the time?  
SS: I was very worried about the change. I still am. 
 
Q 2. Did you understand the reason for it?  
SS: I know that my INR was always wrong, I could have had a stroke at any 
time, so I had no choice but to change. The Warfarin was just not working. 
 
Q 3. How long did it take to get used to taking the new medicine?  
SS: I’m still getting used to it now. Really happy that its less tablets to take and 
on the whole, I do feel better, I just think it’s too soon to tell. 
 
Topic:  Living with the new medication.  
Q 4. Now that you have been on your new medication for three months, how are 
things going for you?  
SS: it’s been going ok; I only take 1 tablet a day for the AF now instead of 4 
Warfarin ones. So, I feel good about that, I really struggled to swallow all them 
pills. 
 
Q 5. How are you getting on with the routine of self-medicating?  
SS: I still take a few other tablets and I can’t crush up this new tablet but apart 
from that, I am doing ok. 
 
Q 6. How do you think switching to drug (DOAC) has impacted on your life?  
SS: It’s still too soon to say, but I am already noticing small things like – I 
haven’t had a headache or a nosebleed in a while. My gums still bleed from 
time to time when I’m brushing my teeth, but that maybe because of my 
toothbrush. I feel like I do nothing all day. I have no kids and I’m widowed, so 
I don’t really have much to do, or people to visit. It can get very lonely, this 
clinic has been a God send, I will miss it. 
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Q 7. Have you had any unexpected experiences or events have you had since 
switching to DOAC?  
SS: like what? I suppose as this is a new experience everything is unexpected, 
so I really don’t know how to answer that. 
 
Q 8. Are you glad you switched?  
SS: the jury is still out, I do feel better, there are small things that I have noticed, 
but it’s probably mind over matter, I will have to wait and see…… If I had to 
choose between this one and the Warfarin, I would say this new one. 
 
Topic: Expectations  
Q 9. Are there any expectations that you had initially that have/haven’t been met? If 
so, what are they?  
SS: I was hoping to take less tablets per day really and to have less day to day 
issues. I still worry about the future, I still worry about dying from a stroke, I 
don’t get tested anymore, so it’s a worry. Big concern. Perhaps I need time to 
get used to the change. 
 
Topic: Overall Satisfaction  
Q 10. In broad terms, how happy are you that you made the switch to this new 
medication.  
Very unhappy. 1     2  3  4   5  6  7   Very happy  
SS:4 or 5 
Q 11. Is there any way the hospital could make your medication regimen better for 
you or others with the same condition?  
SS: they should carry on testing my INR, just to see what it is and to give me 
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Day 90         65 - 74 England 
28/06/18 
Patient 10 – MC, 65/M 
 
Topic: The switch over.  
Q 1. How was the switch over for you at the time?  
MC: Pretty straight forward. 
 
Q 2. Did you understand the reason for it?  
MC: oh yes 
 
Q 3. How long did it take to get used to taking the new medicine?  
MC: about a day or two, I felt a bit funny at first…...lightheaded, but all good 
now. 
 
Topic:  Living with the new medication.  
Q 4. Now that you have been on your new medication for three months, how are 
things going for you?  
MC: Pretty good, no real issues. 
 
Q 5. How are you getting on with the routine of self-medicating?  
MC: It’s been much easier than I thought it would be, definitely a lot easier than 
the Warfarin. I was told that there are possible side effects, but so far I haven’t 
had any. 
 
Q 6. How do you think switching to drug (DOAC) has impacted on your life?  
MC: At first, I was sceptical, but I am definitely a convert. The new medication 
really doesn’t bother my other pills, for some reason my joints don’t hurt as 
much, and I feel much better in myself. 
 
Q 7. Have you had any unexpected experiences or events have you had since 
switching to DOAC?  
MC: No, just the initial dizziness 
 
Q 8. Are you glad you switched?  
MC: Absolutely, I have a little control back, not much but a little. 
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Topic: Expectations  
Q 9. Are there any expectations that you had initially that have/haven’t been met? If 
so, what are they?  
MC: I was hoping to have better coagulation control, my INR was all over the 
shop which made you feel sick all the time, and now, I feel much better – new 
lease on life. 
 
Topic: Overall Satisfaction  
Q 10. In broad terms, how happy are you that you made the switch to this new 
medication.  
Very unhappy. 1     2  3  4   5  6  7   Very happy  
MC: 10! So very happy 
 
Q 11. Is there any way the hospital could make your medication regimen better for 
you or others with the same condition?  
MC: I still have some concerns about the reversal, so perhaps there should be 
some form of testing, I mean I feel better, but how do I know it’s working? Will 
I still be able to come to the clinic if I have questions? 
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APPENDIX 15 - Statistics underpinning the scale data analysis. 
 
 Table 1 – PSS ANOVA DATA Statistics unperpinning Figure 7.1 
 
Anova: Single 
Factor       
              
SUMMARY        
Groups Count Sum Average Variance    
Time Point 1 3 56.19 18.73 0.50    
Time Point 2 3 42.08 14.03 0.46    
Time Point 3 3 39.60 13.20 0.94    
         
         
ANOVA        
Source of Variation SS df MS F P-value F crit 
Between Groups 53.37 2 26.68 42.24 0 5.14 
Within Groups 3.79 6 0.63     
         
Total 57.16 8         
Anova: Single 
Factor       
              
SUMMARY        
Groups Count Sum Average Variance    
Time Point 1 3 56.19 18.73 0.50    
Time Point 2 3 42.08 14.03 0.46    
Time Point 3 3 39.60 13.20 0.94    
         
        
ANOVA        
Source of Variation SS df MS F P-value F crit 
Between Groups 53.37 2 26.68 42.24 0 5.14 
Within Groups 3.79 6 0.63     
         
Total 57.16 8         
 








Average of PSS 
Total Scores T3 
65-74 19.53 14.11 14.00 
75-84 18.48 14.67 13.48 
85-94 18.19 13.31 12.13 
Grand Total 18.75 14.09 13.27 
 
Table 3 – Mean PSS Scores by age and sex Statistics underpinning Figure 7.2 and 7.3 
Row Labels 
Mean of PSS 
Total Scores 
T1 
Mean of PSS 
Total Scores 
T2 
Mean of PSS 
Total Scores 
T3 
65-74 19.53 14.11 14 
F 19.75 13.92 13.33 
M 19.14 14.43 15.14 
75-84 18.48 14.67 13.48 
F 17.17 14.83 13.17 
M 19.00 14.6 13.6 
85-94 18.19 13.31 12.13 
F 17.89 15.00 11.56 
M 18.57 11.14 12.86 
Grand Total 18.75 14.09 13.27 
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 Table 4 – Total PSS Scores by age and sex Statistics underpinning Figure 7.3 
UPN Age Sex PSS Total Scores T1 PSS Total Scores T2 PSS Total Scores T3 
1 91 F 19 21 14 
2 84 F 24 25 16 
3 84 M 14 11 15 
4 84 F 12 19 9 
5 91 M 16 2 9 
6 65 M 16 23 28 
7 73 F 22 14 14 
8 75 F 10 6 17 
9 84 M 21 22 15 
10 65 M 19 15 17 
11 92 M 18 13 16 
12 65 M 21 18 14 
13 76 M 18 15 17 
14 65 F 23 17 17 
15 73 F 17 14 19 
16 75 M 21 12 12 
17 85 M 17 15 19 
18 81 M 19 16 19 
19 80 M 22 15 13 
20 92 M 17 15 12 
21 83 M 17 18 12 
22 65 F 19 14 10 
23 83 M 17 18 11 
24 65 F 19 14 14 
25 83 M 20 18 13 
26 68 F 19 14 12 
27 69 M 20 14 13 
28 66 M 22 14 6 
29 89 F 20 17 12 
30 67 F 19 13 6 
31 65 F 22 12 17 
32 78 M 19 12 16 
33 69 F 16 16 12 
34 76 F 22 13 9 
35 89 F 16 14 12 
36 91 F 21 10 13 
37 82 M 16 11 9 
38 94 F 14 18 7 
39 84 M 22 7 14 
40 75 M 20 16 12 
41 65 F 22 10 19 
42 85 M 19 13 9 
43 84 M 19 14 14 
44 82 M 20 14 12 
45 81 F 15 14 17 
46 86 F 17 13 10 
47 90 F 22 20 14 
48 66 M 16 7 12 
49 85 M 22 10 13 
50 69 M 20 10 16 
51 68 F 22 15 10 
52 71 F 17 14 10 
53 85 M 21 10 12 
54 85 F 15 9 9 
55 86 F 17 13 13 
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Time 1 38.37 39.01 4390.00 
Group1 39.33 39.58 1278.00 
64 48.23 28.81 64.00 
66 38.72 42.45 132.00 
67 41.37 35.33 67.00 
68 42.19 35.72 136.00 
69 36.47 40.76 207.00 
71 41.27 37.59 71.00 
73 27.63 49.25 146.00 
Group2 37.68 39.58 1696.00 
75 43.88 38.52 225.00 
76 36.59 39.22 152.00 
78 37.84 36.42 78.00 
80 30.80 38.80 80.00 
81 40.87 39.34 162.00 
82 35.69 39.96 246.00 
83 38.67 39.92 249.00 
84 35.50 40.59 504.00 
Group3 38.12 37.60 1416.00 
85 41.16 34.67 425.00 
86 35.89 34.88 172.00 
89 39.30 38.94 178.00 
90 40.15 37.90 90.00 
91 35.80 41.83 273.00 
92 34.59 40.26 184.00 
94 36.96 36.66 94.00 
 
 







Not stated 238 
Grand Total 3972.5 
 
 






F 40.84 37.65 
M 39.94 36.51 
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Count of Warfarin/ DOAC Difference Colum  
Row Labels F M
Grand 
Total
Better ac control and QoL 1 1
Better ac control and QoL. Able to cook/eat a woder variriety of meals and 
foods.. 1 1
Better ac control, feels better 1 1
Better ac control, less calcification post 90 days. Reduced risk of stroke. 1 1
Better ac control, no dosage issues 1 1 2
Better ac control, no dosage issues, no more interactions 6 3 9
Can now eat chick peas, greens and drink alcohol 1 1
Can stop DOAC on the day of op. Not worried about forming clots. DOAC easier 
to take than warfarin 2 2
Contacts the clinic/GP to ask questions. 1 1
Does not miss the clinic. Now has time for other things. No ill effects from DOAC 1 1
Easier to take regularly 2 2
Has nerve damage in his back, unable to exercise, drinks a lot as he is in a lot of 
pain and is overweight. 1 1
Has to take the tablet at the same time each day which may not always be 
practical 1 1
Misses clinic, No pain meds, Had wait 2 weeks for GP appointment. 1 1
Misses the health professional contact. 1 1
No difference 1 1
No difference. 1 1
No difference. Travels more 1 1 2
No dosage issues, feels better 3 6 9
No longer has increased heartrate. Does not need to stop his meds 5 days before 
his op. No longer dizzy. 1 1
No more interactions. Clinic visits. Feek better 2 2
None stated 2 2
Not sure if drop in BP was caused by switching to DOAC. 1 1
Now has a better diet and is able to eat Kale etc which he wasn't able to before. 
No more interactions. 1 1
Parties 1 1
Prefers warfarin 1 1
Sill contacts the clinic regularly. No dosage issues 1 1
Still in a lot of pain, but no more night sweats and is now on medication for 
ADHD. 1 1
Takes the tablet at the same dose and time everyday. Much easier than warfarin. 
Has had a reduction in kidney function since DOAC. Being  monitored. 1 1
Grand Total 24 27 51
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Appendix 15 table 16 - SPSS Statistics 
UPN Age Sex PSS Total Scores T1 PSS Total Scores T2 PSS Total Scores T3 
1 91 F 19 21 14 
2 84 F 24 25 16 
3 84 M 14 11 15 
4 84 F 12 19 9 
5 91 M 16 2 9 
6 65 M 16 23 28 
7 73 F 22 14 14 
8 75 F 10 6 17 
9 84 M 21 22 15 
10 65 M 19 15 17 
11 92 M 18 13 16 
12 65 M 21 18 14 
13 76 M 18 15 17 
14 65 F 23 17 17 
15 73 F 17 14 19 
16 75 M 21 12 12 
17 85 M 17 15 19 
18 81 M 19 16 19 
19 80 M 22 15 13 
20 92 M 17 15 12 
21 83 M 17 18 12 
22 65 F 19 14 10 
23 83 M 17 18 11 
24 65 F 19 14 14 
25 83 M 20 18 13 
26 68 F 19 14 12 
27 69 M 20 14 13 
28 66 M 22 14 6 
29 89 F 20 17 12 
30 67 F 19 13 6 
31 65 F 22 12 17 
32 78 M 19 12 16 
33 69 F 16 16 12 
34 76 F 22 13 9 
35 89 F 16 14 12 
36 91 F 21 10 13 
37 82 M 16 11 9 
38 94 F 14 18 7 
39 84 M 22 7 14 
40 75 M 20 16 12 
41 65 F 22 10 19 
42 85 M 19 13 9 
43 84 M 19 14 14 
44 82 M 20 14 12 
45 81 F 15 14 17 
46 86 F 17 13 10 
47 90 F 22 20 14 
48 66 M 16 7 12 
49 85 M 22 10 13 
50 69 M 20 10 16 
51 68 F 22 15 10 
52 71 F 17 14 10 
53 85 M 21 10 12 
54 85 F 15 9 9 
55 86 F 17 13 13 
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Appendix 16 – Critical Appraisal Skills Programme (CASP) Checklist 
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